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OUTLINE AND AIMS 
Prilling represents an innovative technology for continuous particle processing and has been 
intensively used for the production of urea pellets. The process converts a molten liquid into droplets 
followed by cooling of the droplets in a prilling tower, generating solid spherical particles with 
uniform size distribution. Up until now, only a few studies evaluated the suitability of the prilling 
technique for pharmaceutical applications. Furthermore, lipid matrix excipients offer an interesting 
alternative for conventional polymers to achieve controlled drug release as they cover a large group 
of non-toxic materials with highly versatile physicochemical properties. Hence, the combination of 
the continuous prilling technique and the use of lipid excipients provides an encouraging platform to 
address certain formulation challenges.  
The general aim of this work was to evaluate the potential of prilling as continuous process for 
the manufacturing of lipid-based multiparticulate dosage forms. As the use of fatty acids is rather 
limited in lipid-based drug delivery, this class of lipid excipients was selected as controlled release 
matrix formers. In Chapter 1, 2 and 3 prilling was carried out using a pneumatic nozzle device 
producing lipid droplets which were quench cooled in liquid nitrogen, whereas in Chapter 4 the 
droplets were solidified by means of a vertical prilling tower. 
In the Introduction, the technology of prilling is described in terms of equipment, mechanisms 
for droplet formation and process challenges. In the second part, the introduction provides a general 
overview of lipid-based drug delivery with the main focus on oral solid dosage forms. Available lipid 
excipients, pharmaceutical applications, processing techniques and formulation challenges are 
highlighted.  
In Chapter 1 the potential of long-chain saturated fatty acids as matrix excipients for controlled 
drug release is investigated. Therefore, metoprolol tartrate (MPT), a highly water soluble drug with 
short elimination half-life, was embedded in matrices consisting of stearic acid or behenic acid. Drug 
OUTLINE AND AIMS 
4 
 
release from these matrices was investigated as function of pH and ionic strength of the dissolution 
medium. The effect of the prilling process on crystallinity of drug and fatty acids as well as molecular 
interactions between both were studied. A stability study evaluated aging of the fatty acids and its 
effect on drug release kinetics. In addition, the MPT bioavailability in dogs was compared to a 
commercial available controlled release reference formulation.  
Chapter 2 further extends the possibilities of prilling to prepare fixed-dose combinations, 
combining controlled-release prills containing MPT and immediate-release prills containing 
hydrochlorothiazide (HCT) in a single capsule. Polyethylene glycol (PEG) was added as hydrophilic 
compound in order to tailor drug release from the fatty acid-based matrices. The impact of different 
PEG molecular weights (4000 to 10 000) and the PEG/fatty acid ratio was evaluated.  
During prilling a complete molten state of the fatty acids is required to allow continuous droplet 
formation. In addition, these process conditions allow maximal interaction between drug and the 
fatty acids. Therefore, in Chapter 3, a comparative study was performed with solid lipid extrusion 
whereby the formulations are processed below the melting temperature of the fatty acids. Both 
binary MPT/fatty acid mixtures as well as ternary mixtures (i.e. MPT embedded in a mixture of 2 fatty 
acids) were used for this purpose. Drug release from spherical prills and cylindrical extrudates was 
compared by means of mathematical modeling which considered the differences in geometry 
between these systems. The impact of both processing techniques on the inner structure, solid state 
characteristics and stability was evaluated.  
Finally, the feasibility and efficiency of larger prilling towers to solidify the lipid droplets was 
explored in Chapter 4. The pneumatic nozzle device used to generate the molten lipid-based droplets 
was incorporated in a 5 m high prilling tower and different cooling setups were tested. In a second 
part of this study, a vibrating nozzle device was applied generating droplets < 1 mm which were 
solidified in a 2.2 m high column. In addition, these different setups allowed to study the effect of the 
cooling rate on drug and matrix crystallinity.  
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1. PRILLING OF LIPIDS FOR THE DEVELOPMENT OF MULTIPLE-UNIT SYSTEMS 
Multiple-unit systems, also termed multiparticulate dosage forms, consist of multiple sub-units 
over which the drug dose is uniformly distributed (e.g. pellets, granules or mini-tablets). They are 
administered as a single dose by filling them in capsules or sachets, or by compressing them into 
tablets. In this latter case, a prerequisite is that the properties of the individual sub-units are 
maintained and that the tablets immediately disintegrate upon contact with water [1-3]. Several 
methods have been proposed for the production of multiple-unit systems including 
extrusion/spheronisation, melt pelletization, spray-drying, spray-congealing and prilling (Fig. 1). From 
a formulators’ point of view, the major advantage of multiparticulate dosage forms originates from 
their flexible design since the dose can be easily adjusted by increasing or decreasing the number of 
particles and thus, without the need of formulation or process changes and without any effect on the 
drug release profile. In addition, these systems allow to combine mini-matrices of the same drug with 
different drug release profiles or mini-matrices containing different drugs (e.g. fixed-dose 
combination) [1, 4]. Multiparticulate systems also offer some pharmacokinetic benefits. If the 
dimensions of the mini-matrices are sufficiently small (< 2 mm), they can immediately pass the 
pylorus and reach the small intestine, independent of gastric emptying. Since gastric emptying is 
strongly subjected to intra- and inter-individual variability, the general reproducibility of the 
therapeutic effect is tremendously increased using multiparticulates. Compared to single-unit dosage 
forms, multiparticulates are dispersed more uniformly over large surfaces in the gastro-intestinal 
tract which reduces the risk of high local drug concentrations and minimizes local side effects. 
Furthermore, they show less tendency to dose-dumping as the drug dose is distributed over multiple 
sub-units [1, 2, 4-6].  
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Figure 1. Multiparticulate drug delivery system obtained by prilling. 
 
Prilling 
Prilling has originated from the chemical industry where it is used for the production of fertilizers 
such as ammonium nitrate and urea. The technique basically consists of converting a liquid melt into 
droplets which are subsequently cooled below their solidification temperature during their fall in a 
temperature-controlled prilling tower. Under influence of the surface tension, the droplet adopts a 
shape with the smallest surface area-to-volume ratio, which is a sphere [7]. Recently, the technique 
has been explored for the processing of pharmaceutical multiparticulate dosage forms for oral 
administration [8-10]. For this purpose, the prilling process initially involves the solubilization or 
dispersion of a drug into a molten lipid before the extrusion through calibrated nozzles. The break-up 
of the liquid jet allows perfect calibration of the droplets and finally results in the production of 
regularly, spherically shaped particles with narrow size distribution [8, 9]. Due to the hydrophobic 
properties of the lipids, the process is able to produce controlled release formulations. Other 
advantages of the prilling process include its continuous character, the limited number of processing 
steps and a large production capacity [11]. The process can be easily scaled-up by a simple 
multiplication of the number of nozzles [8, 9]. No solvents are involved which avoids environmental 
requirements of solvent capture and recycling, thereby reducing processing time. Furthermore, the 
process requires no downstream processing as the particles exhibit excellent flow properties and are 
suitable for filling in capsules or sachets. However, in specific cases prilling can be performed as an 
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intermediate step to obtain solid lipid microparticles which are subsequently compressed into 
tablets.  
The major drawback of prilling is that high prilling towers are required which increases 
processing costs. A mathematical study performed by Yuan et al. (2007) demonstrated that a tower 
of unrealistic height is required to obtain particles ≥ 2 mm. At a larger droplet size, the fall velocity as 
well as the resistance of the solid shell to heat transfer increases, indicating that the height of the 
prilling tower is strongly related to the desired particle size [11]. Considering the relatively high 
process temperature (i.e. a complete molten state of the lipid is required) and due to the long 
residence time of the drug/lipid mixture in the heated feeding unit, the process is less suitable for 
thermosensitive compounds. In addition, processability of high drug loads is challenging as the 
viscosity of the drug/lipid mixture is limited to allow continuous feeding through the narrow prilling 
nozzles.  
Prilling equipment 
The typical mechanisms of droplet formation differentiate prilling from spraying methods such 
as spray-drying and spray-congealing [8, 9]. Different mechanical technologies for droplet formation 
have been described in literature. The industrial prilling process of urea is generally performed using 
a rotating perforated cylindrical drum. Molten liquid is pumped into the drum and a long curved jet is 
produced from the holes in the surface of the drum. Due to centrifugal instability, the jets break up 
into droplets which subsequently solidify and form spherical pellets [12]. However, this process 
suffers from uncontrolled jet break-up, yielding broad particle size distributions. To overcome these 
issues, full process optimization is necessary, which is time-consuming and increases the production 
cost [13]. Hence, this process appears to be less suitable for pharmaceutical applications where a 
controlled droplet formation, resulting in a narrow particle size distribution, is desired.  
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For pharmaceutical prilling processes, the use of vibrating nozzle technologies has raised 
considerable interest since it provides highly monodisperse particles [14]. Via this process, a molten 
lipid is extruded through vibrating nozzles, which break the liquid jet into a row of mono-sized 
droplets. An illustration of the process is shown in Fig. 2A. Droplet size mainly depends on the nozzle 
diameter, jet speed, the applied vibration frequency and the viscosity of the liquid [15]. Although this 
technology has been intensively applied as method for microencapsulation (see below), it was 
already implemented by Pivette et al. (2009) for prilling of lipid materials. They used a single 
vibrating nozzle which was incorporated at the top of a 1.8 m high cylindrical column (diameter: 40 
cm) with controlled temperature of 10°C (Fig. 2B). The melt was fed from a pressurized heated 
feeding tank connected to the prilling nozzle through a heated silicone tubing. Using a 200 µm nozzle 
diameter, uniform particles with a diameter close to 400 µm and a smooth surface were successfully 
obtained [8, 9].  
An alternative prilling technology is based on a dripping mechanism which is conducted at low 
flow velocities. The molten lipid adheres to the nozzle until the gravitational force is high enough to 
overcome the surface tension, resulting in the release of a drop [15]. This mechanism forms the 
operating principle of the prilling equipment used in this work. The design is illustrated in Fig. 3. The 
equipment (PrillDrop®, Peira, Belgium) consists of a pressurized melt reservoir directly connected to 
a pneumatic nozzle system. Under a constant pressure, the melt is fed towards the nozzle which is 
equipped with a valve (controlling the melt flow) and a needle (inner diameter: 0.33 mm). The melt 
flow can be regulated by the period during which the valve remains open (i.e. drop time). The 
combination of low pressure and low melt flow finally results in the formation of droplets at the 
needle. For lab-scale experiments, these droplets are quench cooled in liquid nitrogen, yielding solid 
spherical particles of ± 2.4 mm.  
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Figure 2. (A) Droplet formation via a vibrating nozzle device and (B) Schematic setup for prilling of lipid using a 
vibrating nozzle device (both figures are obtained from [10]). 
 
 
Figure 3. Design of PrillDrop® (developed by Peira, Belgium) with 1: melt reservoir, 2: reservoir heating, 3: 
nozzle, 4: nozzle heating, 5: valve, 6: needle 
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Pharmaceutical applications of prilling 
Up until now, prilling of lipids has been barely applied and to our knowledge, only one research 
group investigated its suitability for pharmaceutical applications [8, 9]. The prilling process was 
carried out using a vibrating nozzle technology incorporated at a temperature-controlled air column. 
In a first part of their study, the impact of the prilling process on the solid state of paraffin and 
Compritol® 888 ATO (i.e. glyceryl dibehenate) was evaluated. X-ray diffraction showed that the 
individual structure and thermal properties were mainly preserved after prilling. Thermal analysis of 
a binary mixture of both compounds (50/50; w/w) revealed that the melting enthalpies were not 
proportional to the respective amounts of each ingredient, indicating interactions between the lipid 
compounds [8]. In a subsequent study, the binary mixture was used as controlled release matrix for a 
highly water soluble antiepileptic drug (i.e. mix of sodium valproate and valproic acid) [9].  
Several authors reported about the use of prilling as technique for microencapsulation via the so 
called ‘sol-gel process’. By means of a vibrating nozzle device, a laminar jet of a polymer solution is 
separated into calibrated droplets. These droplets fall into a polymer-gelling solution where they are 
solidified as beads. The technique has been successfully applied to obtain alginate beads: droplets of 
a sodium alginate solution are collected in a CaCl2 solution [14]. Due to the low solubility of the 
calcium-alginate matrix in acidic media, this technology was used to manufacture gastroresistent 
dosage forms containing non-steroidal anti-inflammatory drugs such as ketoprofen and piroxicam 
[16, 17]. Also piroxicam-loaded pectin beads and celecoxib-loaded poly(lactic-co-glycolic acid) beads 
have been developed via the sol-gel process [18, 19]. 
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2. ORAL LIPID-BASED DOSAGE FORMS: AN OVERVIEW 
Being derived from the food industry where they are used as additives, lipid excipients represent 
an emerging platform in the development of innovative drug delivery systems. Naturally occurring 
lipids have been chemically modified and fine-tuned to develop excipients suitable for 
pharmaceutical applications. A wide range of lipid excipients - including triglycerides, partial 
glycerides, oils, fatty acids, waxes and fatty alcohols - with diverse physicochemical properties has 
become available to provide solutions to multiple drug delivery challenges [20]. Lipids offer 
numerous advantages for oral drug delivery since they are low-cost, physiologically non-toxic and 
biodegradable excipients [21].  
2.1 Liquid and semi-solid dosage forms 
Lipid-based dosage forms can be divided into liquid, semi-solid and solid formulations depending 
on the physical state of the lipid at room temperature [22]. Over the last 15 years, liquid and semi-
solid lipid-based formulations - including lipid solutions and self-emulsifying drug delivery systems 
(SEDDS) - have generated increased interest as a novel approach to improve oral bioavailability of 
poorly water soluble drugs. The main mechanism responsible for enhancing bioavailability is the 
elimination of the drug solubilization step in the gastro-intestinal tract. Other mechanisms 
contributing to the improved bioavailability include increased bile secretion, protection from 
chemical and enzymatic degradation in the aqueous environment and stimulation of lymphatic 
transport which circumvents first-pass metabolism in the liver [22-25]. Lipid solutions are the 
simplest lipid-based formulations consisting of the drug solubilized in a single excipient such as 
vegetable oils or a triglyceride [25]. Examples of commercialized formulations of this type are 
Rocaltrol® (calcitriol) and Avodart® (dutasteride) [26]. SEDDS are physically stable isotropic mixtures 
of oils, surfactants, co-surfactants, co-solvents and the solubilized lipophilic drug substance. The 
presence of surfactants assists to form water-in-oil emulsions upon dilution with water and under 
gentle agitation. Depending on the size of the dispersed droplets, SEDDS can be further classified into 
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self-microemulsifying and self-nanoemulsifying drug delivery systems, SMEDDS and SNEDDS, 
respectively. When these systems enter the gastro-intestinal tract, the motility of stomach and small 
intestine provides the agitation required for emulsification [23, 24]. SEDDS are available as oral 
solution or can be filled in gelatin capsules. Many poorly water soluble drugs have been formulated 
using this approach of which cyclosporine (Neoral®) and ritonavir (Norvir®) are the best known [24, 
27]. However, liquid formulations show some limitations such as incompatibility with capsule shells, 
leakage from capsules, drug precipitation during storage and the need for specialized capsule filling 
equipment [22, 28]. To overcome these barriers, several methods have been proposed to transform 
liquid-based lipid formulations into solid dosage forms (e.g. powders, granules or pellets) via 
solidification techniques such as spray drying, physical adsorption onto solid carriers, freeze-drying, 
melt granulation and extrusion/spheronisation [28].  
2.2 Solid dosage forms 
Solid lipids have a crystalline nature and do not exhibit a glass transition temperature. Depending 
on their composition, lipid excipients exhibit versatile physicochemical properties (e.g. melting 
temperature and melting range) which makes them suitable for a broad range of processing 
techniques such as mechanical compression and thermal methods or a combination of both. These 
processing techniques have the advantage that they are solvent-free, which avoids additional drying 
steps, reduces processing costs and minimizes the environmental impact [20, 29, 30]. Lipids with a 
melting point exceeding 50°C are generally recommended in solid dosage forms to avoid softening 
during storage and to maintain the structural integrity of the matrix at body temperature in order to 
avoid dose-dumping [31]. 
The major pharmaceutical application of solid lipid excipients is linked to their ability to control 
or delay drug release kinetics. Controlled release systems deliver the drug over an extended period 
of time and are beneficial for drugs with short half-life. Compared to conventional dosage forms, 
they provide longer therapeutic action which requires less frequent dosing and improves patient 
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compliance. Moreover, the delivery of a drug in a controlled way impedes fluctuations of drug 
plasma concentration and reduces the risk of side effects [6]. Due to their hydrophobic and water 
insoluble character, lipids offer an interesting tool to create diffusion-controlled drug delivery 
systems from which the drug is gradually released. In these systems, drug release is controlled by the 
rate of penetration of the dissolution medium in the lipid matrix. Upon contact with aqueous media, 
water gradually penetrates into the matrix creating channels and pores. Subsequently, the drug 
dissolves and the dissolved drug is released via diffusion through the pore network. Delayed release 
systems aim to deliver the drug to a particular area of the gastro-intestinal tract. This site-specific 
drug delivery is desirable for drugs with narrow absorption window or for local treatment of 
inflammatory diseases in the lower part of the gastro-intestinal tract (e.g. Crohn’s disease) [6]. This 
mechanism can be achieved in particular using fatty acids since their solubility increases at higher pH 
of the dissolution medium, resulting in a faster drug release [32]. In addition to the applications of 
lipids in oral dosage forms, controlled protein delivery from lipid-based implants has been 
increasingly investigated as an alternative for the commonly used poly(lactic-co-glycolic acid)-based 
(PLGA) parenteral formulations. Although PLGA is a biocompatible and biodegradable polymer, 
problems of protein stability have been described due to the creation of an acidic micro-environment 
during polymer degradation. Hence, the inertness of lipid implants offers a promising alternative for 
delivery of protein-based drugs [33]. 
Also the taste-masking effect of lipids originates from their hydrophobic properties. Before the 
unpleasant taste of a drug can be experienced, the drug should be presented in dissolved state at the 
receptors in the taste buds on the tongue [34]. Hence, a reduced drug solubility via incorporation of 
the drug in a lipid matrix contributes to the taste-masking effect [35-37]. Another taste-improving 
effect can be achieved via a lipid coating layer which covers the drug crystals and hinders the contact 
with taste receptors in the oral cavity [34, 37].  
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The combination of their hydrophobic character and their low density makes lipids suitable for 
the design of floating dosage forms. Due to the longer gastric residence time, these systems provide 
more time for drug absorption, resulting in a higher bioavailability. As some drugs suffer from low 
bioavailability because of their narrow absorption window in the upper gastro-intestinal tract, 
floating dosage forms ensure maximum contact at the site of absorption. Moreover, site-specific 
drug delivery for local treatment in the stomach or the upper gastro-intestinal tract can be achieved 
[38].  
Finally, lipid matrices have been used to protect drugs from physical and chemical degradation. 
For instance, embedding of acetylsalicylic acid within a lipid matrix was a successful approach to 
avoid moisture-uptake during storage and to protect the drug from hydrolysis [39]. A similar 
stabilization effect was described for enalapril maleate [40]. 
Nevertheless, the use of lipids, especially triglycerides and partial glycerides, in pharmaceutical 
development of solid dosage forms is still hindered by their complex solid state behavior and 
consequently, the number of currently marketed lipid-based solid dosage forms is still limited. 
Problems of solid state transformations can arise during storage when the lipid has not been 
processed in its most thermodynamically stable polymorphic form. These transformations can alter 
matrix integrity as well as drug release properties. Process understanding in terms of controlling the 
parameters which influence the formation of unstable polymorphs, represents the main barrier to 
overcome during development of lipid-based solid dosage forms [41].  
Since a large number of potential lipid excipients with diverse composition are available, the 
following part reviews the most commonly used lipids as well as their applications in the 
development of solid lipid-based dosage forms. Subsequently, the most frequently applied 
manufacturing techniques will be discussed in relation to processing needs and pharmaceutical 
applications.  
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2.3 Excipients for solid lipid-based dosage forms 
Triglycerides 
Triglycerides (also defined as triacylglycerols) are derived from vegetable oils and represent the 
most commonly used excipients in lipid-based drug delivery (Table 1). Their molecular structure 
consists of 3 fatty acids esterified with glycerol (Fig. 4). Based on the length of their carbon chains, 
they are classified as short- (< 5), medium- (6 - 12) or long-chain triglycerides (> 12). Triglycerides are 
highly lipophilic and are therefore intensively used as controlled release agents [25, 42-44]. 
Glycerides (triglycerides as well as partial glycerides (see below)) are known to exhibit polymorphism. 
Generally, 3 polymorphs have been described: the least thermodynamically stable α form, the 
metastable β’ form and the most stable β form exhibiting the densest packing mode. All polymorphic 
forms are identified by a different melting point [45-47]. Frequently used triglycerides are glyceryl 
trimyristate (Dynasan® 114), glyceryl tripalmitate (Dynasan® 116) and glyceryl tristearate (Dynasan® 
118). 
 
Figure 4. Chemical structure of glyceryl trimyristate (Dynasan® 114) 
 
Partial glycerides 
Partial glycerides, generally known as monoglycerides or diglycerides, are formed via a 
transesterification of triglycerides with glycerol. Other preparation methods include direct 
esterification of glycerol with selected fatty acids and interesterification which redistributes the 
position of the fatty acids on the hydroxyl groups of glycerol. Partial glycerides exhibit diverse 
physical properties, melting points and HLB-values depending on the nature of the constituting fatty 
acids and the degree of esterification with glycerol. Their applications in lipid-based drug delivery are 
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therefore correlated with these characteristics: partial glycerides with low melting point and high 
degree of unsaturation are often used in the field of bioavailability enhancement, while those with 
high melting point consisting of long chain fatty acids find applications as matrices for sustained drug 
delivery [42]. Commonly used examples of the latter group are glyceryl dibehenate (Compritol® ATO 
888), glyceryl palmitostearate (Precirol® ATO 5) and glyceryl monostearate (Imwitor® 491).  
Fatty acids 
Fatty acids are monocarboxylic acids of saturated or unsaturated aliphatic hydrocarbons (Fig. 5). 
Their melting point increases in proportion to the hydrocarbon chain length and decreases with 
increasing degree of unsaturation [43]. Even-numbered fatty acids can crystallize in at least 4 
polymorphic forms: A, B, C and E. Form C is thermodynamically stable and only this form can be 
obtained from the melt [48]. Fatty acids have been applied as lubricant during tablet compression 
[49], as binder during melt granulation [50, 51], as controlled release agent [52, 53], as enteric 
coating [54], as plasticizer [55, 56] and as stabilizer for moisture-sensitive drugs [40]. Myristic acid 
(C14), palmitic acid (C16), stearic acid (C18) and behenic acid (C22) represent the most commonly 
used fatty acids in solid dosage forms [20].   
 
Figure 5. Chemical structure of stearic acid 
 
Fatty alcohols 
Fatty alcohols, also termed long-chain alcohols, are a mixture of aliphatic alcohols with as 
general formula CH3(CH2)nOH [57]. Generally known examples are cetylalcohol (C16H34O) and 
stearylalcohol (C18H38O), which are also available as a mixture: cetostearylalcohol. Fatty alcohols are 
mainly used as meltable binder [31] and as controlled release agents [58].  
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Hydrogenated vegetable oils 
Hydrogenated vegetable oils are mixtures of triglycerides, fatty acids and phospholipids, having 
a melting point between 60 and 80°C [20]. Examples are hydrogenated soybean oil (Sterotex® HM) 
and hydrogenated castor oil (Cutina® HR). They find applications as controlled release agents [59] 
and as binders during melt granulation [31]. 
Waxes 
Waxes are complex mixtures containing esters of fatty acids and long-chain alcohols. Examples 
are carnauba wax and beeswax [60]. Microcrystalline wax (Lunacera®) is a mixture of straight-chain 
and branched-chain hydrocarbons obtained from petroleum [57]. They are mainly used as controlled 
release excipient [61, 62] and as coating agent in hot-melt coating processes [60]. 
Polyoxylglycerides 
Polyoxylglycerides (or macrogolglycerides) represent a group of inert, semi-solid waxy 
amphiphilic excipients consisting of a mix of mono-, di- and triglycerides with mono- and di-fatty acid 
esters of polyethylene glycol (Fig. 6) [63]. They have been commercialized as Gelucire® (e.g. 
Gelucire® 44/14, Gelucire® 43/01 and Gelucire® 50/13) and are identified by 2 numbers: the first 
corresponding to the melting point and the second to the hydrophilic-lipophilic balance (HLB, varying 
from 1-18) [64]. Gelucires with low HLB-value can be applied as matrix for sustained drug delivery 
[65, 66], while Gelucires® with high HLB-value are typically used as dissolution enhancer in solid 
dispersions [67, 68]. Due to their surfactant properties, they find many applications as emulsifier in 
SEDDS and SMEDDS [24, 25, 28, 44, 63]. Furthermore, they served as binder in melt granulation [63, 
66] and as excipients to design floating dosage forms [65, 66]. 
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Figure 6. Chemical structure of polyethylene glycol/fatty acid monoesters (A) and diesters (B); R: carbon chain 
of fatty acid.  
 
 
 
 
  
 
Table 1. Overview of most commonly used lipid excipients in solid dosage forms. 
 Composition Examples Melting point (°C) Reference 
Triglycerides Triglycerides Glyceryl trimyristate (Dynasan® 114) 
Glyceryl tripalmitate (Dynasan® 116) 
Glyceryl tristearate (Dynasan® 118) 
Hard fat (Witocan® 42/44) 
55-58 
63 
71 
42-44 
[21] 
[69] 
[45] 
[70] 
Partial glycerides Mono- and diglycerides Glyceryl monostearate (Imwitor® 491) 
Glyceryl palmitostearate (Precirol® ATO 5) 
Glyceryl dibehenate (Compritol® 888 ATO) 
77-83 
53-57 
69-74 
[29, 71] 
[21] 
[72] 
Fatty acids Even-numbered long-chain fatty acids Myristic acid 
Palmitic acid 
Stearic acid 
Behenic acid 
53-59 
63-64 
68-73 
75-82 
[53] 
[57] 
[52] 
[52] 
Fatty alcohols Mixtures of aliphatic alcohols Cetostearylalcohol 
Stearylalcohol 
Cetylalcohol 
47-59 
54 
46-52 
[58] 
[62] 
[57] 
Hydrogenated vegetable oils Mixtures of triglycerides, fatty acids 
and phospholipids 
Hydrogenated soybean oil (Sterotex®HM, Dynasan® 120) 
Hydrogenated castor oil (Cutina® HR) 
59-68 
80-88 
[59] 
[72] 
Waxes Esters of fatty acids and long-chain 
alcohols 
Carnauba wax 
Beeswax 
Microcrystalline wax (Lunacera®) 
82-85 
61-66 
52-74 
[72] 
[57] 
[57] 
Polyoxylglycerides Mixtures of mono-, di- and 
triglycerides with mono- and di-fatty 
acid esters of polyethyleneglycol 
Lauroyl polyoxyl-32 glycerides (Gelucire® 44/14) 
Stearoyl polyoxyl-32 glycerides (Gelucire® 50/13) 
Stearoyl polyoxyl-32 glycerides (Gelucire® 53/10) 
30-46 
37-51 
50-63 
[73] 
[68] 
[74] 
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2.3 Processing techniques for solid lipid-based dosage forms 
Direct compression 
Direct compression represents the most popular method for manufacturing matrix-based solid 
dosage forms. Over the last decade, there has been growing interest in direct compression of lipids 
to create hydrophobic matrix tablets. In this case, the drug is blended with lipid excipient, diluents 
and lubricants followed by a single compression step. The amount of lipid excipient usually ranges 
between 10 and 50% [20]. While glyceryl dibehenate has been originally used as lubricant during 
tableting, several authors reported its potential in the formulation of lipophilic matrix tablets for 
sustained drug release [75]. Roberts et al. (2012) showed that sustained release of theophylline from 
12 mm diameter tablets could be achieved over a 12h period using an amount of 15% glyceryl 
dibehenate. However, this amount was not sufficient when formulating mini-tablets of 2, 3 and 
4 mm diameter, attributed to shorter drug diffusion pathways in mini-tablets, and the amount of 
glyceryl dibehenate was raised to 45% [75]. The efficiency of different lipid matrices in controlling 
drug release - i.e. glyceryl monostearate, glyceryl palmitostearate, cetostearylalcohol and glyceryl 
dibehenate - was compared to the hydrophobic polymer Eudragit® RS PO by Singh et al. (2009). All 
tablet formulations yielded acceptable tablet properties including friability, hardness and tensile 
strength. However, at a hydrophobic content of 50%, tablets containing Eudragit® RS PO showed a 
significant higher hardness due to a higher degree of plastic deformation of the polymer during 
compression. Glyceryl dibehenate represented the best sustained-release agent, followed by glyceryl 
monostearate, Eudragit® RS PO, cetostearylalcohol and glyceryl palmitostearate [76]. Kreye et al. 
(2011) developed cylindrical lipid implants (diameter: 2 mm, height: 2 mm) based on the model drugs 
theophylline and propranolol hydrochloride and different lipid matrix formers (glyceryl tristearate, 
glyceryl tripalmitate, glyceryl trimyristate, glyceryl palmitostearate, hydrogenated cottonseed oil and 
hydrogenated soybean oil). Depending on the matrix former, a broad range of release periods 
(ranging from one day to several months) could be achieved. Using glyceryl tristearate and an initial 
drug load of 10% (w/w), the release rate could be controlled over a period of 1 month in the case of 
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propranolol hydrochloride, while less than 50% of the total theophylline amount was released after 
100 days. The slow drug release from theophylline matrices was related to insufficient water 
penetration to dissolve all drug crystals. In contrast, glyceryl palmitostearate induced a very fast 
release (<1 day in case of propranolol hydrochloride) linked to a high water uptake and subsequent 
matrix swelling. By means of mathematical modeling, diffusion was identified as the dominant mass 
transport mechanism in systems where the degree of water influx was sufficient to dissolve all drug 
particles [33]. To further prolong the release from lipid-based tablets, additional thermal treatments 
(called sintering) whereby the tablets are stored above the melting point of the lipid, have been 
applied. The slower drug release of sintered tablets was attributed to melting and redistribution of 
the lipid, forming a matrix surface with lower porosity and wettability [77]. However, Jannin et al. 
(2015) showed that post-compression thermal treatment could induce polymorphism of glyceryl 
dibehenate [78].  
Although direct compression of lipids offers a promising method for one-step production of 
sustained-release tablets, the amount of hydrophobic material in powder blends is limited as 
extreme punch sticking has been noticed at levels above 50% [79]. In addition, multiple studies 
indicated that compression of a milled solid dispersion of drug and lipid (prepared via the fusion 
method) was more effective to sustain drug release compared to direct compression of the 
corresponding physical mixture [80, 81].  
Spray-congealing 
Spray-congealing, also termed spray-chilling or spray-cooling, consists of the atomization of a 
liquid mixture (i.e. a dispersion or solution of the API in a molten lipid) into a cooling chamber at a 
temperature below the melting point of the lipid carrier. The contact of the molten carrier with the 
cold air flow causes the droplets to solidify, yielding solid microparticles commonly ranging between 
50 and 500 µm [31, 82]. Scanning electron microscopy images of microparticles containing 20% 
metoprolol tartrate and 80% stearic acid are illustrated in Fig. 7. The process is similar to spray-drying 
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with the exception of the energy flow: while during spray-drying energy is applied to the droplets to 
evaporate the solvent, during spray-congealing energy is removed from the droplets, forcing the melt 
to solidify. The same equipment can be used as for spray-drying, however some modifications are 
required: atomizing air, feeding tubes and nozzle should be heated to prevent crystallization of the 
lipid, and the spray cylinder should be sufficiently cooled. The performance of the spray-congealing 
process mainly depends on the atomization efficiency. Atomization can be obtained via 4 types of 
devices: disk or rotary devices, pressure nozzles, two-fluid nozzles and ultrasonic atomizers, of which 
the two-fluid nozzles are most commonly used [82, 83]. Passerini et al. (2009) showed that the 
application of different nozzles had a significant impact on particle morphology, encapsulation 
efficiency and drug release behavior [84]. 
 
Figure 7. Scanning electron microscopy images of spray-congealed microparticles containing 20% metoprolol 
tartrate and 80% stearic acid. 
 
Except for the atomization step resulting in a smaller particle size, spray-congealing uses the 
same operating principle as prilling, hence similar process limitations are encountered. Processing at 
10 - 30°C above the melting point of the lipid carrier involves the risk of thermal degradation and 
processability issues arise during production of mixtures with high drug load. Moreover, the 
atomization of highly viscous mixtures frequently results in the formation of aggregated particles 
with a broad particle size distribution [31]. 
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Spray-congealing has been used to enhance the dissolution rate of diclofenac [67], 
carbamazepine [85] and praziquantel [86] as well as to sustain the release of verapamil 
hydrochloride [62] and theophylline [87]. Spray-chilled stearic acid microspheres containing 
cefuroxime acetil were developed by Robson et al. (2000) to mask the bitter taste of the antibiotic. 
These microspheres have been commercialized as pediatric suspension (Zinnat®) which requires 
reconstitution prior to administration. Moreover, the pH-dependent drug release illustrated the 
potential of stearic acid-based microspheres for delayed drug release in the lower gastro-intestinal 
tract [32]. Furthermore, Gelucire® 53/10 was successfully combined with mucoadhesive polymers 
(i.e. chitosan, sodium carboxymethylcellulose and poloxamers) to develop mucoadhesive 
microparticles for the vaginal delivery of econazole nitrate [74]. Besides the processing of small drug 
molecules, Maschke et al. (2006) developed a spray-congealing method for the preparation of 
controlled release insulin-loaded microparticles based on glyceryl tripalmitate. Lipid microparticles 
could be processed without loss of insulin content and protein stability was not affected by thermal 
processing. In addition, these lipid microparticles exhibited great potential for long term release as 
insulin was released over a period of 28 days [88].  
Solid lipid extrusion  
During extrusion of pharmaceutical dosage forms, a blend of a drug, thermoplastic polymers and 
other additives is heated in the extruder under controlled conditions and forced through a die [89, 
90]. The technique offers several advantages over conventional pharmaceutical production methods: 
the process is continuous and solvent-free, the material residence time is short and due to intense 
mixing the final product has excellent content uniformity [90, 91]. Twin-screw extruders consist of 2 
rotating screws transporting the material towards the die. Compared to single-screw extruders, they 
provide higher kneading and dispersing capacities, less risk of over-heating and shorter transit times 
[91]. The screws can rotate either in the same (co-rotating) or in the opposite (counter-rotating) 
direction. Fully intermeshing co-rotating screws are the most popular in pharmaceutical industry as 
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they allow intensive mixing. The self-wiping design ensures near complete emptying of the extruder 
barrel, thereby minimizing product wastage at the end of the process. Furthermore, non-motion and 
overheating of the material inside the barrel are limited. As most extruders have a modular screw 
design, a specific screw configuration can be selected to meet particular requirements such as high 
and low shear [89, 91, 92].  
Recently, twin-screw extrusion of lipids was introduced by Reitz et al. (2007). They proposed a 
new approach called ‘solid lipid extrusion’ in which lipids are extruded below their melting point in 
order to avoid complete melting of the lipid mass. By means of a thermo-mechanical treatment at 
moderate pressure and temperature, the lipid mass is sufficiently softened to mould it through the 
extrusion die. As the formulation only partially melts, a solid matrix is formed via the combined 
action of thermal effects and mechanical compression during screw extrusion [21]. The low process 
temperature favors the processing of thermosensitive compounds. In contrast to several polymers, 
lipids can be extruded without the addition of a plasticizer and the lubricating effect of lipids enables 
the processing of mixtures with a high drug load [20]. Solid lipid extrusion using glycerides has been 
applied to develop sustained release dosage forms [21] as well as immediate release pellets [70] and 
for taste-masking [35, 36]. In addition, triglycerides were successfully combined with release 
modifiers including polyethylene glycol of different molecular weights (1500 – 7 000 000), 
hydrocolloids, pore formers and desintegrants [41, 93, 94].  
As glycerides are known to exhibit complex solid state behavior, Reitz et al. (2007) compared the 
effect of solid lipid extrusion on the solid state of two lipids: Dynasan® 114 (glyceryl trimyristate) and 
Precirol® ATO 5 (glyceryl palmitostearate). They showed that softening of the lipids during extrusion, 
instead of thoroughly melting, did not induce the formation of the low-melting, metastable α 
polymorph. Dynasan® 114 matrices showed a stable drug release during storage, whereas drug 
release from Precirol® ATO 5 matrices was not straightforward which was mainly attributed to its 
heterogeneous composition (i.e. mixture of mono-, di- and triglycerides of C16 and C18 fatty acids 
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[57]), thereby leading to complex aging processes [21]. A study performed by Windbergs et al. (2009) 
illustrated that the die temperature must be higher than the melting point of the unstable α-form to 
avoid the formation of this polymorph: extrusion of tristearin at 55°C partially formed the α-form, 
whereas extrusion at 65°C exclusively generated the stable β-form. This effect was attributed to 
frictional forces causing partial melting of the lipid mass. Consequently, the temperature of the 
extrusion die determines the final crystal structure: at a temperature exceeding the melting point of 
the unstable α-form, the lipid mass will irreversibly crystallize into the stable β-form [45]. However, a 
follow-up study performed by the same research group indicated that the combination of tristearin 
with a partial glyceride (i.e. glyceryl monostearate) yielded more of the unstable α-form, even during 
extrusion at 65°C [29]. In summary, these studies demonstrated that the chemical composition of 
glycerides is a key factor for the solid-state characteristics of extruded matrices and that a thorough 
understanding of their polymorphic behavior is essential during the development of solid lipid 
dosage forms.   
Spheronization of lipid extrudates has been performed to obtain spherically shaped pellets 
(± 1.5 mm diameter) with narrow size distribution [70, 95]. The process can be carried out in a 
conventional spheronizer equipped with heating jacket and requires lipid excipients which show 
sufficient brittleness at room temperature to allow breakage of the cylindrical extrudates. Moreover, 
a certain degree of thermal plasticity is required for softening and rounding of the pellets. The 
process has significant drawbacks since the efficiency of the spheronization process is formulation- 
and temperature dependent. Material temperature is difficult to control as it is determined by the 
jacket temperature as well as by interparticular friction and shear forces which are formulation-
dependent. In addition, the operating temperature window is very narrow: it should be high enough 
to allow softening of the lipid, but also low enough to avoid melting of the lipid and subsequent 
agglomeration of the pellets [95]. Either controlled release [95] and immediate release [70] pellets 
have been prepared via extrusion/spheronization of lipid formulations.  
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Melt granulation/melt pelletization 
Melt granulation is an agglomeration technique in which granules are obtained by means of a 
softened or molten binder. The technique operates near or above the melting point of the binder 
which acts as granulation fluid to establish liquid bridges between the particles. During cooling to 
room temperature the binder solidifies, yielding a solid end product. Compared to conventional wet 
granulation, the drying step is eliminated as a molten binder liquid is used, thus reducing the number 
of processing steps and limiting energy consumption [31, 96, 97]. The type of binder determines the 
drug release kinetics of the granules. Hydrophilic binders (i.e. PEG [96]) are used for immediate 
release granules as they quickly disintegrate or dissolve in aqueous media. Controlled release 
granules are prepared using lipophilic binders (i.e. fatty acids [50, 51], waxes [61], castor oil [98], 
glycerides [97, 98]) as their matrix integrity is retained upon contact with water. Melt granules 
commonly exhibit a higher density compared to wet granules, as the binder liquid is not removed 
from the end product [31]. 
Melt granulation processes have been most frequently performed using a high-shear mixer 
equipped with a heated jacket, whereby granules are obtained in a short, single-step, ‘one-pot’ 
process. The solid binder can be either pre-blended with the other compounds before the 
temperature of the heating jacket is raised (melt-in method), or it can be heated in a separate 
reservoir and then sprayed in molten state onto the powder bed in the granulator [20, 31]. Several 
studies identified the binder concentration as a key parameter to control granule growth [98, 99]. In 
addition, the material temperature must be carefully controlled as it could result in ‘over-wetting’ 
upon complete melting of the binder [97]. Since melt granulation allows processing of mixtures with 
high drug load, Eckert et al. (2014) applied this technique for the development of an immediate 
release pediatric dosage form containing a high dose of sodium benzoate and hard fat (Witocan® 
42/44) as meltable binder. In addition, this study identified that melt granules had improved powder 
flowability, making them suitable for tableting [37]. Furthermore, several studies identified high-
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shear melt granulation using lipids as a method to achieve sustained release dosage forms with drug 
loads up to 60% [50, 51, 97]. Low-melting lipids are generally preferred since they exhibit broad 
melting ranges, however these lipids are less beneficial to create sustained release matrices. To 
circumvent this effect, Hamdani et al. (2002) combined 2 lipids with distinct melting properties (i.e. 
glyceryl palmitostearate and glyceryl dibehenate having a low and high melting range, respectively). 
The granulation process was performed at a temperature (i.e. 50°C) which induced sufficient 
softening of the lower melting lipid, while the higher melting lipid maintained its solid state and 
served as additional matrix excipient for controlled drug release [20, 97]. Additionally, melt 
granulation has been used to develop floating dosage forms [100].  
A major drawback of high-shear granulation involves the batch-wise production method. 
Difficulties in scale-up can arise since the granulator type and bowl dimensions are key factors 
influencing the production process and granule characteristics [96]. In order to avoid these scale-up 
issues, continuous twin-screw granulation has generated substantial interest. The process can be 
performed using a twin-screw extruder via modification of the screw configuration and removal of 
the die block [101]. Up until now, most studies evaluating twin-screw granulation used polyethylene 
glycol as meltable binders. To our knowledge, twin-screw granulation by means of lipid binders has 
not been reported so far.  
Hot-melt coating 
Polymeric coating of tablets, capsules and pellets has been intensively applied to improve drug 
stability (i.e. prevention of physical and chemical degradation) as well as for coloring, taste-masking 
and modification of drug release. However, as the process involves dissolution or suspension of the 
polymer in water, organic solvent or a mixture of both, additional processing steps are required to 
remove these solvent residues. The process of hot-melt coating overcomes these problems via the 
use of a molten substance (hydrophilic or lipophilic) as coating liquid. In case of lipid coatings, 
glycerides, fatty acids, waxes and polyoxylglycerides have been commonly used as agents for 
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sustained drug release. Although the technique represents many advantages, it has received limited 
attention in pharmaceutical development [102, 103]. 
Conventional coating equipment such as fluid bed systems can be employed, however some 
modifications such as heating of feeding tubes, nozzle and atomization air are required. Top-spray 
coating systems are preferred as they can operate at the highest material temperature which is 
ideally set close to the solidification temperature of the coating liquid. The powder bed temperature 
is a critical parameter influencing coating efficiency and is controlled via regulation of the fluidization 
air temperature. If this temperature is set too low, the coating droplets tend to cool down quickly 
when they enter the fluidized bed which increases their melt viscosity. Hence, the droplets can 
insufficiently spread on the substrate particles. On the other hand, too high temperatures will cause 
particle agglomeration. Additionally, the temperature of the coating liquid and the atomization air as 
well as droplet size have to be adjusted as function of coating efficiency [60, 104].  
Hot-melt coating requires materials with low melt viscosity and sharp melting transitions. Chen 
et al. (2010) evaluated the suitability of 5 lipids for the hot-melt coating process: stearic acid, glyceryl 
monostearate, Compritol®, carnauba wax and beeswax. As stearic acid showed the lowest melt 
viscosity, it was selected as hydrophobic coating agent. To tailor drug release from the pellets, PEG 
was added as hydrophilic compound in different ratios. PEG 6000 was selected among other PEG 
molecular weights as it has a similar melting range compared to stearic acid. Moisture analysis 
showed that stearic acid coatings as well as mixed PEG/stearic acid coatings were efficient to protect 
hygroscopic drugs from moisture sorption [102].  
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3. A VIEW TO THE FUTURE 
Nowadays, the implementation of innovative pharmaceutical production processes suffers from 
competition of low-cost generic drug manufacturing, reduction of health care budgets and increased 
development time of new active pharmaceutical ingredients. Hence, today’s biggest challenge in 
pharmaceutical industry is the implementation of highly efficient, flexible and cost-effective 
technologies. To overcome these barriers, continuous manufacturing of pharmaceuticals represents 
an emerging platform since production time and costs can be tremendously reduced [105].  
Prilling of lipid formulations offers a promising tool because of its ease of processing: via a single-
step solvent-free process, narrow-sized spherical particles are produced in a continuous way. In 
contrast to other manufacturing techniques such as extrusion and granulation, which often require 
further downstream processing or compression steps, the particles obtained via prilling exhibit 
excellent flow properties and can be immediately filled in capsules or sachets. Taking into account 
the influence of particle size on drug release, the ability of vibrating nozzle devices to vary droplet 
size improves the flexibility of the prilling technique.  
Restrictions of the prilling process are associated with the thermal processing as well as the 
processability issues of mixtures with high drug load. The latter also raises concerns about the 
processability of suspensions and about the content uniformity in these formulations. However, the 
main barrier for the implementation of the prilling process involves the solidification of the lipid 
droplets in high prilling towers. Since tower height is strongly related to the desired particle size, a 
particle size exceeding 2 mm is not feasible. In addition, the investment of these prilling towers as 
well as their high maintenance costs must be considered. There is also stringent need to evaluate the 
influence of formulation composition on final particle properties to allow full understanding of the 
solidification mechanism. Minor changes of the composition can affect physical properties such as 
viscosity, surface tension and density.  
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Also the use of lipid excipients is an important factor while considering the implementation of 
prilling. A broad range of lipids with varying physicochemical properties (i.e. melting range, HLB 
value) has been fine-tuned for pharmaceutical applications which allows formulation scientists to 
overcome specific challenges in terms of drug product processability or drug release kinetics [20]. 
Furthermore, the use of lipid excipients reduces processing costs and avoids safety issues [21]. 
Although lipids represent promising alternative excipients for conventional polymers, their use in 
pharmaceutical development is up to now rather limited as reflected by the limited number of 
marketed lipid-based formulations. This phenomenon is mainly attributed to their complex solid 
state behavior which has been associated with changes of drug release kinetics during storage. 
However, as most studies evaluating their suitability as pharmaceutical excipients were performed 
on triglycerides and partial glycerides, additional research concerning the stability of other lipid 
excipient classes such as fatty acids is highly recommended. This type of lipids offers an encouraging 
future for the development of lipid-based matrices as they exhibit some particular advantages. 
Compared to glycerides, fatty acids are less susceptible to polymorphism when they are crystallized 
from the melt: only one polymorph (i.e. the thermodynamically stable C-form) can be formed upon 
cooling and thus, solid state transformations during storage are avoided. In addition, while most 
glycerides are available as heterogeneous mixtures of mono-, di- and triglycerides, the production 
process of fatty acids yields an end product with a higher purity resulting in a better control during 
further pharmaceutical processing. A higher purity also results in sharper melting transitions which is 
a key parameter for efficient cooling during the prilling process. Furthermore, as their hydrophobic 
character increases with the aliphatic chain length, drug release from fatty acid-based matrices can 
be tailored via selection of the appropriate chain-length.  
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INTRODUCTION 
The need for alternative excipients that allow for the continuous production of solid dispersions 
to improve the dissolution of poorly water soluble drugs or to create sustained release dosage forms 
has been reported by different authors [1-4]. The application of oral sustained release formulations 
has improved patient compliance due to a lower dosing frequency and a reduced incidence of 
adverse side effects [5]. Moreover, the production of sustained release multiparticulate dosage 
forms is advantageous since their transport in the gastro-intestinal tract is independent of gastric 
emptying and they exhibit a reduced risk of dose accumulation and local irritation when compared to 
single-unit dosage forms [6]. 
Lipid-based excipients such as triglycerides and fatty acids have been used for the development 
of solid dosage forms as matrices for controlled drug release [7-10], as taste-masking agents [11], to 
enhance drug solubility [12-14] and for the manufacturing of floating dosage forms [15, 16]. 
Compared to polymers [17], triglycerides exhibit several advantages, including low cost, non-toxicity 
and biodegradability. Nevertheless, their physical instability during storage (reflected in changes in 
the melting enthalpy and melting range which modify drug release [10]), remains the main barrier to 
overcome when applying these excipients for drug formulation [7, 18].  
While lipid-based solid dosage forms have been processed using techniques such as solid lipid 
extrusion [19], extrusion/spheronisation [20], melt granulation [21], melt pelletization [7, 9] and 
spray-congealing [13], prilling has received limited attention in the pharmaceutical industry as a 
technique to efficiently incorporate drugs in a multiparticulate lipid-based solid dosage form. The 
prilling process consists of pumping a mixture of drug and lipid through calibrated nozzles, creating a 
liquid jet. By applying vibrational energy, the liquid jet breaks up into droplets which are then cooled 
by falling through a temperature-controlled prilling tower [22]. This technique offers the advantage 
of obtaining in a continuous fashion spherically shaped particles with a narrow particle size 
distribution. Having excellent flow properties, the particles can be easily filled into gelatin capsules 
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[23], creating a multiparticulate formulation. Additionally, no solvent is involved, resulting in a 
shorter and environmentally friendly pharmaceutical process. However, the major disadvantage of 
the prilling process is the need of a high prilling tower, linked to higher costs and difficulties in 
operation and maintenance [24]. 
The aim of this study was to evaluate the use of prilling for the manufacturing of multiparticulate 
dosage forms using fatty acids as potential matrix formers to control the release of highly water 
soluble drugs. For this purpose, stearic acid (SA) and behenic acid (BA), C18 and C22 fatty acids, 
respectively, were combined with metoprolol tartrate (MPT) as model drug and the in vitro 
performance was assessed. The solid state of the formulations, termed ‘prills’ further on in this 
study, was characterized using modulated differential scanning calorimetry (MDSC), X-ray diffraction 
(XRD), Raman spectroscopy, Raman microscopic mapping and attenuated total reflection Fourier-
transform (ATR FT-IR) spectroscopy. Furthermore, the physical stability of the prills during 6 months 
storage at 25 and 40 °C was monitored. Finally, the bioavailability of the different formulations was 
evaluated after oral administration to dogs and compared to a commercial sustained release 
formulation.  
MATERIALS AND METHODS 
Materials 
Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain) was selected as a model drug 
(Fig. 1). Behenic acid (Radiacid 0560) was purchased from Oleon (Ertvelde, Belgium) and had a C22 
purity of 89%. Stearic acid, with a C18 purity of 98.7%, was purchased from Mosselman (Ghlin, 
Belgium). All other chemicals were of analytical grade. 
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Figure 1. Chemical structure of metoprolol tartrate 
 
Prilling 
Prilling was carried out using the Prilldrop® device developed by Peira (Turnhout, Belgium). After 
melting the fatty acid and heating the melt to 90 °C (stearic acid) or 100 °C (behenic acid), MPT was 
added to the melt under stirring. Droplet formation was started after complete dissolution of the 
drug in the molten matrix. By applying air pressure, the mixture was fed towards the thermostated 
nozzle (90 °C) equipped with a valve and a needle (inner diameter: 0.33 mm). To manufacture solid 
particles containing 10% MPT using behenic acid as matrix former, a drop time (i.e. period during 
which the valve is open) of 0.04 s and an air pressure of 0.5 bar were applied, whereas the drop time 
and air pressure were set at 0.07 s and 0.5 bar for the 20% MPT and 30% MPT formulations. When 
the drug load was increased to 40%, a drop time of 0.07 s and a pressure of 1 bar were used. A drop 
time of 0.04 s and an air pressure of 0.5 bar were needed for all MPT/stearic acid combinations. 
Droplets formed at the needle were quench cooled in liquid nitrogen in order to obtain solid 
spherical particles. 
Particle size and shape 
The particle size and shape were determined using an image analysis system. Photomicrographs 
of the prills were taken with a digital camera (Camedia® C-3030 Zoom, Olympus, Tokyo, Japan), 
linked with a stereomicroscope system (SZX9 DF PL 1.5x, Olympus, Tokyo, Japan). A cold light source 
(Highlight 2100, Olympus, Germany) and a ring light guide (LG-R66, Olympus, Germany) were used to 
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obtain top illumination of the prills against a dark surface. The images were analyzed by an image 
analysis software (AnalySIS®, Soft Imaging System, Münster, Germany). At least 30 particles were 
analyzed from each batch. Each individual particle was characterized by the mean Feret’s diameter 
(FD) (average of 180 calliper measurements with an angle of rotation of 1°). An average value for all 
prills has been calculated as the mean particle size (mean FD). To evaluate sphericity, particles were 
characterized by the aspect ratio (AR) (ratio of the longest Feret’s diameter and its longest 
perpendicular diameter).  
In vitro drug release 
In vitro drug release was measured using USP dissolution apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system coupled with a VK 8000 automatic sampling station 
(Vankel, New Jersey, USA). An amount of prills corresponding to 30 mg MPT was inserted into the 
baskets. The basket rotational speed was set at 100 rpm and the temperature of the dissolution 
medium was maintained at 37 ± 0.5 °C. Samples of 5 ml were withdrawn after 0.5, 1, 2, 4, 6, 8, 12, 
16, 20 and 24 h and analyzed spectrophotometrically at 222 nm using a double beam 
spectrophotometer (UV-1650PC, Shimadzu, Antwerp, Belgium). MPT concentrations were calculated 
from a calibration curve between 0 and 33 µg/ml. Demineralized water, 0.1N HCl (pH 1) and a 
phosphate buffer (USP, pH 7.4) were used as dissolution media. The influence of the ionic strength µ 
on MPT release was studied in diluted phosphate buffer with µ = 0.0089 (10-fold dilution), µ = 0.018 
(5-fold dilution) and µ = 0.045 (2-fold dilution), phosphate buffer (µ = 0.089), phosphate buffer with 
increasing NaCl concentrations (µ = 0.14 and µ = 0.20), 0.1N HCl and 0.1N HCl with µ = 0.20. Each 
experiment was performed in triplicate. The similarity between dissolution profiles was evaluated 
using the similarity factor f2, according to Shah et al. (1998), and was calculated using the following 
equation (Eq. 1): 
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where Rt and Tt represent the cumulative drug release at each sample point of the reference and the 
test sample with n equal to the number of sample points. As f2 is sensitive to the number of sample 
points leading to bias, only one sample point exceeding a drug release of 85% was considered in the 
calculation. f2 values higher than 50 indicate similarity between 2 dissolution profiles based on an 
average difference of less than 10%, while f2 values below 50 represent significant differences [25].  
Modulated differential scanning calorimetry 
The thermal behavior of the pure compounds (MPT, stearic acid and behenic acid), the physical 
mixtures and the corresponding formulations was evaluated using a differential scanning calorimeter 
Q2000 (TA Instruments, Zellik, Belgium) equipped with a refrigerated cooling system. The DSC was 
calibrated for temperature and enthalpy using an indium standard. Tzero calibration was performed 
in 2 steps; baseline calibration (without samples or pans) and sapphire calibration (using large 
sapphire disks on both the sample and reference positions). Small sapphire disks, placed in a Tzero 
pan, were used for the heat capacity (MDSC) calibration. Samples (± 5 mg) were run in Tzero pans 
(TA Instruments, Zellik, Belgium) with an underlying heating rate of 2 °C/min. The modulation period 
and amplitude were set at 60 s and 0.318 °C, respectively (heat-iso method). Dry nitrogen was used 
as a purge gas through the DSC cell at a flow rate of 50 ml/min. MDSC data were analyzed using the 
Universal Analysis software (TA Instruments). Melting enthalpies were determined in the total heat 
flow signal. Melting temperatures were reported as onset temperatures. 
X-ray diffraction 
Crystallinity was analyzed using X-ray diffraction on the pure compounds, the physical mixtures 
and the corresponding formulations. X-ray diffraction was performed with a D5000 Cu Kα diffractor 
(λ = 1.54 Å) (Siemens, Karlsruhe, Germany) with a voltage of 40 mV in the angular range of 10° < 2θ < 
60° using a step scan mode (step size = 0.02°, counting time = 1s/step). 
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ATR FT-IR analysis 
 Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was performed 
on the pure substances, physical mixtures and prills to identify the interactions that were formed 
between MPT and the fatty acids during prilling. Spectra were recorded using a Bruker Vertex 70 
FT-IR spectrometer equipped with a Hyperion FT-IR microscope and MCT detector. A Ge ATR crystal 
was pressed against the prills in order to obtain the ATR FT-IR spectra (4 cm-1 resolution, 50 scans). 
Raman spectroscopy 
Raman spectra were collected with a Raman Rxn1 spectrometer (Kaiser Optical Systems, Ann 
Arbor, MI, USA), equipped with an air-cooled CCD detector. The laser wavelength was the 785 nm 
line from a 785 nm Invictus NIR diode laser. All spectra were recorded over the 0 – 1800 cm-1 range 
with a resolution of 4 cm-1 and an exposure time of 5 s, using a laser power of 400 mW. Data 
collection and data transfer were automated using the HoloGRAMSTM data collection software, the 
HoloREACTTM reaction analysis and profiling software and the Matlab software (version 7.1, The 
MathWorks Inc., Natick, MA). Data analysis was performed using SIMCA P+ (Version 12.0.1.0, 
Umetrics, Umeå, Sweden). All spectra were SNV-preprocessed. Raman spectroscopy was performed 
on the pure compounds, the physical mixtures and the corresponding formulations. 
The solid state distribution of MPT in the prills was evaluated by Raman microscopic mapping 
using a Raman Rxn1 Microprobe. Cross sections of prills were scanned by a 10x long working distance 
objective lens (spot size 50 µm) in area mapping mode using an exposure time of 4 s and a step size 
of 50 µm in both the x and y directions (= 234 spectra per mapping). The resulting images provide 
information about the distribution of the solid state of MPT in the prills.  
Storage 
The formulation containing 30% MPT and 70% behenic acid was selected for a stability study. 
Immediately after prilling, the formulation was filled in hermetically sealed bags under controlled 
circumstances (35% RH) and stored at 25 °C and 40 °C. To investigate the influence of storage on 
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solid state and drug release, the prills were studied immediately after manufacturing, after 1 week, 1 
month, 3 months and 6 months storage. The solid state properties were analyzed using MDSC, XRD, 
Raman spectroscopy and Raman microscopic mapping. 
In vivo evaluation 
All procedures were performed in accordance with the guidelines and after approval by the 
Ethics Committee of the Institute for Agricultural and Fisheries Research (ILVO) (Merelbeke, 
Belgium). To study the influence of MPT concentration, the following formulations were 
administered to 6 dogs:  
- Formulation 1 (F1): prills containing 30% MPT and 70% behenic acid          
- Formulation 2 (F2): prills containing 40% MPT and 60% behenic acid  
- Formulation 3 (F3): Slow-Lopresor® 200 Divitabs® (Sankyo, Louvain-la-Neuve, Belgium), a 
commercial sustained release formulation consisting of matrix tablets containing 200 mg 
MPT. 
The test formulations F1 and F2 were filled in hard-gelatin capsules, corresponding to 200 mg 
MPT. Slow-Lopresor® 200 Divitabs® (1 tablet) was used as a reference formulation (F3). All 
formulations were administered to 6 male mixed-breed dogs (23 - 41.5 kg) in a cross-over study with 
a wash-out period of at least 8 days. The dogs were fasted 12 h prior to the administration and 12 h 
after administration, although water was available ad libitum. Before the administration, an 
intravenous cannula was placed in the lateral saphenous and a blank blood sample was collected. 
The formulations were administered with 20 ml water and blood samples were collected in dry 
heparinized tubes at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h after administration. The obtained blood 
samples were centrifugated at 1500 g during 5 min.  
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Metoprolol tartrate assay 
A validated HPLC method with fluorescence detection was used for the determination of MPT in 
dog plasma. Plasma samples (300 µl) were mixed with 20 µl of a 2.75 µg/ml aqueous bisoprolol 
hemifumarate (internal standard, IS) solution and 320 µl of a 4% (v/v) aqueous phosphoric acid 
solution. The mixtures were vortexed during 30 s. Drug and internal standard were extracted using 
solid phase extraction (SPE) cartridges (Oasis® MCX 1 cc (30 mg), Waters, Brussels, Belgium) and a 
10-port vacuum extraction manifold. After conditioning the SPE columns with 1 ml methanol and 
1 ml water, the plasma samples were transferred to the columns. The columns were rinsed with 1 ml 
of a 2% (v/v) aqueous formic acid solution, followed by 1 ml methanol. 1 ml of a 5% (v/v) solution of 
ammonium hydroxide in methanol was used to elute MPT and IS. Samples were evaporated to 
dryness under a N2-flow and reconstituted in 150 µl distilled water. 20 µl was injected into the HPLC 
system. MPT plasma concentrations were calculated from a calibration curve, determined by adding 
20 µl of a MPT standard (0.38, 0.56, 0.75, 1.50, 2.25, 3.75 and 5.25 µg/ml), 20 µl of the IS solution 
and 320 µl of an aqueous phosphoric acid solution (4% (v/v)) to 280 µl of blank plasma. The mixtures 
were then treated as described previously. The method validation indicated a linear relationship 
between MPT plasma concentration and response (range: 0 – 353.5 ng/ml; R2 = 0.999 ± 0.001 (n = 
8)). The limit of detection and limit of quantification were 10.1 and 30.6 ng/ml, respectively. MPT 
showed a retention time of 14 min, while the IS eluted after 18 min.  
The HPLC system consisted of an isocratic solvent pump (L-7100, Merck, Hitachi LaChrom, Tokyo, 
Japan), an automatic autosampler (L-2200, Merck, Elite LaChrom, Tokyo, Japan), a guard column 
(LiChroCart® 4-4, LiChrospher® 100 CN (5 µm), Merck, Darmstadt, Germany) followed by a reversed 
phase CN column (LiChroCart® 250-4, LiChrospher® 100 CN (5 µm), Merck, Darmstadt, Germany) and 
a variable wavelength fluorescence detector (L-7480, Merck, Hitachi LaChrom, Tokyo, Japan). Peak 
integration was performed using the software package D-7000 HSM Chromatography Data Station 
(Hitachi Instruments, San Jose, CA, USA). The mobile phase consisted of a phosphate buffer solution 
(2M sodium phosphate monobasic dihydrate), acetonitrile and water (0.5/3.5/96; v/v/v) adjusted to 
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pH 3 with phosphoric acid. The pump flow was set at 1.1 ml/min and the excitation and emission 
wavelength were 275 nm and 300 nm, respectively.  
Data analysis 
The peak plasma concentration (Cmax), the extent of absorption (AUC0-12h) and the time needed to 
reach the highest plasma concentration (tmax) were determined. The controlled release 
characteristics of the formulations were evaluated by means of the HVDt50%Cmax (half-value duration) 
defined by the period during which the plasma concentration exceeds 50% of the Cmax [26, 27]. The 
effect of the formulation on the bioavailability was statistically evaluated by repeated-measures 
ANOVA (univariate analysis) using SPSS 17 (SPSS, Chicago, USA). To compare the effects of the 
different treatments on the pharmaco-kinetic parameters, a multiple comparison among pairs of 
means was performed using a Bonferroni post-hoc test with p < 0.05 as significance level. 
RESULTS AND DISCUSSION 
Prilling was performed using a process temperature ranging between 90 °C and 100 °C. 
Thermogravimetric analysis (TGA), performed on MPT, stearic acid and behenic acid, indicated 
thermal stability of these compounds at the process temperature (data not shown). In a first step, 
the fatty acids were molten and MPT was added to the melt. Next, droplet formation was started 
after complete dissolution of the drug in the molten carrier. Process parameters were chosen in 
order to obtain a fast droplet formation at the needle-end and to limit the residence time of the 
drug/lipid mixture in the reservoir. Drug load influenced the processability as a higher air pressure 
was required to process mixtures with a higher melt viscosity. The mean particle size and shape of 
the prills, determined by measuring the mean Feret’s diameter and aspect ratio (AR), are shown in 
Table 1 for prills containing 10%, 20%, 30% and 40% MPT in a behenic acid matrix and for prills 
containing 30% MPT in a stearic acid matrix. Only minor variations in particle size were noticed for 
the 10%, 20% and 30% MPT formulations, however the 40% MPT prills had a remarkable smaller 
particle size possibly attributed to the higher air pressure needed to process this mixture. As all 
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aspect ratio’s approached the ideal sphericity value of 1, these data indicated that prilling resulted in 
spherically shaped particles with a narrow particle size distribution. All particles exhibited a smooth 
surface.  
Table 1. Mean particle size (± S.D.) and aspect ratio (± S.D.) for prills containing different amounts of MPT in 
combination with stearic acid or behenic acid. 
% MPT 
% Behenic 
acid 
% Stearic 
acid 
Mean FD  
(mm) 
AR 
10 90 - 2.35 ± 0.07 1.07 ± 0.03 
20 80 - 2.36 ± 0.05 1.07 ± 0.04 
30 70 - 2.37 ± 0.06 1.09 ± 0.05 
40 60 - 1.83 ± 0.03 1.05 ± 0.02 
30 - 70 2.35 ± 0.05 1.08 ± 0.04 
 
In vitro drug release 
The influence on drug release using behenic acid or stearic acid as matrix formers, in 
combination with 30% MPT, is illustrated in Fig. 2A. Drug release in water was found to be faster 
using stearic acid as matrix former since 94% of the total drug load was released after 4 h, while only 
62% was released when MPT was incorporated in a behenic acid matrix. The slower drug release 
using behenic acid could be attributed to its longer fatty acid chain relative to stearic acid. In a study 
performed by Desai et al. (2010), a similar influence of chain length on drug release was reported 
[28]. Since behenic acid released MPT over longer periods, only the combination of MPT and behenic 
acid is discussed further on in this study. 
Fig. 2B represents the dissolution profiles in water for prills containing 10%, 20%, 30% and 40% 
MPT in a behenic acid matrix. At low drug load (10%), only 38% of the MPT was released after 24 h. 
The release rate was enhanced by increasing the drug load, although only minor differences between 
prills containing 20% MPT and 30% MPT were observed, reflected by a similarity factor of 53. The 
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influence of pH on drug release of the 10% and 30% MPT formulations was evaluated in two 
dissolution media: 0.1N HCl (pH 1) and phosphate buffer (USP, pH 7.4) to mimic the pH conditions in 
the stomach and the small intestine, respectively. Drug release was pH-dependent at low drug 
concentration (10%) (Fig. 2C). After 24h, 91% of MPT was released at pH 7.4 compared to 62% at 
pH 1. This effect was attributed to (partial) ionization of the carboxyl group of behenic acid at higher 
pH, resulting in a less hydrophobic matrix. When the drug load was increased to 30%, drug release in 
the two dissolution media was similar: at pH 1, 93% of MPT was released after 12 h, compared to 
97% at pH 7.4 (Fig. 2D). Due to the higher drug load, an extended channel system was possibly 
generated in the prills during immersion, consequently the matrix effect of behenic acid was less 
pronounced. Since the morphology of the prills was unchanged after dissolution, MPT release from 
the lipid matrices was diffusion-controlled. 
 
Figure 2. Drug release in function of (A) fatty acid: 30% MPT in combination with stearic acid (●) and behenic 
acid (▲); (B) drug load: 10% (●), 20% (■), 30% (▲) and 40% MPT (▼); (C and D) pH of the dissolution medium: 
10% MPT (C) and 30% MPT (D) in pH 1 (●) and pH 7.4 (■). 
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Next, the influence of the ionic strength of the dissolution medium on the drug release was 
investigated. Fig. 3A demonstrates that at pH 7.4, for prills containing 30% MPT and 70% behenic 
acid, the slowest drug release was obtained in the dissolution medium with the highest ionic 
strength. Only 62% MPT was released after 8 h in a medium of µ = 0.20, whereas 88% and 97% were 
released after 8 h in the media of µ = 0.089 and µ = 0.018, respectively. Further dilution (µ = 0.009) of 
the medium had no influence anymore on the release profiles. Increasing the ionic strength at pH 1 
did not alter the release profile in this medium (Fig. 3B). At higher pH, the ionized carboxyl group of 
behenic acid interacts with positively charged ions from the dissolution medium, resulting in slower 
drug release. A similar influence of the ionic strength on drug release was noticed for the 10% MPT 
formulation (data not shown). Johnson et al. (1992) reported that the electrolyte composition of the 
gastrointestinal fluids ranged from 0.010 to 0.166 and hence, the drug release from behenic acid 
matrices will likely be affected during the transit in the gastrointestinal tract [29]. The susceptibility 
of lipid formulations to ionic strength was also reported by Chang et al. (1997). The release of 
propranolol hydrochloride from monoglyceride matrices showed only a minor susceptibility to the 
ionic strength at pH 7.4 as monoglycerides are non-ionic amphiphilic molecules [30].  
 
Figure 3. MPT release as function of ionic strength of the dissolution medium: (A) PBS (pH 7.4) with µ = 0.009 
(●), 0.018 (■), 0.044 (▲), 0.089 (▼), 0.1445 (♦) and 0.20 (x); (B) 0.1N HCl (pH 1) with µ = 0.1 (▲) and µ = 0.20 
(■). 
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Thermal behavior and crystallinity 
Fig. 4 shows the MDSC thermograms for MPT, stearic acid, behenic acid, the 30/70 MPT/fatty 
acid physical mixtures and the corresponding formulations. Metoprolol tartrate showed an onset 
melting temperature at 120.7 °C, while stearic acid and behenic acid started melting at 68.2 °C and 
74.7 °C, respectively, indicating the crystalline state of these compounds. Even-numbered saturated 
fatty acids can crystallize in at least four polymorphs, named A, B, C and E. As form C is 
thermodynamically stable at high temperature, all other polymorphs irreversibly transform into form 
C upon heating [31]. However, as no solid-solid transformations were detected prior to the melting 
endotherms of stearic and behenic acid (i.e. 68 and 75 °C, corresponding to the melting point of the 
C polymorph), it indicates that only the polymorph C was present in the formulations [32]. These 
findings were in agreement with Kobayashi (1988), who stated that only the thermostable C-form 
could be formed from a melt [31]. In contrast, Corvis et al. (2011) reported recrystallization of stearic 
acid in the E-form from a ibuprofen/stearic acid melt. Upon heating, this polymorph converted to the 
thermostable C-form at about 45 °C [32]. Thermal analysis of the physical mixtures and the 
formulations only revealed a melting endotherm of the fatty acids due to dissolution of the MPT 
crystals in molten stearic acid or behenic acid. Addition of MPT lowered the melting temperature of 
the fatty acids with a few degrees. A glass transition temperature of MPT could not be detected in 
the reversed heat flow signal of the formulations. In the physical mixtures and the formulations, the 
melting enthalpy of fatty acids was higher than expected, suggesting that the excess of energy was 
needed to dissolve the MPT crystals.  
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Figure 4. DSC thermograms of MPT (A), stearic acid (B), behenic acid (C), physical mixture containing 30% MPT 
and 70% stearic acid (D), physical mixture containing 30% MPT and 70% behenic acid (E), prills containing 30% 
MPT and 70% stearic acid (F) and prills containing 30% MPT and 70% behenic acid (G). 
 
 
Figure 5. X-ray diffraction patterns of MPT (A), behenic acid (B), physical mixture containing 30% MPT and 70% 
behenic acid (C) and corresponding prills (D). 
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Figure 6. Raman spectra of MPT (green), behenic acid (blue), physical mixture containing 30% MPT and 70% 
behenic acid (black) and corresponding prills (red). 
 
The solid state was also characterized using XRD and Raman spectroscopy. The X-ray diffraction 
patterns of the pure compounds, the 30/70 MPT/behenic acid physical mixture and the 
corresponding formulation are shown in Fig. 5. MPT showed representative peaks for 2θ at 10.7°, 
16.0°, 19.6° and 23.3°. The highly crystalline state of behenic acid was indicated by sharp diffraction 
peaks at 21.7° and 24.3°. As these peaks also showed up in the formulation, it could be concluded 
that the crystallinity of the fatty acid was not affected by thermal processing via prilling. The X-ray 
diffraction pattern of the formulation also revealed diffraction peaks of MPT (as indicated in red on 
Fig. 5), demonstrating that the crystalline state of MPT was at least partially maintained in the prills. 
These results were in agreement with the Raman spectra shown in Fig. 6. However, the 
representative Raman peaks for MPT in the region 800 – 875 cm-1, representing the out-of-plane O-H 
vibration of the carboxyl group [33], had broadened in the formulation (Fig. 6A) in comparison with 
the physical mixture. In the 920 – 980 cm-1 region, depicting the O-H deformation [33], MPT bands in 
the formulation had almost disappeared, indicating a decrease in crystallinity and the presence of 
amorphous MPT. Moreover, the MPT band at 1210 cm-1, corresponding to the C-N stretching 
vibration [33], was shifted to a lower wavenumber (Fig. 6B), revealing interactions between the drug 
and the fatty acid. During processing at higher temperature, MPT dissolved in the molten behenic 
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acid phase and the interactions between drug and carrier were partially retained after cooling as 
indicated by changes in the Raman spectrum. Based on the crystalline nature of the fatty acid matrix, 
it is unlikely that the MPT fraction interacting with the carrier is molecularly dispersed throughout 
the lipid carrier, hence it is suggested that an amorphous MPT fraction is distributed as separate 
phases throughout the entire matrix. The combination of MPT with stearic acid via prilling resulted in 
similar changing Raman bands of MPT (data not shown).  
 
Figure 7. ATR FT-IR spectra of MPT (A), prills containing 30% MPT and 70% behenic acid (B), corresponding 
physical mixture (C) and behenic acid (D). 
 
ATR FT-IR spectroscopy (Fig. 7) confirmed that the prilling process generated hydrogen bonds 
between MPT and the fatty acids and that the complete MPT molecule was involved in these 
interactions. Fig. 7 illustrates that the ratios of the vibration peaks of MPT and fatty acids in the prills 
were significantly different from the physical mixture with the characteristic vibration peaks of MPT 
(1584 cm-1 and 1512 cm-1, 1249 cm-1, 1109 cm-1 and 821 cm-1 for the C=C stretch vibrations of the 
aromatic ring,  in-plane bending of the hydroxyl groups, C-OH stretching of the hydroxyl groups and 
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 out-of-plane bendings of the aromatic C-H bonds, respectively) appearing less intense in the prills. 
Since no additional carboxyl vibrations appeared in the prills, electrostatic interactions between MPT 
and the fatty acids could be excluded.  
Physical stability 
Stability issues when using lipid excipients have been reported by different authors [7, 10, 18]. 
Influences of storage parameters on drug release were observed by Hamdani et al. (2002). The 
prolonged release of phenylephrine hydrochloride from fatty binder mixtures (Precirol® and 
Compritol®) was significantly affected by storage after 6 weeks at 40 °C and 75% relative humidity 
(RH) [7]. In a study performed by San Vicente et al. (2000), salbutamol hydrochloride release was 
altered after storage for 1 year at room temperature, depending on the type of Gelucire used [18].  
 
 
Figure 8. Influence of storage at 25 °C (A) and 40 °C (B) on drug release. Mean dissolution profiles (± S.D.) of 
prills containing 30% MPT and 70% behenic acid immediately after manufacturing (●), after 1 week (■), 1 
month (▲) and 6 months (♦) of storage. 
 
To investigate the physical stability, the prills containing 30% MPT and 70% behenic acid were 
stored, immediately after manufacturing, in hermetically sealed bags at 25 °C and 40 °C during 6 
months. The influence of storage on drug release is shown in Fig. 8. Drug release profiles remained 
similar during storage at 25 °C as indicated by the f2 values, ranging between 73 and 85, whereas the 
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release rate increased during storage at 40 °C. After one week of storage at 40 °C, 73% MPT was 
released after 4 h, compared to 62% immediately after manufacturing. The drug release after 4h was 
increased to 80% after one month of storage. Drug release profiles obtained after one month, 3 
months and 6 months of storage were not significantly different (f2 > 50), but differed significantly 
from the freshly prepared formulation (f2 < 50).  
X-ray patterns of the 30% MPT formulation stored during 6 months at 25 °C and 40 °C are 
compared with the X-ray pattern of the formulation immediately after processing in Fig. 9. MPT 
diffraction peaks (indicated in red) show similarity between the 3 formulations. The sharp diffraction 
peaks of behenic acid at 21.7° and 24.3° are unchanged during storage at both conditions, indicating 
the stability of the crystalline structure. These results were confirmed by MDSC measurements (Table 
2). Only small fluctuations in onset melting temperature and peak melting temperature (Tm) were 
detected during storage at 25 °C and 40 °C. Moreover, the melting enthalpy of behenic acid showed a 
similar trend at both storage conditions.  
 
Figure 9. X-ray patterns of prills containing 30% MPT and 70% behenic acid immediately after manufacturing 
(A), after 6 months storage at 25°C (B) and 40°C (C). 
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Table 2. Thermal behavior of the prills during 6 months storage at 25 °C and 40 °C. The melt onset, peak 
melting temperature (Tm) and the melting enthalpy of the prills immediately after manufacturing were 69.8 ± 
0.5 °C; 73.7 ± 0.1 °C and 144.8 ± 4.2 J/g, respectively.  
 Melt onset (°C)  Tm (°C)  Melting enthalpy (J/g) 
25°C 40°C  25°C 40°C  25°C 40°C 
1 Week 70.4 ± 0.3 70.5 ± 0.1  73.6 ± 0.2 73.8 ± 0.1  154.8 ± 5.8 161.7 ± 2.2 
1 Month 70.4 ± 0.2 70.8 ± 0.2  73.7 ± 0.2 73.9 ± 0.1  145.7 ± 3.9 153.0 ± 3.4 
3 Months 70.7 ± 0.2 70.9 ± 0.2  74.1 ± 0.1 74.1 ± 0.1  157.2 ± 1.1 157.4 ± 2.3 
6 Months 70.5 ± 0.1 70.8 ± 0.1  73.7 ± 0.1 74.0 ± 0.1  166.3 ± 1.9 164.9 ± 3.4 
 
Differences in MPT solid state during storage were observed with Raman spectroscopy (Fig. 10). 
At both storage conditions, Raman absorption bands for MPT (800 – 875 cm-1) had sharpened after 
1 week compared to the formulation immediately after prilling and MPT bands that were absent in 
the 920 – 980 cm-1 region due to the prilling process, became visible again. The MPT band at 
1206 cm-1 was shifted back to 1210 cm-1 after 1 week. This indicated a transition of MPT from its 
amorphous state to its crystalline state during the first week of storage. The Raman spectra collected 
after 1 month, 3 months and 6 months storage were not significantly different. The influences of 
storage on Raman bands of behenic acid are shown in Fig. 10G and 10H, respectively. No changes or 
shifts were detected at 25 °C, neither at 40 °C, indicating no polymorphism of behenic acid during 
both production and storage of the prills.  
To evaluate the distribution of the solid state during storage, Raman microscopic mapping was 
performed and compared with the formulation immediately after processing. The peak width of the 
Raman band of MPT in the 810 - 830 cm-1 region was monitored to map the solid state of MPT in the 
matrix since there was no interference of behenic acid in this region. Fig. 11 shows the distribution of 
MPT in the inner and outer layers immediately after prilling and after 2 days storage, a red color 
corresponds to a broad peak width, while a blue color corresponds to a smaller peak width. The MPT 
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band in the 810 – 830 cm-1 region showed a broad peak width in the outer (Fig. 11A) and inner layers 
(Fig. 11B) confirming the initial presence of amorphous MPT which can be attributed to the fast 
cooling rate applied to the droplets. Raman microscopic mapping after 2 days of storage at 25 °C and 
40 °C (Fig. 11C - 11F) indicated that the amorphous MPT fraction was recrystallized in the entire 
matrix. Although difficult to conclude for the inner layers in the stored prills (Fig. 11D and 11F), the 
mean Raman spectra collected in this region showed increased MPT crystallinity. In comparison with 
the freshly prepared formulation, the Raman peaks in the 810 - 875 cm-1 had sharpened and the peak 
at 1206 cm-1 was shifted to 1210 cm-1. Raman microscopic mapping performed after 6 months 
storage did not show significant differences with the images obtained after 2 days. MPT crystals 
remained homogenously distributed in the fatty acid matrix. 
Although the faster dissolution rate of MPT during the first month of storage at 40 °C could not 
be clarified by means of solid state characterization, a higher mobilization of the fatty acid chains at 
higher storage temperature might be a contributing factor, thereby inhibiting crystallization of MPT 
or yielding smaller drug crystals, thus affecting the release rate.  
 
CHAPTER 1 – PRILLING OF FATTY ACIDS AS A CONTINUOUS PROCESS FOR THE DEVELOPMENT OF CONTROLLED RELEASE 
MULTIPARTICULATE DOSAGE FORMS 
62 
 
 
Figure 10. Raman bands for MPT (A – F) and behenic acid (G – H) in prills containing 30% MPT and 70% behenic 
acid immediately after manufacturing (black) and after 1 week (red), 1 month (green), 3 months (blue) and 6 
months (orange) storage at 25 °C (A, C, E and G) and at 40 °C (B, D, F and H).   
CHAPTER 1 – PRILLING OF FATTY ACIDS AS A CONTINUOUS PROCESS FOR THE DEVELOPMENT OF CONTROLLED RELEASE 
MULTIPARTICULATE DOSAGE FORMS 
63 
 
 
Figure 11. Solid state mapping of MPT in prills containing 30% MPT and 70% behenic acid immediately after 
prilling (A-B), after 2 days storage at 25 °C (C-D) and 40 °C (E-F). Figures A, C and E represent the outer layers, 
whereas the inner layers are represented in figures B, D and F. A red color corresponds to a broad peak width, 
blue corresponds to a smaller peak width.  
 
 
Figure 12. In vitro MPT release from prills containing 30% MPT (F1, ●), prills containing 40% MPT (F2, ■) and 
the reference Slow-Lopresor® (F3, ▲). 
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In vivo evaluation 
To study the MPT bioavailability, the prills containing 30% MPT (F1) and 40% MPT (F2) in a 
behenic acid matrix, were selected for in vivo evaluation in dogs. The bioavailability was compared 
with a commercially available controlled release reference formulation (F3): Slow-Lopresor® 200 mg 
Divitabs®. The in vitro drug release from the reference, with a complete drug release after 12 h, was 
faster compared to F1 and slower compared to F2 (Fig. 12). The mean plasma concentration-time 
profiles (n = 6) after oral administration of F1, F2 and F3 are illustrated in Fig. 13, while the mean 
pharmacokinetic parameters (AUC, Cmax, tmax and HVDt50%Cmax) are reported in Table 3. The fast in vitro 
drug release from F2 was reflected in the in vivo study since this formulation showed a burst release 
with a mean Cmax of 6.75 (µg/ml)*kg obtained after 1.67 h compared with a Cmax of 4.20 and 3.44 
(µg/ml)*kg obtained after 2.33 h and 3.83 h after administration of F1 and F3, respectively. 
Moreover, F2 was characterized by a lower HVDt50%Cmax, illustrating less controlled release 
characteristics. Prills containing 30% MPT (F1) showed a similar plasma concentration-time profile 
compared with the reference (F3). Statistical analysis of the pharmacokinetic parameters (AUC, Cmax, 
tmax and HVDt50%Cmax) revealed no significant differences between the 3 formulations (p > 0.05). 
Remnants of prills, which still contained 4.39% MPT, were found in the faeces of the dogs after 
administration of F1. Although the prills containing 40% MPT (F2) were intact after in vitro 
dissolution, no prills were recovered from the faeces after oral administration of these 
multiparticulates to dogs, indicating that the composition of gastro-intestinal fluid and motility play 
an important role in the disintegration of these solid lipid dosage forms.  
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Table 3. Mean pharmacokinetic parameters (± S.D.) after oral administration of 200 mg MPT to dogs (n = 6) as 
prills containing 30% MPT and 70% behenic acid (F1), as prills containing 40% MPT and 60% behenic acid (F2) 
and as Slow-Lopresor
®
 200 mg Divitabs
®
 (F3). 
 Cmax ((µg/ml)kg) Tmax (h) AUC ((µg/ml)kg h) HVDt50%Cmax (h) 
F1 4.20 ± 1.82 2.33 ± 1.03 21.25 ± 10.96 4.29 ± 1.23 
F2 6.75 ± 3.79 1.67 ± 0.52 25.01 ± 11.41 3.37 ± 0.94 
F3 3.44 ± 1.52 3.83 ± 2.23 22.18 ± 12.16 5.98 ± 2.88 
 
 
Figure 13. Mean plasma-concentration time profiles (± S.D.) after oral administration of 200 mg MPT to dogs 
(n = 6) as prills containing 30% MPT and 70% behenic acid (●), as prills containing 40% MPT and 60% behenic 
acid (■), and as Slow-Lopresor
®
 200 Divitabs
® 
(▲). 
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CONCLUSION 
In this study we have demonstrated that prilling is a promising technique for the production of 
multiparticulate dosage forms. Using the fatty acids stearic acid and behenic acid, sustained release 
of the hydrophilic drug MPT could be achieved. In vitro drug release was dependent on the drug 
load, type of fatty acid, pH and ionic strength of the dissolution medium. Solid state characterization 
indicated that the crystalline state of the fatty acids was not affected by thermal processing via 
prilling, while the crystallinity of MPT was decreased. During storage, the amorphous MPT fraction 
recrystallized in the entire matrix but no polymorphism of behenic acid was detected. The in vivo 
bioavailability of MPT, after oral administration of the test formulations to dogs, did not significantly 
differ from a commercial sustained release reference formulation. 
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INTRODUCTION 
Fixed-dose combination therapy has been widely implemented for the treatment of 
hypertension and offers several advantages. While monotherapy often implies high doses, the 
combination of two lower dosed drugs shows increased efficacy and reduces dose-dependent side 
effects. Hence, tolerability and patient compliance are increased. Moreover, reducing the dosing 
frequency will dramatically increase long-term adherence [1, 2]. The increased effectiveness of a 
fixed-dose combination of a beta-blocker and a thiazide diuretic has been reported by different 
authors [3-5]. Since hypertension is a multifactorial disease involving several pathophysiological 
mechanisms, combination of two complementary drug classes allows maximum blood pressure 
control. Thiazide diuretics are known to reduce blood volume and sodium levels which trigger renin 
activation and angiotensin II production. These effects are then indirectly antagonized by beta-
blockers [6].  
In this study, metoprolol tartrate (MPT) and hydrochlorothiazide (HCT) were formulated via 
prilling in extended- and immediate-release multiparticulates, respectively. During prilling, a solution 
or homogeneous dispersion of a drug in a molten lipid is pumped through calibrated nozzles. 
Application of vibrational energy to the nozzles breaks up the liquid jet, creating droplets which are 
cooled during their fall in a temperature-controlled prilling tower in order to generate solid spherical 
particles [7, 8]. Despite its limited use in pharmaceutical industry, prilling is beneficial since particles 
reproducible in size and shape are produced in a continuous way. Due to their excellent flow 
properties, these particles are suitable for capsule filling [9]. Prilling is a solvent-free technique 
resulting in an environmental friendly pharmaceutical process. Furthermore, this technique requires 
matrix materials which melt without decomposition and have a melt with a low viscosity but high 
surface tension [10].  
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Although prilling has been extensively used in the industry for the processing of urea [10], the 
pharmaceutical applications are rather limited. Pivette et al. (2012) investigated the controlled-
release mechanism of a highly water-soluble anti-epileptic from lipid microspheres composed of 
Compritol 888 and paraffin wax [8].  
To formulate MPT and HCT in extended- and immediate-release multiparticulate dosage forms, 
these drugs were embedded in matrices composed of fatty acids and polyethylene glycol (PEG). The 
type of fatty acid and the PEG molecular weight were varied in order to tailor drug release. Drug 
release was studied using in vitro dissolution. The solid state of the formulations, termed prills 
further on in this study, was characterized using modulated differential scanning calorimetry (MDSC), 
X-ray diffraction (XRD), Raman spectroscopy, Raman microscopic mapping and attenuated total 
reflection Fourier-transform (ATR FT-IR) spectroscopy. To evaluate bioavailability, the HCT and MPT 
prills were orally co-administered to dogs and compared to a fixed-dose combination reference.  
MATERIALS AND METHODS 
Materials 
Metoprolol tartrate (MPT) (Esteve Quimica, Barcelona, Spain) and hydrochlorothiazide (Utag, 
Amsterdam, The Netherlands) (Fig. 1) were selected as model drugs. Behenic acid (BA, Radiacid 
0560) was purchased from Oleon (Ertvelde, Belgium) and had a C22 purity of 89%. Stearic acid (SA), 
with a C18 purity of 98.7%, was purchased from Mosselman (Ghlin, Belgium). Polyethylene glycol 
4000 and 6000 were obtained from Fagron (Waregem, Belgium), while polyethylene glycol 10 000 
was supplied by Sigma Aldrich (Bornem, Belgium) (Fig. 2). All other chemicals were of analytical 
grade. 
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Figure 1. Chemical structure of hydrochlorothiazide 
 
 
Figure 2. Chemical structure of polyethylene glycol 
 
Prilling 
Prilling was performed using a custom-made prilling equipment (Prilldrop®) developed by Peira 
(Turnhout, Belgium). The fatty acid (stearic acid or behenic acid) and polyethylene glycol (PEG 4000, 
PEG 6000 or PEG 10 000) were simultaneously molten and the drug, MPT or HCT, was added under 
stirring. The mixtures were heated to 95°C (HCT) or 100°C (MPT) before droplet formation was 
started. By applying air pressure, the mixtures were fed towards the thermostated nozzle consisting 
of a valve and a needle (inner diameter: 0.33 mm). Depending on the viscosity of the mixtures, an 
appropriate drop time (i.e. period during which the valve is open) and air pressure were selected in 
order to generate droplets at the needle. Finally, these droplets were quench cooled in liquid 
nitrogen yielding solid spherical particles. All MPT formulations were processed using a material 
temperature of 100°C, a nozzle temperature of 90°C, a drop time of 0.04 s and an air pressure of 0.5 
bar. For the HCT formulations, the material and nozzle temperatures were 95°C and the air pressure 
was set at 0.5 bar. A higher drop time (i.e. 0.07 s) was necessary to process the HCT mixtures, due to 
their higher melt viscosity. An overview of the composition of the prills is listed in Table 1. 
  
 
Table 1. Composition, mean particle size (± SD) and aspect ratio (± SD) of MPT and HCT prills. 
 % Drug   % PEG    % FA   Mean FD (mm)  AR 
 MPT HCT  4000 6000 10 000  SA BA     
F1 10 -  - - -  - 90  2.33 ± 0.06  1.07 ± 0.03 
F2 10 -  - - 1  - 89  2.30 ± 0.08  1.07 ± 0.04 
F3 10 -  - - 3  - 87  2.34 ± 0.08  1.08 ± 0.04 
F4 10 -  - - 5  - 85  2.33 ± 0.09  1.08 ± 0.04 
F5 10 -  - - 10  - 80  2.31 ± 0.08  1.08 ± 0.04 
F6 10 -  5 - -  - 85  2.32 ± 0.08  1.09 ± 0.04 
F7 10 -  10 - -  - 80  2.28 ± 0.07  1.09 ± 0.05 
F8 10 -  - 5 -  - 85  2.33 ± 0.07  1.09 ± 0.07 
F9 10 -  - 10 -  - 80  2.34 ± 0.08  1.08 ± 0.05 
F10 - 10  50 - -  40 -  2.16 ± 0.06  1.09 ± 0.07 
F11 - 10  60 - -  30 -  2.16 ± 0.07  1.15 ± 0.08 
F12 - 10  70 - -  20 -  2.25 ± 0.08  1.11 ± 0.06 
F13 - 10  70 - -  - 20  2.30 ± 0.10  1.15 ± 0.07 
F14 - 10  65 - 5  20 -  2.30 ± 0.10  1.13 ± 0.07 
F15 - 10  60 - 10  20 -  2.28 ± 0.17  1.13 ± 0.09 
F16 - 10  50 - 20  20 -  2.37 ± 0.05  1.07 ± 0.05 
F17 - 10  35 - 35  20 -  2.18 ± 0.08  1.06 ± 0.04 
F18 - 10  25 - 25  40 -  2.31 ± 0.13  1.13 ± 0.09 
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Particle size and shape 
The particle size and shape were determined using an image analysis system. Photomicrographs 
of the prills were taken with a digital camera (Camedia® C-3030 Zoom, Olympus, Tokyo, Japan), 
linked with a stereomicroscope system (SZX9 DF PL 1.5x, Olympus, Tokyo, Japan). A cold light source 
(Highlight 2100, Olympus, Germany) and a ring light guide (LG-R66, Olympus, Germany) were used to 
obtain top illumination of the prills against a dark surface. The images were analyzed by an image 
analysis software (AnalySIS®, Soft Imaging System, Münster, Germany). At least 30 particles were 
analyzed from each batch. Each individual particle was characterized by the mean Feret’s diameter 
(FD) (average of 180 calliper measurements with an angle of rotation of 1°). An average value for all 
prills was calculated as the mean particle size (mean FD). To evaluate sphericity, particles were 
characterized by the aspect ratio (AR) (ratio of the longest Feret’s diameter and its longest 
perpendicular diameter).  
In vitro drug release 
In vitro dissolution was performed using USP dissolution apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system coupled with a VK 8000 automatic sampling station 
(Vankel, New Jersey, USA). An amount of prills, corresponding to 30 mg MPT and 13 mg HCT, was 
inserted into the baskets. Basket rotational speed was set at 100 rpm and the temperature of the 
dissolution medium was maintained at 37 ± 0.5 °C. Samples of 5 ml were withdrawn after 0.5, 1, 2, 4, 
6, 8, 12, 16, 20 and 24 h for MPT and after 10, 20, 30, 40 and 50 minutes, 1, 1.5, 2, 3 and 4 h for HCT 
and analyzed spectrophotometrically at 222 nm (MPT) and 272 nm (HCT) using a double beam 
spectrophotometer (UV-1650PC, Shimadzu, Antwerp, Belgium). Drug concentrations were calculated 
from a calibration curve between 0 and 33 µg/ml for MPT and between 0 and 14.5 µg/ml for HCT.  
In order to examine the influence of hydrodynamic flow and stress in the gastro-intestinal tract, 
the reciprocating cylinder method (USP III) (Bio-Dis, Vankel, New Jersey, USA) was performed at a 
speed of 21 dips/min using 250 ml dissolution medium.  
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As we observed in our previous study that MPT release depended on the ionic strength of the 
dissolution medium, MPT release was studied in demineralized water [11]. According to the USP, HCT 
release studies were performed in 0.1N HCl (pH 1).  
The similarity between dissolution profiles was evaluated using the similarity factor f2, according 
to Shah et al. (1998), and was calculated using the following equation (Eq. 1): 
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where Rt and Tt represent the cumulative drug release at each sample point of the reference and 
the test sample with n equal to the number of sample points. As f2 is sensitive to the number of 
sample points, only one sample point exceeding a drug release of 85% was considered in the 
calculation. f2 values higher than 50 indicate similarity between 2 dissolution profiles based on an 
average difference of less than 10%, while f2 values below 50 represent significant differences [12] . 
Differential scanning calorimetry 
The thermal behavior of pure compounds (MPT, HCT, PEG 4000, PEG 6000, PEG 10 000, stearic 
acid and behenic acid), physical mixtures and corresponding formulations was evaluated using a 
differential scanning calorimeter Q2000 (TA Instruments, Zellik, Belgium) equipped with a 
refrigerated cooling system. The DSC was calibrated for temperature and enthalpy using an indium 
standard. Tzero calibration was performed in 2 steps; baseline calibration (without samples or pans) 
and sapphire calibration (using large sapphire disks on both the sample and reference positions). 
Small sapphire disks, placed in a Tzero pan, were used for the heat capacity (MDSC) calibration. For 
MDSC experiments, samples (± 5 mg) were run in Tzero pans (TA Instruments, Zellik, Belgium) with 
an underlying heating rate of 2°C/min. The modulation period and amplitude were set at 60 s and 
0.318°C, respectively (heat-iso method). DSC experiments were performed in hermetic aluminum 
pans (TA Instruments, Zellik, Belgium) using a heating rate of 10°C/min. Dry nitrogen was used as a 
purge gas through the DSC cell at a flow rate of 50 ml/min. MDSC data were analyzed using the 
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Universal Analysis software (TA Instruments). Melting enthalpies were determined in the total heat 
flow signal. Melting temperatures were reported as onset temperatures. 
Raman spectroscopy 
Raman spectra were collected with a Raman Rxn1 spectrometer (Kaiser Optical Systems, Ann 
Arbor, MI, USA) equipped with an air-cooled CCD detector, using a fiber-optic non-contact probe. 
The laser wavelength was the 785 nm line from a 785 nm Invictus NIR diode laser. All spectra were 
recorded over the 0 – 1800 cm-1 range with a resolution of 4 cm -1 and an exposure time of 5 s, using 
a laser power of 400 mW. Data collection and data transfer were automated using the HoloGRAMSTM 
data collection software, the HoloREACTTM reaction analysis and profiling software and the Matlab 
software (version 7.1, The MathWorks Inc., Natick, MA). Data analysis was performed using SIMCA 
P+ (Version 12.0.1.0, Umetrics, Umeå, Sweden). All spectra were standard normal variation (SNV) 
corrected. Raman spectroscopy was performed on the pure compounds, the physical mixtures and 
the corresponding formulations. 
The distribution of all compounds in the prills was evaluated by Raman microscopic mapping 
using a Raman Rxn1 Microprobe. Cross sections of prills were scanned by a 10x long working distance 
objective lens (spot size 50 µm) in area mapping mode using an exposure time of 5 s and a step 
size of 50 µm in both the x and y directions (= 234 spectra per mapping). The resulting images 
provide information about the distribution and the solid state of the compounds in the prills. 
ATR FT-IR analysis 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was performed 
on pure substances, physical mixtures and prills in order to identify molecular interactions formed 
during prilling. Spectra were recorded using a Nicolet iS5 ATR FT-IR spectrometer (Thermo Fisher 
Scientific). Samples were pressed against a diamond ATR crystal. Each spectrum was collected in the 
4000 - 550 cm-1 range with a resolution of 4 cm-1 and averaged over 16 scans. 
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Storage 
To study the influence of storage on drug release, moisture content and solid state, the MPT 
prills were stored for 6 months in open vials at accelerated conditions (40°C/75% RH), while the HCT 
prills were stored in open vials at 25°C/60% RH. Samples were investigated after 1 week, 1, 3 and 6 
months storage.  
Karl Fischer 
The moisture uptake of the prills during storage was determined by volumetric Karl Fischer 
titration using a V30 volumetric KF titrator (Mettler Toledo, USA). Methanol (Hydranal, Sigma Aldrich, 
Germany) was used as solvent. Before titration, approximately 250 mg of the prills was stirred and 
dissolved in methanol during 1000 s. All measurements were performed in triplicate. 
In vivo evaluation 
All procedures were performed in accordance with the guidelines and after approval by the 
Ethics Committee of the Faculty of Veterinary Medicine (Ghent University). The following 
formulations were administered to 6 dogs (Table 1): F6 (prills containing 10% MPT, 5% PEG 4000 and 
85% behenic acid), F12 (prills containing 10% HCT, 70% PEG 4000 and 20% stearic acid) and a 
commercial reference formulation consisting of tablets containing 95 mg metoprolol succinate 
(equivalent to 100 mg MPT) and 12.5 mg hydrochlorothiazide (Zok-Zid®, Pfizer). An oral dose of 25 mg 
HCT and 200 mg MPT, either as prills (filled in hard-gelatin capsules) or as reference (Zok-Zid®, 2 
tablets), was administered to 6 male mixed-breed dogs in a cross-over study with a wash-out period 
of at least 8 days. The dogs were fasted 12h prior to the administration and 12 h after administration, 
although water was available ad libitum. Before administration, a blank blood sample was collected. 
The formulations were administered with 20 ml water and blood samples were collected in dry 
heparinized tubes at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10 and 12 h after administration. The 
obtained blood samples were centrifugated at 1500 g during 5 min.  
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Metoprolol tartrate and hydrochlorothiazide assay 
The bioavailability of MPT and HCT was determined via 2 different HPLC methods. MPT was 
determined using a validated HPLC method with fluorescence detection [11]. Bisoprolol 
hemifumarate was used as internal standard. Drug and internal standard were extracted by means of 
solid phase extraction. A validated HPLC-UV method was applied to determine HCT plasma 
concentrations using hydroflumethiazide as internal standard [13]. Drug and internal standard were 
extracted via liquid – liquid extraction.  
Data analysis 
The peak plasma concentration (Cmax), the extent of absorption (AUC0-12h) and the time needed to 
reach the highest plasma concentration (tmax) were determined. The controlled release 
characteristics were evaluated by means of HVDt50%Cmax (half value duration), defined by the time 
span during which the plasma concentrations were at least 50% of the Cmax value [14, 15]. The effect 
of the formulations on the bioavailability was statistically evaluated by independent samples t-test 
using SPSS 17 (SPSS, Chicago, USA) with p < 0.05 as significance level. 
RESULTS AND DISCUSSION 
Prilling 
Thermogravimetric analysis (TGA), performed on MPT, HCT, PEG and the fatty acids indicated 
that these substances could be processed at temperatures used during prilling without the risk of 
thermal degradation (data not shown). All MPT formulations were processed using a temperature 
ranging between 90°C and 100°C. At these temperatures, MPT completely dissolved in the behenic 
acid/PEG melt. This interaction between MPT and the fatty acids, stearic (SA) or behenic acid (BA), 
was also described in Chapter 1 [11]. Prilling of the HCT formulations was performed at 95°C. 
Solubilization of HCT depended on the PEG concentration: HCT was dissolved starting from a PEG 
concentration of 70%, while at lower PEG concentrations, a suspension was obtained. Depending on 
the viscosity of the mixtures, an appropriate drop time and air pressure were selected in order to 
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generate droplets in a continuous way. These droplets were quench cooled in liquid nitrogen, 
yielding solid spherical particles. An overview of the composition of all processed MPT and HCT prills 
and their corresponding particle size and aspect ratio is listed in Table 1. The particle size was not 
influenced by variation of the composition. Considering pellet sphericity, all particles showed an 
aspect ratio between 1 and 1.2 which complied with the recommended range for acceptable pellet 
sphericity defined by Chopra et al. (2002) [16]. In general, these data demonstrated that prilling 
provided narrow-sized spherically shaped particles. 
In-vitro drug release 
Since polyethylene glycol and fatty acids showed excellent miscibility in molten state, 
polyethylene glycol was studied as potential hydrophilic compound to tailor drug release from fatty 
acid matrices. In Chapter 1, MPT release was investigated from matrices consisting of stearic acid or 
behenic acid and it was noticed that behenic acid released MPT over longer periods relative to stearic 
acid. Prills containing 10% MPT and 90% behenic acid only released 54% MPT after 24h and 
therefore, these prills were selected to study the influence of PEG addition on MPT release from 
behenic acid matrices. The amount of PEG and the PEG molecular weight were varied to study the 
influence on drug release. Figure 3A illustrates drug release profiles of prills containing 10% MPT and 
increasing concentrations of PEG 10 000 (0, 1, 3, 5 and 10%) while the percentage of behenic acid 
was reduced (F1 to F5). Incorporation of 1% and 3% PEG 10 000 yielded a similar release profile and 
accelerated the drug release. Further addition of PEG 10 000, i.e. 5% (F4) and 10% (F5), extensively 
increased the drug release rate (F4 showed a complete drug release after 24h, while F5 released all 
MPT after 12h) and a burst release was observed. 
The influence of addition of PEG 4000 and PEG 6000 on MPT release is illustrated in Figure 3B. At 
the highest PEG concentration (i.e. 10%), drug release was independent of PEG molecular weight: the 
release profiles of prills containing 10% PEG 4000 (F7), 10% PEG 6000 (F9) and 10% PEG 10 000 (F5) 
were quite similar. Prills containing 5% PEG 4000 (F6) and 5% PEG 6000 (F8) also showed similarity, 
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however, release from prills containing 5% PEG 10 000 (F4) was faster. To clarify this faster drug 
release, drug-free prills were analyzed in order to study if a difference in matrix could be detected. 
Drug-free prills containing PEG 10 000:behenic acid and PEG 4000:behenic acid in a 5:85 ratio (i.e. 
same ratio as in F4 and F6) were processed and the distribution of PEG 4000 and PEG 10 000 in the 
fatty acid matrix was analyzed using Raman microscopic mapping of a cross-sectioned prill. Every 
50 µm, a Raman spectrum was collected. The ratio between the behenic acid bands in the 875 – 
925 cm-1 region and the PEG bands in the 800 – 870 cm-1 region was monitored to map the 
distribution of both compounds in the prills. Fig. 4A and 4B represent the mappings of prills 
containing PEG 4000 and PEG 10 000, respectively. A red color corresponds to a high peak ratio and a 
relative higher concentration of behenic acid. A blue color corresponds to a low peak ratio, and thus 
a relative higher concentration of PEG. More color differences were observed in the prills containing 
PEG 10 000, indicating that PEG 10 000 was less homogeneously distributed throughout the matrix 
(Fig. 4B). As pockets with a high PEG content were detected in prills formulated with PEG 10 000, this 
can affect the porosity of the fatty acid matrices during dissolution testing as PEG 10 000 will leach 
more easily from these PEG-rich zones. By consequence, MPT release from these matrices is faster 
(93% after 24 h). In contrast, the more homogeneous distribution of PEG 4000 in the behenic acid 
matrix (Fig. 4A) yielded a slower drug release (86% after 24 h).  
 
Figure 3. MPT release in function of (A) PEG 10 000 concentration from F1 (●), F2 (■), F3 (▲), F4 (▼), F5 (♦) 
and (B) PEG 4000 and PEG 6000 concentration from F1 (●), F6 (■), F7 (x), F8 (▼) and F9 (♦). 
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Figure 4. Distribution mapping of PEG (4000 or 10 000) and behenic acid in drug-free prills containing 5:85 PEG 
4000:behenic acid (A) and 5:85 PEG 10 000:behenic acid (B). A: ratio of behenic acid and PEG 4000 bands, B: 
ratio of behenic acid and PEG 10 000 bands. A red color corresponds to a high peak ratio and a relative higher 
concentration of behenic acid, while a blue color corresponds to a low peak ratio, and thus a relative higher 
concentration of PEG. 
 
From the dissolution experiments, it was concluded that the MPT release could be tailored in a 
wide range by variation of the PEG concentration and the PEG molecular weight. Since F6 showed no 
burst release and released MPT in a controlled way, this formulation was selected for a bioavailability 
study in dogs. 
In order to formulate immediate-release prills, HCT was combined with polyethylene glycol and 
stearic acid. Prilling of binary mixtures of HCT and PEG was not possible due to the high melt 
viscosity. Therefore, small amounts of stearic acid were incorporated which remarkably decreased 
the viscosity. The addition of the fatty acid probably caused a weakening of the intermolecular 
hydrogen bonds between –OH end groups and ether oxygen groups in the PEG chains [17]. HCT 
concentration was constant at 10%. In a first step, prills were prepared with increasing concentration 
of PEG 4000, from 50% to 70%, while lowering the amount of stearic acid (F10 to F12). Fig. 5A 
illustrates the influence of the PEG 4000 concentration on HCT release. Only 32% was released within 
1h from the prills containing 50% PEG 4000 (F10). Prills formulated with 70% PEG 4000 (F12) showed 
almost complete drug release (i.e. 96%) after 4h, however, already 85% was released within the first 
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hour. To evaluate the influence of the fatty acid type on the drug release, prills were prepared with 
the same amount of drug and PEG 4000, but stearic acid was replaced by behenic acid (F13). These 
prills resulted in a similar dissolution profile indicating that low amounts of different fatty acids do 
not influence the drug release (Fig. 5B). Moreover, replacing 70% PEG 4000 by 70% PEG 6000 also 
yielded a similar dissolution profile (data not shown). 
 
Figure 5. HCT release in function of (A) PEG 4000 concentration from F10 (●), F11 (■), F12 (▲); (B) fatty acid 
from F12 (▲) and F13 (♦). 
 
The influence of PEG 10 000 on HCT release was also investigated. Due to its high melt viscosity, 
only small amounts of PEG 10 000 could be incorporated in the matrices. Therefore, prills were 
prepared with a total PEG amount of 70% formulated with mixtures of PEG 4000 and PEG 10 000. 
Different compositions were processed: 65:5, 60:10, 50:20 and 35:35 PEG 4000:PEG 10 000 (F14, 
F15, F16 and F17, respectively). Drug release from these prills was compared with the drug release 
from F12 (formulated with only PEG 4000). As illustrated in Figure 6A, none of these formulations 
showed a different release rate compared to F12. However, at a PEG concentration of 50%, a faster 
drug release (73% after 4h) was obtained when 25% PEG 4000 was combined with 25% PEG 10 000 
(F18), in comparison with prills containing 50% PEG 4000 (51% after 4h) (Fig. 6B). In accordance to 
the MPT prills, these data demonstrated that variation of the PEG molecular weight is more effective 
to tailor the drug release when lower PEG concentrations are incorporated in the prills. 
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Figure 6. HCT release from (A) prills containing a total PEG amount of 70% with varying PEG 4000 : PEG 10 000 
ratio, 70:0 (F12, ▲), 65:5 (F14, ■), 60:10 (F15,▼), 50:20 (F16,●) and 35:35 (F17, ♦); (B) prills containing a total 
PEG amount of 50% with varying PEG 4000 : PEG 10 000 ratio, 50:0 (F10, ●) and 25:25 (F18, ■) 
 
Based on the dissolution properties, prills containing 10% HCT, 70% PEG 4000 and 20% stearic 
acid (F12), and prills containing 10% MPT, 5% PEG 4000 and 85% behenic acid (F6) were selected for 
further solid state characterization and included in a stability study. Finally, HCT and MPT prills were 
filled into capsules and co-administered to dogs. 
Solid state characterization 
 MPT prills 
The MDSC thermograms of the pure compounds, a physical mixture and the corresponding prills 
are illustrated in Fig. 7. All compounds, as received, were in a crystalline state. The physical mixture 
and the prills exhibited a similar thermal behavior, revealing only melting endotherms of PEG 4000 
and behenic acid, as a result of dissolution of MPT in these molten substances. Based on the MDSC 
results, we concluded that the crystallinity of PEG 4000 and behenic acid was maintained after 
prilling. To evaluate the solid state of MPT, Raman spectroscopy was performed (Fig. 8). 
Characteristic Raman bands of MPT were found at 643 cm-1 and 822 cm-1, representing the out-of-
plane O-H vibration of the secondary alcohol and the carboxyl group, respectively [18, 19]. In the 
prills, the band at 822 cm-1 had broadened indicating a loss in crystallinity and the existence of 
amorphous MPT fractions. Moreover, the peak at 643 cm-1 was shifted to a lower wavenumber (i.e. 
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641 cm-1). Since similar results were obtained in Chapter 1 [11], this peak shift could be mainly 
attributed to intermolecular interactions between drug and behenic acid. Raman spectroscopy also 
confirmed the crystalline state of PEG 4000 and behenic acid after processing (data not shown).   
 
Figure 7. MDSC thermograms of MPT (A), PEG 4000 (B), behenic acid (C), physical mixture containing 10% MPT, 
5% PEG 4000 and 85% behenic acid (D) and the corresponding prills (E). 
 
Figure 8. Raman spectra of prills containing 10% MPT, 5% PEG 4000 and 85% behenic acid (red) and the 
corresponding physical mixture (black). 
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HCT prills 
In order to study the interaction between HCT and PEG 4000, binary mixtures with increasing 
concentrations of HCT (i.e. 12.5%, 30%, 50% and 70%) were analyzed using DSC (Fig. 9). HCT revealed 
a melting endotherm at 268.0°C. In physical mixtures containing 12.5% and 30% HCT, no melting 
endotherm for HCT was detected indicating that HCT completely dissolved into molten PEG 4000. At 
50% drug load, a melting peak for HCT appeared with lower melt onset (i.e. 226°C). Further 
increment of the drug load moved the melting endotherm towards the melting point of the pure 
drug. In the next step, the melting endotherm of PEG 4000 was analyzed. In all physical mixtures, a 
lower melting enthalpy was detected than theoretically expected based on the ratio between both 
compounds. These findings demonstrated an interaction between HCT and PEG 4000 which was 
already reported in literature [20]. 
 
Figure 9. DSC thermograms of HCT (A), PEG 4000 (B) and HCT/PEG 4000 binary mixtures with increasing HCT 
concentration: 12.5% (C), 30% (D), 50% (E) and 70% (F). 
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Figure 10. MDSC thermograms of PEG 4000 (A), stearic acid (B), physical mixture containing 10% HCT, 70% PEG 
4000 and 20% stearic acid (C) and the corresponding prills (D). 
 
MDSC profiles of PEG 4000, stearic acid, a physical mixture containing 10% HCT, 70% PEG 4000 
and 20% stearic acid and the corresponding prills (F12) are illustrated in Fig. 10. The physical mixture 
and prills were heated to 100°C, i.e. below the melting point of HCT, since thermogravimetric analysis 
indicated a degradation temperature for stearic acid of 180°C. Comparison of the physical mixture 
and prills revealed a similar melting enthalpy of stearic acid. However, this enthalpy represented a 
crystallinity of only ± 75% (compared to pure stearic acid) which is probably attributed to dissolution 
of stearic acid in molten PEG during the DSC experiment. In the prills, the melt onset and melting 
enthalpy of PEG 4000 were lowered. 
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Figure 11. Raman bands of HCT (A-B), PEG 4000 (C-D), stearic acid (D) and new bands (E-F) in spectra of prills 
containing 10% HCT, 70% PEG 4000 and 20% stearic acid (red), the corresponding physical mixture (black), 
unprocessed PEG 4000 (green) and prills containing exclusively PEG 4000 (blue).  
 
To investigate the solid state of HCT, Raman spectroscopy was performed. Fig. 11A - 11E 
illustrate different regions of the Raman spectrum of the HCT prills (F12, red) compared to the 
corresponding physical mixture (black). To distinguish from stearic acid and PEG 4000, characteristic 
Raman bands for HCT can be found in the 200 - 340 cm-1 region (Fig. 11A) and the 660 - 770 cm-1 
region (Fig. 11B). It was noticed that the Raman bands for HCT at 215 cm-1, 253 cm-1, 267 cm-1, 
322 cm-1 and the bands in the 660 – 770 cm-1 region appeared weak in the prills. In addition, the 
bands at 322 cm-1 and 677 cm-1 were shifted to lower wavenumbers. Raman analysis of prills 
containing lower concentrations of PEG 4000 (i.e. 50% and 60%) showed that the intensity of these 
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characteristic HCT bands increased at lower PEG concentration (data not shown). These data 
indicated that a higher PEG fraction in the prills contributed to a higher fraction of molecularly 
dispersed HCT. Compared to the physical mixture, the prills also revealed new bands at 1003 cm-1 
and 1033 cm-1 (Fig. 11E). The origin of these bands could be attributed to PEG 4000 since they were 
also observed in prills formulated exclusively with PEG 4000 (Fig. 11F). In accordance with a lower 
melt onset and melt enthalpy observed by MDSC (cfr. supra), the authors suggested the formation of 
a less stable crystal structure of PEG 4000. 
Characteristic Raman bands for PEG 4000 and stearic acid are shown in Fig. 11C and 11D. The 
Raman spectrum of PEG 4000 exhibited a specific doublet in the 830 – 880 cm-1 region, 
corresponding to C-O-C stretching vibrations, and a band at 1281 cm-1, corresponding to CH2 twisting 
[21]. A representative Raman band for stearic acid could be found at 1297 cm-1, depicting the δ(CH2) 
twist vibration [22]. All these bands appeared almost identical in physical mixture and prills, 
indicating the crystalline state of both compounds after processing.  
In order to identify intermolecular interactions in the HCT prills, FT-IR spectroscopy was 
performed (Fig. 12). In its crystalline state, HCT exhibited strong N-H stretching vibrations in the 3450 
- 3100 cm-1 region due to the presence of a primary and secondary sulphonamide, and a secondary 
amine. Moreover, strong absorption bands in the 1360 - 1315 cm-1 and 1180 - 1140 cm-1 regions, 
attributed to asymmetric stretching and symmetric stretching vibration of the SO2 group, 
respectively, could be observed [19]. PEG 4000 mainly shows CH2 symmetric stretching bands at 
2882 cm-1 and C-O stretching bands in the 1170 – 1000 cm-1 region. A weak band can be noticed in 
the 3600 cm-1 to 3200 cm-1 range, resulting from intermolecular hydrogen bond formation between –
OH end groups and ether oxygens in PEG chains [17]. The FT-IR spectrum of stearic acid shows strong 
CH2 stretch vibration bands at 2847 cm
-1 and 2914 cm-1 and a OH deformation band at 941 cm-1. 
Thorough analysis of the spectra of the physical mixture and the prills indicated that N-H stretching 
peaks of HCT in the region 3450 – 3100 cm-1 had completely disappeared in the prills. Moreover, the 
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HCT peaks at 1163 cm-1 and 1179 cm-1 had fused to a single peak at 1160 cm-1. All these changes 
belong to typical functional groups of HCT involved in the formation of hydrogen bonds with PEG [20, 
23]. These findings were in agreement with the Raman results and confirmed the transformation of 
HCT from the crystalline state to its amorphous state during prilling. In comparison to the physical 
mixture, the spectrum of the prills revealed an altered ratio between the peaks at 946 cm-1 and 
959 cm-1, which mainly originated from PEG 4000. Similar changes were also observed in the FT-IR 
spectrum of prills consisting exclusively of PEG 4000. As described above, the crystalline structure of 
PEG 4000 was affected after processing.  
 
Figure 12. ATR FT-IR spectra of HCT (green), PEG 4000 (blue), stearic acid (brown), physical mixture containing 
10% HCT, 70% PEG 4000 and 20% stearic acid (black) and the corresponding prills (F12, red).  
 
Physical stability 
The physical stability of MPT and HCT prills (F6 and F12, respectively) was studied during 6 
months storage, evaluating drug release, moisture content and solid state after 1 week, 1, 3 and 6 
months. Due to the relative low melting onset of PEG 4000 in the HCT prills (i.e. 51.7°C) and in order 
to evaluate the influence of humidity, these prills were stored in open vials at 25°C/60% RH. Using 
the Karl Fischer titration method, water uptake was studied during storage but no significant increase 
of the water content (< 1%) was observed. Storage of the HCT prills did not affect the drug release 
rate (Fig. 13A). Raman spectroscopy indicated that the amorphous state of HCT was stable (Fig. 14A). 
Moreover, no changes in the characteristic Raman bands of stearic acid and PEG 4000 were observed 
(data not shown). Raman bands at 1003 cm-1 and 1033 cm-1, noticed immediately after prilling and 
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attributed to PEG 4000, were still present in the spectra collected after 1 week, 1 month and 3 
months, but appeared remarkably decreased after 6 months storage (Fig. 14B). 
 
Figure 13. Influence of storage on drug release. Mean dissolution profiles (± SD) of prills containing (A) 10% 
HCT, 70% PEG 4000 and 20% stearic acid (F12) and (B) 10% MPT, 5% PEG 4000 and 85% behenic acid (F6) 
immediately after manufacturing (●), after 1 week (■), 1 month (▲), 3 months (▼) and 6 months (♦) storage. 
 
Figure 14. Raman bands of HCT (A) and PEG 4000 (B) in prills containing 10% HCT, 70% PEG 4000 and 20% 
stearic acid (F12) immediately after manufacturing (red) and after 1 week (purple), 1 month (green), 3 months 
(blue) and 6 months (orange) storage at 25°C/60% RH, compared to the corresponding physical mixture (black). 
 
In addition, the melting behavior of PEG 4000 and stearic acid in the HCT prills was studied and is 
shown in Table 2. The melting enthalpy of PEG 4000 remarkably increased during storage, indicating 
an increased crystallinity. These observations could be correlated to the decrease in intensity of the 
Raman bands at 1003 and 1033 cm-1 and by consequence, the transformation to a more stable, 
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crystalline PEG conformation. As noticed in Table 2, the melting enthalpy of stearic acid remained 
stable during storage, which confirmed the results obtained using Raman spectroscopy.  
Since only a small amount (i.e. 5%) of PEG 4000 was present in the MPT prills, this formulation 
was stored at 40°C/75% RH. No significant water uptake (< 1%) was observed. Similar to the findings 
reported in Chapter 1, Raman spectroscopy showed that the amorphous MPT fraction recrystallized 
during the first week of storage. Nevertheless, this modification had no significant impact on the 
drug release rate (Fig. 13B). Raman spectra collected after 1 week, 1 month, 3 months and 6 months 
were similar. Thorough analysis of the Raman bands of behenic acid revealed no polymorphism 
during storage. Moreover, PEG 4000 crystals remained stable. These data were confirmed by MDSC 
and X-ray diffraction (data not shown). 
Table 2. Melting enthalpies (J/g) of PEG 4000 and stearic acid in the HCT prills (F12) during 6 months storage at 
25°C/60% RH. The melting enthalpies of PEG 4000 and stearic acid immediately after prilling were 102.2 ± 
1.9 J/g and 35.9 ± 0.8 J/g, respectively.  
 
Melting enthalpy (J/g) 
PEG 4000 Stearic Acid 
1 week 104.3 ± 4.6 35.6 ± 1.3 
1 month 116.7 ± 0.3 33.5 ± 1.1  
3 months 124.9 ± 1.1 35.8 ± 0.6 
6 months 116.9 ± 1.8 34.2 ± 0.8 
Table 3. Mean pharmacokinetic parameters (± SD) after oral co-administration of 25 mg HCT and 200 mg MPT 
to dogs (n = 6) as prills containing 10% HCT, 70% PEG 4000 and 20% stearic acid (F12), as prills containing 10% 
MPT, 5% PEG 4000 and 85% behenic acid (F6) and as Zok-Zid®.  
 
HCT  MPT 
Prills Zok-Zid®  Prills Zok-Zid® 
Cmax ((µg/ml)*kg) 14.3 ± 7.4 14.1 ± 6.1  8.3 ± 3.0 1.8 ± 0.7 
Tmax (h) 1.3 ± 0.4 1.7 ± 0.8  4.0 ± 2.1 6.6 ± 4.6 
AUC ((µg/ml)*kg*h) 50.3 ± 16.2 44.6 ± 18.6  44.1 ± 24.5 12.6 ± 5.5 
HVDt50%Cmax (h) - -  4.4 ± 2.8 7.7 ± 3.5 
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In vivo evaluation 
Prills containing 10% MPT, 5% PEG 4000 and 85% behenic acid (F6) and prills containing 10% 
HCT, 70% PEG 4000 and 20% stearic acid (F12) were selected for an in vivo evaluation and orally co-
administered to 6 dogs. HCT and MPT bioavailability was compared to a commercial fixed-dose 
combination, Zok-Zid® (Pfizer). The Zok-Zid® tablets immediately disintegrated into pellets, yielding a 
multiparticulate dosage form. Fig. 15 illustrates the in vitro drug release of HCT and MPT from the 
prills, compared to the in vitro drug release from the reference. The mean plasma concentration-
time profiles after oral co-administration of MPT prills (F6) and HCT prills (F12) compared to the 
reference (Zok-Zid®) are shown in Fig. 16. The mean pharmacokinetic parameters (AUC0-12h, Cmax and 
tmax) are reported in Table 3.  
 
Figure 15. In vitro HCT (A) and MPT (B,C) release from F6 and F12 (dotted line) and reference (full line) using 
the basket method (A, B) and the reciprocating cylinder method (C). 
 
Figure 16. Mean plasma concentration-time profiles (± SD) after oral co-administration of 25 mg HCT and 
200 mg MPT to dogs (n = 6) as (A) prills containing 10% HCT, 70% PEG 4000 and 20% stearic acid (dotted line), 
(B) prills containing 10% MPT, 5% PEG 4000 and 85% behenic acid (dotted line) and as Zok-Zid® (full line). 
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In vitro dissolution of the reference indicated a complete HCT release within 15 minutes, while 
the HCT prills showed a complete drug release within 4h (Fig. 15A). Despite this difference, in vivo 
administration of HCT prills and Zok-Zid® tablets yielded a similar plasma concentration-time profile 
and by consequence, the pharmacokinetic parameters did not differ significantly (p>0.05). These 
findings could be attributed to the low permeability of HCT, since it is classified as a class III drug in 
the biopharmaceutical classification system (BCS) [24]. Although the drug is immediately released 
from the reference formulation, its absorption represents the rate-limiting step. In contrast, the prills 
released the drug more gradually, resulting in a similar tmax as obtained with the reference.  
In vitro metoprolol release from the reference was sustained during 24h. Relative to this 
reference, a faster MPT release from the prills was observed (Fig. 15B): after 4h, the prills released 
45% of the total drug load compared to only 28% for the reference. However, these dissolution 
profiles could not be considered as significantly different (f2 > 50). In vivo, MPT prills resulted in a 
significantly higher bioavailability (p < 0.05) since a mean AUC0-12h of 44.1 (µg/ml)*kg*h was 
obtained, while administration of the reference yielded a mean bioavailability of 12.6 (µg/ml)*kg*h. 
Since this significant difference in MPT bioavailability was not expected according to the dissolution 
data, additional in vitro dissolution experiments were considered to clarify these results. Therefore, 
MPT release from the prills and reference was studied using the reciprocating cylinder method (USP 
III) in order to examine the influence of hydrodynamic flow and stress in the gastro-intestinal tract 
(Fig. 15C). From these experiments, it was observed that MPT prills showed a significant faster drug 
release relative to the reference (f2 < 50), indicating that hydrodynamic flow and stress remarkably 
contributed to the drug release rate. MPT release from the reference was not influenced by the 
hydrodynamic flow, since it yielded a similar dissolution profile as obtained with the basket method 
(Fig. 15B). These dissolution experiments revealed that for the controlled release prills, a better in 
vitro/in vivo correlation was achieved using the reciprocating cylinder method and that they are 
more sensitive to the hydrodynamic stress conditions in the gastro-intestinal tract, resulting in a 
higher MPT bioavailability.  
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The controlled release characteristics of MPT prills and reference were evaluated by means of 
HVDt50%Cmax and tmax. MPT prills showed tmax  and HVDt50%Cmax values of 4.0h and 4.4h, respectively. The 
reference showed a delayed onset and a more constant plasma concentration-time profile, reflected 
in a mean tmax of 6.6h and HVDt50%Cmax of 7.7h. However, statistical analysis of these parameters did 
not reveal significant differences, indicating that MPT prills yielded sufficient controlled release 
characteristics. 
CONCLUSION 
This study demonstrated that prilling offers a potential tool in pharmaceutical industry for the 
manufacturing of multiparticulate fixed-dose combination dosage forms. Both controlled- and 
immediate-release multiparticulates were successfully processed. Using different PEG molecular 
weights and varying the PEG/fatty acid ratio in the controlled-release prills, drug release could be 
tailored over a wide range. Since high concentrations of PEG were incorporated in the immediate-
release prills, HCT release was independent on PEG molecular weight. The MPT crystallinity was 
decreased, yielding amorphous MPT fractions, whereas HCT was molecularly dispersed throughout 
the matrix. Compared to a reference formulation, the in vivo study revealed a significant higher 
bioavailability for the MPT controlled-release prills, while administration of HCT via immediate-
release prills resulted in a similar bioavailability.  
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INTRODUCTION 
The use of lipids as excipients for drug delivery has generated substantial interest since they are 
non-toxic, biodegradable, low cost, physiologically inert and pharmaceutically approved products [1]. 
In addition, lipid excipients cover a diverse group of products (oils, waxes, triglycerides, partial 
glycerides, fatty alcohols, fatty acids) with different physicochemical properties which – in 
combination with specific processing techniques – allows their use for different oral dosage form 
applications: enhancement of the solubility and permeability of drugs with a low bioavailability, 
development of sustained release systems, taste-masking of drugs and protection of moisture-
sensitive drugs [2-6]. In Chapter 1, we identified the long chain fatty acids, stearic acid and behenic 
acid, as excellent matrix formers in a multiparticulate dosage form manufactured via prilling [7]. As 
lipid-based formulations can be processed using different techniques (direct compression, melt 
granulation, melt extrusion, molding, spray congealing/prilling, solid lipid extrusion, hot-melt 
coating), this paper evaluates the impact of 2 continuous processing techniques (prilling and solid 
lipid extrusion) on the characteristics of multiparticulate fatty acid-based formulations. In contrast to 
prilling where the entire lipid fraction must be molten to obtain a liquid with adequate viscosity for 
pumping through a calibrated nozzle to create droplets [8, 9], solid lipid extrusion (SLE) operates 
below the melting point of the lipid component. Via a thermo-mechanical treatment at moderate 
pressure and temperature, the mass is sufficiently plasticized to mould it through the die of the 
extruder. As the formulation only partially melts, a solid matrix is formed via the combined action of 
thermal effects and mechanical compression during screw extrusion. Solid lipid extrusion has already 
been described for the manufacturing of lipid-based dosage forms using glycerides as matrix former 
[1, 10-12]. The low process temperature is beneficial for thermosensitive compounds, and the 
lubricating effect of the lipids during extrusion allows the processing of mixtures with a high drug 
load [2]. Solid lipid extrusion using glycerides has been applied to develop sustained release dosage 
forms [1] as well as immediate release pellets [10] and for taste-masking of bitter-tasting drugs [13, 
14]. Furthermore, via this technique triglycerides were successfully combined with release modifiers 
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including polyethylene glycol of different molecular weights (1500 – 7 000 000), hydrocolloids, pore 
formers and desintegrants [15-17].  
In this study, the solid state characteristics, drug release and stability of fatty acid-based 
formulations were evaluated after processing via prilling and solid lipid extrusion. Myristic acid (MA), 
stearic acid (SA) and behenic acid (BA) were used as matrix formers combined with metoprolol 
tartrate (MPT) as model drug. In addition, process analytical technology (PAT) via in-line Raman 
spectroscopic monitoring was used to investigate the impact of the extrusion conditions on the 
physical properties of drug and fatty acid during solid lipid extrusion.  
MATERIALS AND METHODS 
Materials 
Myristic acid, with a C14 purity of 99.2%, and stearic acid, with a C18 purity of 98.7%, were 
purchased from Mosselman (Ghlin, Belgium). Behenic acid (Radiacid 0560) was purchased from 
Oleon (Ertvelde, Belgium) and had a C22 purity of 89%. The melting point of the fatty acids was 
correlated with their chain length: 54.9, 69.5 and 78.0 °C for myristic acid, stearic acid and behenic 
acid, respectively. These fatty acids were combined with metoprolol tartrate (MPT) (Utag, Almere, 
The Netherlands), which has a melting point of 122.8°C. All mixtures contained 30% MPT. 
Processing 
Prilling was performed using the PrillDrop® device developed by Peira (Turnhout, Belgium), 
equipped with a pneumatic nozzle. The fatty acids were molten and MPT was added under stirring. 
The mixtures were heated to 100°C before droplet formation was started. Using a pressurized vessel, 
the liquid mixtures were fed towards the temperature-controlled nozzle consisting of a valve and a 
needle (inner diameter: 0.33 mm). All formulations were processed using a drop time (i.e. period 
during which the valve is open) of 0.07 s and an air pressure of 0.5 bar. Droplets generated at the 
needle were quench cooled in liquid nitrogen, yielding solid particles with a mean particle size of 
2.4 mm, a narrow particle size distribution and a high sphericity (mean aspect ratio of 1.1).  
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Solid lipid extrusion was performed using a Prism Eurolab 16 co-rotating, fully intermeshing twin-
screw extruder (Thermo Fisher Scientific, Germany). The extruder was equipped with a DD Flexwall® 
18 feeder (Brabender Technologie, Germany) which was set in gravimetric feeding mode. The 
temperature of each barrel segment (BS) and the extrusion die could be controlled separately. The 
geometry of the screws is illustrated in Fig. 1. Before extrusion, MPT and the fatty acids were 
premixed in a tumbling mixer (Turbula® T2F, W.A. Bachofen, Basel, Switzerland) for 15 minutes. All 
mixtures were extruded using a throughput of 0.3kg/h and a screw speed of 40 rpm. The barrel 
temperature profiles are listed in Table 1. After cooling to room temperature, the extrudates were 
manually cut into mini-cylinders of 4 mm length.  
 
Table 1. Overview of the composition of the extrudates (E), and the extrusion temperatures used to process 
the formulations.  
 % MPT % MA % SA % BA BS 2-5 (°C) BS 6 (°C) Die (°C) 
E1 30 - - 70 63 63 63 
E2 30 - - 70 80 80 64 
E3 30 - 70 - 70 60 54 
E4 30 70 - - 60 60 47 
E5 30 20 - 50 80 65 46 
E6 30 20 - 50 70 60 50 
E7 30 20 - 50 60 60 50 
E8 30 20 - 50 50 50 50 
E9 30 - 20 50 80 70 57 
E10 30 50 - 20 80 50 42 
E11 30 50 - 20 70 55 40 
E12 30 50 - 20 60 50 40 
E13 30 50 - 20 50 50 40 
E14 30 50 - 20 40 40 40 
E15 30 - - 70 67 67 67 
E16 30 20 - 50 57 57 50 
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Figure 1. Configuration of the intermeshing co-rotating screws with transport zones (A), kneading zones (B) and 
densification zone (C) (obtained from Thermo Fisher Scientific).  
 
In vitro drug release 
In vitro drug release was determined using the USP dissolution apparatus 1 (baskets). The 
equipment consisted of a VK 7010 system coupled with a VK 8000 automatic sampling station 
(Vankel, New Jersey, USA). An amount of prills or extrudates, corresponding to 30 mg MPT, was 
exposed to the dissolution medium, consisting of 900 ml of demineralized water. Basket rotational 
speed was set at 100 rpm and the temperature of the dissolution medium was maintained at 37 ± 
0.5 °C. Samples of 5 ml were withdrawn after 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24 h and analyzed 
spectrophotometrically at 222 nm using a double beam spectrophotometer (UV-1650PC, Shimadzu, 
Antwerp, Belgium). MPT concentrations were calculated from a calibration curve between 0 and 
33 µg/ml.  
The similarity between dissolution profiles was evaluated using the similarity factor f2, according 
to Shah et al. (1998), and was calculated using the following equation (Eq. 1): 
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where Rt and Tt represent the cumulative drug release at each sample point of the reference and 
the test sample with n equal to the number of sample points. As f2 is sensitive to the number of 
sample points, only one sample point exceeding a drug release of 85% was considered in the 
calculation. f2 values higher than 50 indicate similarity between release profiles based on an average 
difference of less than 10%, while f2 values below 50 represent significant differences [18]. 
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Modulated differential scanning calorimetry 
The thermal behavior of pure compounds, physical mixtures and corresponding formulations was 
evaluated using a differential scanning calorimeter Q2000 (TA Instruments, Zellik, Belgium) equipped 
with a refrigerated cooling system. The DSC was calibrated for temperature and enthalpy using an 
indium standard. Tzero calibration was performed in 2 steps: baseline calibration (without samples 
or pans) and sapphire calibration (using large sapphire disks on both the sample and reference 
positions). Small sapphire disks, placed in a Tzero pan, were used for the heat capacity (MDSC) 
calibration. Samples (± 5 mg) were run in Tzero pans (TA Instruments, Zellik, Belgium) with an 
underlying heating rate of 2°C/min. The modulation period and amplitude were set at 60 s and 
0.318°C, respectively (heat-iso method). Dry nitrogen was used as a purge gas through the DSC cell at 
a flow rate of 50 ml/min. MDSC data were analyzed using the Universal Analysis software (TA 
Instruments). Melting enthalpies were determined in the total heat flow signal. Melting 
temperatures were reported as peak temperatures. 
Raman spectroscopy 
Raman spectra were collected with a Raman Rxn1 spectrometer (Kaiser Optical Systems, Ann 
Arbor, USA) equipped with an air-cooled CCD detector, using a fiber-optic non-contact probe. The 
laser wavelength was the 785 nm line from a 785 nm Invictus NIR diode laser. All spectra were 
recorded over the 0 – 1800 cm-1 range with a resolution of 4 cm -1 and an exposure time of 20 s, using 
a laser power of 400mW. Data collection and data transfer were automated using the HoloGRAMSTM 
data collection software, the HoloREACTTM reaction analysis and profiling software and the Matlab 
software (version 7.1, The MathWorks Inc., Natick, MA). Data analysis was performed using SIMCA 
P+ (Version 12.0.1.0, Umetrics, Umeå, Sweden). All spectra were standard normal variation (SNV) 
corrected. Raman spectroscopy was performed on the pure compounds, the physical mixtures and 
the corresponding formulations to evaluate crystallinity. For the in-line measurements, a Raman 
Rxn2 spectrometer (Kaiser Optical Systems, Ann Arbor, USA) was used. A fibre-optic Raman Dynisco 
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probe was inserted into the 5th barrel segment (kneading zone) to monitor the extrusion process in-
line. 
X-ray diffraction 
Crystallinity was analyzed using X-ray diffraction on the pure compounds, the physical mixtures 
and the formulations. X-ray diffraction was performed with a D5000 Cu Kα diffractor (λ = 1.54 Å) 
(Siemens, Karlsruhe, Germany) with a voltage of 40 mV in the angular range of 10° < 2θ < 60° using a 
step scan mode (step size = 0.02°, counting time = 1s/step). 
ATR FT-IR spectroscopy 
Attenuated total reflection Fourier-transform infrared (ATR FT-IR) spectroscopy was performed 
on pure substances, physical mixtures and formulations in order to identify molecular interactions 
formed during extrusion and prilling. Spectra were recorded using a Nicolet iS5 ATR FT-IR 
spectrometer (Thermo Fisher Scientific, Germany). Samples were pressed against a diamond ATR 
crystal. Each spectrum was collected in the 4000 - 550 cm-1 range with a resolution of 4 cm-1 and 
averaged over 16 scans. 
High-resolution X-ray CT scanning 
High-resolution X-ray CT (micro-CT) scanning was performed at the custom built dual-head 
system of the Ghent University Centre for X-ray Tomography [19]. The setup consists of a FeinFocus 
FXE160.51 transmission-type X-ray tube with Tungsten target (FeinFocus, Garbsen, Germany) and a 
large Varian Paxscan 2520V flat-panel detect with CsI scintillator (Varian, Palo Alto, USA). The tube 
was operated at a high voltage of 80kVp and a target power of 8W. For each CT scan, 1500 projection 
images were acquired at an exposure time of 2000 ms per projection. A simultaneous phase-and-
amplitude retrieval filter [20] was applied to reduce edge enhancement effects and increase signal-
to-noise ratio [21, 22]. The tomographic reconstruction was performed using Octopus Reconstruction 
(Inside Matters, Aalst, Belgium). The resulting 3D volumes consist of 1450x1450x1800 voxels with an 
isotropic voxel size of 2.1³ µm³ for the prills and 2.5³ µm³ for the extrudates. The datasets were 
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analysed using Octopus Analysis (Inside Matters, Aalst, Belgium) and visualized using VGStudioMax 
(Volume Graphics, Heidelberg, Germany). For the visualization, a linear combination of the phase-
retrieved and unprocessed data was used to enhance the edges of the object, similar to the approach 
presented in [23]. 
Storage 
Extrudates containing 30% MPT and 70% behenic acid (E15) as well as prills and extrudates 
containing 30% MPT, 20% MA and 50% BA (E16) were included in a stability study. Immediately after 
processing, formulations were filled in hermetically sealed bags and stored at 25°C and 40°C. The 
influence of storage on drug release and solid state was evaluated immediately after processing, 
after 1 week, 1 month and 3 months storage.  
Mathematical modeling 
The following analytical solution of Fick’s second law of diffusion was used to describe MPT 
release from the spherical prills. The model considers that drug release is purely controlled by 
diffusion and assumes that the drug is initially homogeneously and molecularly dispersed (monolithic 
solution) within the pellets and that perfect sink conditions are provided [24]:   
        
                                                                                         (2) 
 
where Mt and M∞ denote the cumulative amounts of drug released at time t and at infinite time, 
respectively; R denotes the radius of the spherical prills and D represents the apparent diffusion 
coefficient of MPT or water within the system [25, 26]. MPT release from the cylindrical extrudates 
was described using the following analytical solution of Fick’s second law of diffusion, considering 
axial as well as radial mass transfer [24]: 
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 (3) 
where Mt and M∞ represent the absolute cumulative amounts of drug released at time t and infinite 
time, respectively; qn are the roots of the Bessel function of the first kind of zero order; D represents 
the apparent diffusion coefficient of MPT or water in the extrudates [25, 26] and R and H denote the 
radius and height of the cylinder. Also this model considers that drug release is purely controlled by 
diffusion and assumes that the drug is initially homogeneously and molecularly dispersed (monolithic 
solution) within the system and that perfect sink conditions are provided. 
RESULTS AND DISCUSSION 
Processability 
Myristic acid (MA), stearic acid (SA) and behenic acid (BA) were selected as fatty acids to 
formulate sustained release matrices containing 30% MPT. To process these mixtures via prilling, a 
temperature of 100°C was used to ensure a sufficiently low viscosity of the molten formulation to 
allow continuous feeding through the prilling nozzle which generated the lipid droplets. At this 
temperature MPT was completely dissolved in the molten fatty acid phase. As reported in Chapter 1, 
these process conditions generated hydrogen bonds between drug and fatty acids [7].  
An overview of the compositions of the extruded formulations and the barrel segment 
temperatures is listed in Table 1. Although MPT/fatty acid mixtures could be extruded over a broad 
temperature range (e.g. from 63 to 80°C for MPT/behenic acid matrices), the process temperature 
during extrusion was limited by the melting point of the fatty acid: processing above the melting 
point yielded a mass that could not form a structured extrudate at the die exit. When extruding at a 
temperature close to the melting point of the fatty acid phase, the temperature of the die should be 
set at a lower temperature in order to increase the die pressure and to enable the formation of solid 
extrudates. If this setup is insufficient to cool the mass, the temperature of the last barrel segment 
𝑀𝑡
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(BS 6) should be set at an intermediate temperature to ensure gradual cooling of the material 
towards the die. The temperature of the extrusion die is also critical towards the surface structure of 
the extrudates: shark-skinning was observed if this parameter was set a few degrees below the 
optimal temperature (i.e. ± 15°C below the fatty acid melting point for BA- and SA-based matrices, 
and 8°C below the melting point of MA for MA-based matrices). 
To monitor possible phase transitions (i.e. melting of the fatty acid phase, dissolution of MPT 
crystals) and interactions between drug and fatty acid, an in-line Raman spectroscopic probe was 
inserted at the 5th barrel segment. In-line monitoring showed that the signals of crystalline behenic 
acid in the 1040 - 1150 cm-1 spectral range (attributed to C-C stretching vibrations [27]) were still 
present in the spectra of MPT/behenic acid mixtures (30/70 ratio) extruded in a temperature range 
from 63 to 80°C (E1 and E2). Compared to the unprocessed physical mixture (PM), the spectra 
revealed no evidence of transitions of these characteristic behenic acid bands as function of 
extrusion temperature demonstrating that the major fraction of the lipid remained in its solid state 
(Fig. 2A). This indicated that - even when extruded at a barrel temperature close to the melting point 
of BA - the energy generated by friction during extrusion did not induce complete melting of the lipid 
phase. Hence, this process can be truly defined as solid lipid extrusion of fatty acids. MPT could be 
distinguished from behenic acid by its representative bands in the 800 - 875 cm-1 (Fig. 2C) and 1190 - 
1270 cm-1 (Fig. 2E) spectral ranges. As these bands were similar to the signal of the physical mixture, 
no molecular interactions between MPT and behenic acid were detected during extrusion between 
63 and 80°C.   
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Figure 2. In-line collected Raman spectra during solid lipid extrusion of mixtures containing 30% MPT 70% BA 
(A, C, E) and 30% MPT 20% MA 50% BA (B, D, F). 
 
The addition of a fatty acid with lower melting point (i.e. myristic acid or stearic acid) to a 
behenic acid matrix allowed to extrude over a broader temperature range: from 50 to 80°C when 
20% myristic acid was incorporated (E5 to E8). The Raman spectra collected during extrusion of this 
mixture are shown in Fig. 2B, 2D and 2F. As fatty acids only differ in the length of their aliphatic 
chain, their Raman spectra are very similar and myristic acid can only be distinguished by a small 
Raman signal at 1092 cm-1 [27]. All remaining fatty acid peaks were attributed to both myristic acid 
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and behenic acid. The in-line collected spectra revealed that myristic acid was already in molten state 
during extrusion at 50°C, as reflected by broadening of the 1092 cm-1 band (Fig. 2B). Up to an 
extrusion temperature of 80°C, all other fatty acid peaks did not differ from the physical mixture, 
indicating that the extrusion conditions did not induce melting of behenic acid. In contrast, the 
characteristic MPT bands depended on the barrel temperature (Fig. 2D and 2F). During extrusion at 
80°C, peak broadening occurred in the 800 – 875 cm-1 region (attributed to the out-of-plane OH-
vibration of the carboxyl group [28]) as well as two peak shifts at 1205 cm-1 and 1246 cm-1 (depicting 
C-N stretching vibrations [28]), indicating that this barrel temperature allowed the MPT crystals to 
dissolve in the molten myristic acid phase. 
Binary MPT/fatty acid mixtures 
In Chapter 1, prills were manufactured based on stearic acid and behenic acid [7]. Prilling of 
myristic acid-based matrices was not possible due to oxidative degradation of MPT, probably caused 
by the presence of oxidizing impurities in myristic acid. While drug release from behenic acid-based 
matrices processed via prilling was slower compared to a stearic acid matrix [7], the present study 
illustrated that the drug release profiles of extrudates containing stearic acid (E3) and behenic acid 
(E2) as matrix former were similar with complete drug release after 8h (Fig. 3). The inclusion of MPT 
in an extruded myristic acid matrix (E4) yielded complete drug release already after 4h. A chain-
length dependent drug release was also reported by Windbergs et al. (2009) who developed matrices 
based on mono-acid triglycerides (trilaurin, tripalmitin and tristearin) differing only in their fatty acid 
chain length [11].  
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Figure 3. MPT release from extrudates based on myristic acid (●), stearic acid (■) and behenic acid (▲) 
(MPT/fatty acid, 30/70, w/w). 
 
Since the investigated prills and extrudates do not have the same geometry and dimensions, 
differences in drug release rate are not only attributable to the different preparation method, but 
also to shape and size effects. For this reason, a simple mathematical model was used to quantify 
MPT release from these systems. The idea was to be able to determine a system specific parameter, 
which should be independent of the geometry and size of the device. Since diffusional mass 
transport is likely to play a major role in the control of drug release from this type of dosage forms 
[26], analytical solutions of Fick’s second law of diffusion were applied, considering the spherical 
geometry of the prills (Equation 2) and the cylindrical geometry of the extrudates (Equation 3) (as 
well as the dimensions of the systems). These models consider perfect sink conditions, a 
homogeneous initial drug and lipid distribution, and rapid and complete drug dissolution upon water 
penetration into the system. Equations 2 and 3 can be used to describe two types of mass transport: 
(a) drug diffusion out of the systems, or (b) water diffusion into the prills and extrudates. Hence, in 
case of good agreement between theory and experiment, it cannot be distinguished whether drug or 
water transport is the release rate controlling step [25]. Nevertheless, the apparent diffusion 
coefficients (of MPT or water) can be determined and compared in order to evaluate the impact of 
the processing technique (and of the system’s composition). 
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Table 2. Comparison of the apparent diffusion coefficients of MPT (or water) (D) in formulations processed via 
prilling or solid lipid extrusion (determined by fitting Equations 2 and 3 to sets of experimentally determined 
drug release kinetics). 
Composition 
D (10-8 cm2/s) ± SD 
Prills Extrudates 
30% MPT 70% BA 5.4 ± 0.7 30.7 ± 1.2 
30% MPT 70% SA 22.8 ± 1.6 28.3 ± 2.1 
30% MPT 70% MA n.d. 67.3 ± 2.5 
30% MPT 20% MA 50% BA 1.3 ± 0.0 4.7 ± 0.4 
30% MPT 20% SA 50% BA 2.1 ± 0.1 13.7 ± 0.4 
*n.d.:  not determined, since the prills could not be prepared 
 
As observed in Fig. 4A, good agreement was obtained when fitting Equations 2 and 3 to the 
experimentally determined release kinetics of MPT from prills and extrudates consisting of 30% MPT 
and 70% BA. This can serve as an indication that diffusional mass transport plays a major role in these 
controlled drug delivery systems, irrespective of the type of processing technique. Based on these 
fittings, the apparent diffusivity of MPT (or water) in the investigated formulations could be 
determined (Table 2). Interestingly, the apparent diffusion coefficients were higher in extrudates 
compared to the prills indicating that drug (or water) transport in the extrudates is less hindered 
than in the prills. These findings could at least partially be explained by the inner matrix structure of 
the systems, as revealed by X-ray tomography (Fig. 5A and 5B). In the extrudates (Fig. 5B), numerous 
small pores were distributed all over the system, whereas the outer matrix of the prills (Fig. 5A) 
seemed to be much denser. It is noteworthy that the prills exhibited larger pores close to the center 
of the spheres. Consequently, some caution needs to be paid with respect to the mathematical 
analysis of the prills as Equation 2 assumes a homogeneous inner sphere structure. A more complex 
mathematical model would be required to accurately take the porosity gradient into account, which 
is likely to result in a mobility gradient for the drug and/or water. However, such an analysis was 
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beyond the scope of this study. Hence, the determined apparent diffusion coefficients for prills are 
averaged diffusivities (averaged over the entire inner sphere structure). 
 
Figure 4. (A) Experimental (symbols) and theory (curves): (A) MPT release from prills and extrudates consisting 
of 30% MPT and 70% BA. The solid curves show fittings of Equations 2 (prills) and 3 (extrudates). (B) MPT 
release from prills consisting of 30% MPT and 70% BA. The dotted curve shows the theoretically predicted drug 
release, using the apparent diffusion coefficient determined with extrudates. 
 
 
Figure 5. X-ray tomography cross-sections of matrices containing 30% MPT and 70% BA as prills (A) and 
extrudates (B); and extrudates containing 30% MPT 20% MA and 50% BA (C). (Scale bars are approximate due 
to the rendering geometry). 
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To demonstrate the impact of the difference in the inner structure of prills and extrudates on 
drug release, the apparent diffusion coefficient of MPT (or water) determined with the extrudates 
was used to theoretically predict drug release from prills of the same composition. Fig. 4B shows an 
example for such a theoretical prediction: using the diffusivity determined by fitting Equation 3 to 
the experimental MPT release from extrudates with a diameter of 3 mm and a height of 4 mm, 
consisting of 30% MPT and 70% BA (D = 30.7 x 10-8 cm²/s), drug release was theoretically predicted 
for prills with a diameter of 2.4 mm (dotted curve). Comparing this theoretical prediction with the 
experimental MPT release kinetics from the prills, it becomes evident that drug release was 
substantially overestimated, due to the higher mobility of the drug (or water) in the extrudates 
compared to the prills. 
The extrudates containing 30% MPT and 70% BA (E2) were analyzed via MDSC, Raman and FTIR-
spectroscopy and the results were compared with those obtained for the prills in Chapter 1 [7]. The 
MDSC thermograms of MPT, behenic acid, the physical mixture and corresponding formulations are 
presented in Fig. 6. The thermograms of pure MPT and behenic acid showed a melting endotherm at 
122.8°C and 78.0°C, respectively, indicating their crystalline nature. MDSC did not provide 
information about the solid state of MPT in the prilled and extruded dosage forms as only the 
melting transition of behenic acid was detected due to the dissolution of the drug in the molten fatty 
acid phase during the MDSC experiment. The crystalline character of behenic acid was maintained 
after processing via both techniques, as represented by a melting endotherm at 74.8 and 73.6 °C for 
extrudates and prills, respectively. These transitions corresponded to the melting of the C-polymorph 
of behenic acid which complied with Kobayashi et al. (1988) who reported that only the C-polymorph 
could be obtained from a melt [29]. In agreement with the in-line Raman spectra described above, 
the off-line collected Raman spectra of the extrudates were identical to the physical mixture 
indicative of the crystalline nature of MPT after extrusion (Fig. 7). These results were confirmed using 
FT-IR spectroscopy as no interactions between MPT and behenic acid were observed (data not 
shown). In contrast, prilling of this formulation formed semi-crystalline MPT with the presence of 
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amorphous drug clusters which was reflected in the Raman spectra by a broadening of the MPT 
bands in the 800 - 875 cm-1 spectral range and two peak shifts at 1205 and 1250 cm-1. Moreover, FT-
IR spectroscopy revealed the formation of hydrogen bonds between MPT and behenic acid during 
prilling (cfr. Chapter 1 [7]). 
 
Figure 6. MDSC thermograms of MPT, behenic acid, physical mixture containing 30% MPT and 70% behenic 
acid, corresponding extrudate and prills. 
 
 
Figure 7. Raman bands of MPT in the 800-870 cm
-1
 (A) and 1190-1270 cm
-1
 (B) spectral ranges in spectra of the 
physical mixture containing 30% MPT and 70% behenic acid (blue), corresponding extrudate (red) and prills 
(green). 
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Mixed fatty acid systems 
In a second part of the study, combinations of fatty acids were processed via prilling and 
extrusion. To embed MPT in MA/BA and SA/BA matrices, 20% of myristic acid or stearic acid was 
included in the behenic acid matrix. Surprisingly, the addition of a fatty acid with shorter chain-length 
to the behenic acid matrix significantly reduced (f2 < 50) the drug release rate, irrespective of the 
processing method (illustrated in Fig. 8). The slowest drug release was obtained when myristic acid 
was included. The slower drug release from the mixed fatty acid systems was also reflected in the 
lower apparent diffusion coefficients of both prills and extrudates (Table 2). Moreover, the addition 
of myristic acid had a significant structural impact on the internal structure of the extrudates: while 
larger isolated pores were still detected, the continuous pore network (as observed in the binary 
MPT/behenic acid extrudates) had disappeared (Fig. 5C).  
 
Figure 8. Release from prills (left) and extrudates (right) containing 30% MPT and 70% BA (▲), with addition of 
20% SA (■) or MA (●). 
 
Furthermore, MA/BA mixtures were used to investigate the impact of the extrusion temperature 
on drug release. Drug release from extrudates containing 20% MA (E5 to E8) was not affected by the 
extrusion conditions (Fig. 9A). However, when the amount of myristic acid was increased to 50% (E10 
to E14), the release rate from extrudates processed at 70 and 80°C was significantly lower compared 
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to extrudates processed at 40°C (Fig. 9B). These release data suggested that a higher MA content in 
combination with a higher process temperature contributed to the formation of a matrix with a 
lower porosity, due to a larger molten fraction during solid lipid extrusion. 
 
Figure 9. MPT release from extrudates containing 30% MPT, 20% MA, 50% BA (A) and 30% MPT, 50% MA, 20% 
BA (B) as function of extrusion temperature: 40°C (♦), 50°C (▼), 60°C (▲), 70°C (■), 80°C (●). 
 
Since the addition of myristic acid had the largest impact on drug release, MA/BA mixtures were 
selected for solid state characterization. The Raman spectra of formulations consisting of 30% MPT, 
20% MA and 50% BA are illustrated in Fig. 10. Similar to the binary MPT/behenic acid mixtures, 
amorphous drug fractions were formed via prilling, as detected via band broadening and peak shifts 
in the 800 - 875 cm-1 and 1190 - 1270 cm-1 spectral ranges, respectively (Fig. 10A and 10B). As X-ray 
diffraction also identified MPT crystals in the prills (data not shown), prilling yielded semi-crystalline 
MPT embedded in a fatty acid matrix. Although in-line monitoring during extrusion at 80°C clearly 
showed disruption of the crystalline MPT structure (cfr. Fig. 2D and 2F), the off-line Raman spectra 
revealed that the drug recrystallized during cooling. For myristic acid, a reduced degree of 
crystallinity was found after prilling based on the broadening of its specific C-C stretching vibration 
band at 1092 cm-1 (Fig. 10C) [27]. The other peaks in the 1040 - 1145 cm-1 spectral range, originating 
from both fatty acids, showed that the crystallinity of behenic acid was maintained after processing 
via both techniques. The thermal behavior of the extrudates and prills is illustrated in Fig. 11. The 
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lower crystallinity of myristic acid in the prills was also reflected in its broader melting range. 
Furthermore, heating of the physical mixture revealed that interaction between the fatty acids could 
occur once myristic acid is in molten state: compared to the melting point of pure behenic acid (i.e. 
78.0°C), a substantial lower melting temperature of behenic acid (i.e. 71.3°C) was observed. This 
effect was even more pronounced in the extrudates and prills, indicating that interactions between 
the fatty acids were established via both manufacturing processes.  
 
Figure 10. Raman bands of MPT (A and B) and the fatty acids (C) in the spectra of the physical mixture 
containing 30% MPT, 20% MA and 50% BA (blue) and the corresponding extrudate (red) and prills (green). 
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Figure 11. MDSC thermograms of MPT (A), MA (B), BA (C), physical mixture containing 30% MPT, 20% MA and 
50% BA (D), corresponding extrudate (E) and prills (F). 
 
The interaction between the fatty acids was further investigated via X-ray diffraction (Fig. 12) and 
FT-IR spectroscopy (Fig. 13). Due to interference of MPT with the signal of myristic acid, the analyses 
were performed on binary mixtures containing myristic acid and behenic acid in a 2:5 ratio (without 
the inclusion of MPT) which were processed via extrusion and prilling. In the X-ray pattern of the 
prills, the characteristic diffraction peak of myristic acid at 14.3° had disappeared, while it was shifted 
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in the pattern of the extrudates. Also the intensity of the behenic acid peaks at 12.9 and 16.6° had 
decreased in the prills (Fig. 12). Compared to the unprocessed physical mixture, the FT-IR spectra of 
the extrudates had a different peak ratio in the 1020-840 cm-1 region, attributed to OH-deformating 
vibrations in systems forming hydrogen bonds (Fig. 13) [30]. In addition, the extrusion process caused 
band broadening in the 1450-1390 cm-1 spectral range (attributed to C-OH in plane bending [31]) and 
two peak shifts at 1273 cm-1 and 1286 cm-1, corresponding to C-O stretching vibrations in behenic 
acid and myristic acid, respectively [30]. In contrast, the FT-IR spectra of the prills showed only minor 
differences: a small peak shift at 1274 cm-1 and limited band broadening in the 1390-1450 cm-1 
spectral range. 
Although both manufacturing processes induced molecular interactions between the fatty acids, 
a different impact on the final solid state was suggested. The extrusion process clearly induced 
hydrogen bonds between the fatty acids, even though the crystalline structure of the constituent 
fatty acids was mainly retained as expressed by their separated melting transitions. As the prills were 
characterized by a broad melting endotherm without a clear melting transition of MA and a reduced 
MA crystallinity was identified via Raman spectroscopy and X-ray diffraction, the authors suggested 
the dissolution of the myristic acid crystals in the behenic acid matrix. Due to the high similarity 
between the Raman and FT-IR spectra of both fatty acids, no differences could be observed after 
prilling. Similar to Qi et al. (2006), it was concluded that the fatty acid mixtures exhibited particular 
solid state properties depending on the processing method and cannot be regarded as simple 
mixtures with characteristics corresponding to the constituting fatty acids [32].  
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Figure 12. X-ray patterns of physical mixture (A), extrudate (B) and prills (C) containing MA and BA in a 2:5 
ratio. 
 
Figure 13. ATR FT-IR spectra of 2:5 MA:BA extrudates (red), prills (green) and physical mixture (blue) over the 
1480-1390 cm
-1
 (A), 1325-1270 cm
-1
 (B) and 1020-840 cm
-1
 (C) spectral ranges.  
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Stability study 
In Chapter 1, a stability study of the prills containing 30% MPT and 70% BA indicated a stable 
drug release during storage at 25°C, while drug release increased during storage at 40°C [7]. 
Compared to the prills, the extrudates (E15) showed better stability since the drug release profile 
was not affected during storage at both conditions (f2 > 50) (Fig. 14). These results were confirmed by 
solid state analysis as no transformations of drug and fatty acids were observed (data not shown). 
Since solubilization of drug crystals and melting of the fatty acids were limited, solid lipid extrusion 
created a stable solid dispersion where drug and fatty acids existed as separated crystalline phases. 
 
Figure 14. Influence of storage at 25°C (left) and 40°C (right) on drug release from extrudates containing 30% 
MPT and 70% BA immediately after manufacturing (▼), after 1 week (●), 1 month (■) and 3 months (▲) 
storage. 
 
Also extrudates (E16) and prills containing 30% MPT, 20% MA and 50% BA were included in the 
stability study. Although drug release remained stable during storage at 25°C, storage at 40°C 
induced significant differences between both systems (Fig. 15). After 1 and 3 months, drug release 
from the extrudates was significantly reduced. However, Raman spectroscopy did not reveal 
transitions of MPT and fatty acid bands which could be linked to the reduced drug release. All 
spectral changes observed in the FT-IR spectra immediately after processing were still visible after 3 
months storage, indicating that the hydrogen bonds between the fatty acids were maintained (data 
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not shown). Moreover, the total melt enthalpy (sum of MA and BA) of the extrudates remained 
stable (Table 3). Concerning the prills, similar findings were observed as those of the behenic acid-
based prills reported in Chapter 1 [7]: the release rate from the mixed fatty acid prills was 
significantly faster after 3 months storage at 40°C, while drug release was stable at 25°C. This 
difference in release kinetics between both storage conditions was not reflected in the Raman 
spectra: recrystallization of the amorphous drug clusters was already detected after 1 week storage 
at both storage conditions (Fig. 16A). Furthermore, MDSC analysis indicated that the total melt 
enthalpy of the fatty acids was slightly increased at both storage conditions, possibly attributed to 
recrystallization and rearrangement of the myristic acid crystals (Table 3). These findings were 
confirmed via Raman spectroscopy (Fig. 16B) as the characteristic Raman band at 1092 cm-1 had 
sharpened. In general, the incorporation of a low melting fatty acid via extrusion and prilling led to 
conflicting drug release results upon storage at elevated temperature. A higher degree of 
mobilization of the fatty acid chains at elevated temperature, which inhibited drug crystallization or 
yielded smaller drug crystals, might be a contributing factor for the faster drug release from the 
prills. However, further research is recommended to clarify the slower drug release from the 
extrudates. Due to the reduced melting point of myristic acid in the formulations and taking into 
account that MPT can interact with molten fatty acid, a storage temperature of 40°C seemed 
unfavorable to ensure product quality of the mixed fatty acid systems. 
Table 3. Total melt enthalpy (sum of MA and BA, J/g) of prills and extrudates containing 30% MPT, 20% MA and 
50% BA during 3 months storage at 25°C and 40°C (± SD, n=3). 
 
Storage at 25°C  Storage at 40°C 
Prills Extrudates  Prills Extrudates 
After processing 137.3 ± 3.0 157.5 ± 0.9  137.3 ± 3.0 157.5 ± 0.9 
1 week 144.0 ± 0.7 158.2 ± 2.2  142.9 ± 3.8 160.5 ± 0.7 
1 month 147.2 ± 1.1 162.3 ± 1.1  148.2 ± 3.8 160.5 ± 1.2 
3 months 144.2 ± 0.8 157.4 ± 0.9  145.3 ± 1.9 158.1 ± 0.9 
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Figure 15. Influence of storage at 40°C on drug release from prills (left) and extrudates (right) containing 30% 
MPT, 20% MA and 50% BA immediately after manufacturing (▼), after 1 week (●), 1 month (■) and 3 months 
(▲) storage. 
 
 
 
Figure 16. Raman bands of MPT (A) and fatty acids (B) in Raman spectra of prills containing 30% MPT 20% MA 
50% BA immediately after processing (red), after 1 week (green), 1 month (dark blue) and 3 months (light blue) 
storage at 40°C. 
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CONCLUSION 
 
This study demonstrated that the processing of fatty acid-based formulations via prilling and 
solid lipid extrusion created matrices with different drug crystallinity. The prilling process allowed 
complete dissolution of the drug in the molten fatty acid phase, generating amorphous drug clusters. 
In contrast, as solid lipid extrusion induced only partial melting of the fatty acids, molecular 
interaction with MPT was limited, resulting in a crystalline state of the drug. Extruded matrices 
exhibited a different inner matrix structure which was correlated with a higher apparent diffusion 
coefficient and a faster drug release. Irrespective of the processing method, the addition of a fatty 
acid with shorter chain length to a behenic acid matrix induced a slower drug release, mainly 
attributed to molecular interaction between the fatty acids and a lower matrix porosity. A different 
impact on final matrix crystallinity of fatty acid mixtures was observed depending on the processing 
technique. 
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INTRODUCTION 
For many years, prilling has been used in the chemical industry for the processing of urea and 
ammonium nitrate. The prilling process consists of 2 basic steps: the conversion of a molten liquid 
into droplets and the cooling of the droplets below their solidification temperature [1]. On industrial 
scale, urea droplets are cooled during their fall in a temperature-controlled prilling tower. Recently, 
prilling has been explored for the development of pharmaceutical multiparticulate applications since 
it allows continuous production of spherically shaped particles with narrow particle size distribution 
[2-6]. The technique was successfully applied to embed a mix of valproïc acid and sodium valproate 
into a controlled release matrix based on paraffin wax and Compritol® 888 [4]. Besides its 
advantages, the process encounters some drawbacks such as the requirement of high prilling towers 
which increase the production cost and bring along difficulties in operation and maintenance [7].  
In the previous chapters, lipid droplets were generated via a pneumatic nozzle system. 
Subsequently, the droplets were quench cooled in a recipient containing liquid nitrogen. This lab-
scale method provided a fast and feasible tool for the production of lipid-based multiparticulate 
dosage forms [2, 3]. However, the impact of the extreme cooling rate on drug and matrix crystallinity 
has to be considered during interpretation of solid state analysis. In this chapter, the use of larger 
temperature-controlled prilling towers has been explored in order to lower the cooling rate of the 
lipid droplets during processing. In the first part, the pneumatic prilling nozzle (generating droplets of 
about 2 mm) was integrated in a 5 m-high temperature-controlled column, equipped with different 
cooling setups (co-current and counter-current nitrogen flow, combined prilling tower/fluidized bed 
system) in order to investigate the efficiency of the different setups towards cooling of the droplets. 
The second part of this study employed a vibrating nozzle device which operated based on the 
principle of laminar jet break-up. This technology, where the molten lipid is pumped through 
vibrational nozzles to break up the laminar jet into a row of mono-sized droplets [5, 6], can generate 
droplets smaller than 1 mm. These droplets were solidified in a 2.2 m vertical cooling chamber.  
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The processability of the formulations, the cooling capacity of the different setups and the 
resulting particle morphology were evaluated. Moreover, the application of different cooling 
conditions allowed comparison of the crystallinity of drug and fatty acids as function of the cooling 
rate. Hence, the solid state of the prills obtained using the prilling tower and the prills processed via 
the vibrational nozzle device was compared with the solid state behavior of the quench cooled prills.  
MATERIALS AND METHODS 
Materials 
Metoprolol tartrate (MPT) (Utag, Almere, The Netherlands) was selected as a model drug. 
Behenic acid (Radiacid 0560) was purchased from Oleon (Ertvelde, Belgium) and had a C22 purity of 
89%. PEG 20 000, was purchased from Merck Millipore (Darmstadt, Germany). All other chemicals 
were of analytical grade. 
Prilling 
In the first part of the study, droplets were formed using a pneumatic nozzle device (Peira, 
Turnhout, Belgium). The matrix compounds were simultaneously molten, and the drug was added to 
this molten phase under stirring. The mixtures were heated to 100°C before droplet formation was 
started. By applying air pressure, the mixtures were fed towards the thermostated nozzle consisting 
of a valve and a needle (inner diameter: 0.33 mm). Pure behenic acid as well as the formulations 
were processed using a drop time of 0.04 s (i.e. period during which the valve is open) and an air 
pressure of 0.5 bar. During the lab-scale trials, the droplets were quench cooled in liquid nitrogen. 
For the upscaling experiments, droplets were solidified in a temperature-controlled 5 m-high prilling 
tower (ProCepT, Zelzate, Belgium). A co-current or counter-current flow of cooled nitrogen gas 
(closed loop) was applied to solidify the droplets.  
In a second part of the study, droplets were generated using a vibrating nozzle device. The device 
was connected with a pressure vessel, feeding the lipid mixture through the nozzle. Depending on 
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the formulation, the vibrational frequency ranged between 0.6 and 1 kHz (Table 1). The amplitude 
was set at 99%. Nozzles with a diameter of 250 µm and 400 µm were tested. The generated droplets 
were visualized by means of a stroboscopic light, automatically synchronized with the applied 
vibration frequency. These droplets were solidified in a 2.2 m vertical cooling cylinder. 
Table 1. Vibrational frequency used to generate the droplets for the different formulations. 
% MPT % BA Nozzle 
diameter (µm) 
Vibration 
frequency (kHz) 
- 100 250 0.82 
- 100 400 0.62 
10 90 250 0.95 
20 80 250 0.91 
30 70 250 0.91 
 
Particle size and shape 
The particle size and shape were determined using an image analysis system. Photomicrographs 
of the prills were taken with a digital camera (Camedia® C-3030 Zoom, Olympus, Tokyo, Japan), 
linked with a stereomicroscope system (SZX9 DF PL 1.5x, Olympus, Tokyo, Japan). A cold light source 
(Highlight 2100, Olympus, Germany) and a ring light guide (LG-R66, Olympus, Germany) were used to 
obtain top illumination of the prills against a dark surface. The images were analyzed by an image 
analysis software (AnalySIS®, Soft Imaging System, Münster, Germany). At least 30 particles were 
analyzed from each batch. Each individual particle was characterized by the mean Feret’s diameter 
(FD) (average of 180 calliper measurements with an angle of rotation of 1°). The average value for all 
prills was calculated as the mean particle size (mean FD). To evaluate sphericity, particles were 
characterized by the aspect ratio (AR) (ratio of the longest Feret’s diameter and its longest 
perpendicular diameter).  
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In vitro dissolution 
In vitro dissolution was performed using USP dissolution apparatus 1 (baskets). The equipment 
consisted of a VK 7010 dissolution system coupled with a VK 8000 automatic sampling station 
(Vankel, New Jersey, USA). An amount of prills corresponding to 30 mg MPT was inserted into the 
baskets. The basket rotational speed was set at 100 rpm. Samples of 5 ml were withdrawn after 0.5, 
1, 2, 4, 6, 8, 12, 16, 20 and 24 h and analyzed spectrophotometrically at 222 nm using a double beam 
spectrophotometer (UV-1650PC, Shimadzu, Antwerp, Belgium). MPT concentrations were calculated 
from a calibration curve between 0 and 33 µg/ml. Demineralized water was used as dissolution 
medium (37 ± 0.5 °C). Each experiment was performed in triplicate. The similarity between 
dissolution profiles was evaluated using the similarity factor f2, according to Shah et al. (1998), and 
was calculated using the following equation (Eq. 1): 
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where Rt and Tt represent the cumulative drug release at each sample point of the reference and the 
test sample with n equal to the number of sample points. As f2 is sensitive to the number of sample 
points leading to bias, only one sample point exceeding a drug release of 85% was considered in the 
calculation. f2 values higher than 50 indicate similarity between dissolution profiles based on an 
average difference of less than 10%, while f2 values below 50 represent significant differences [8].  
Raman spectroscopy 
Raman spectra were collected with a Raman Rxn1 spectrometer (Kaiser Optical Systems, Ann 
Arbor, MI, USA), equipped with an air-cooled CCD detector. The laser wavelength was the 785 nm 
line from a 785 nm Invictus NIR diode laser. All spectra were recorded over the 0 – 1800 cm-1 range 
with a resolution of 4 cm-1 and an exposure time of 20 s, using a laser power of 400 mW. Data 
collection and data transfer were automated using the HoloGRAMSTM data collection software, the 
HoloREACTTM reaction analysis and profiling software and the Matlab software (version 7.1, The 
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MathWorks Inc., Natick, MA). Data analysis was performed using SIMCA P+ (Version 12.0.1.0, 
Umetrics, Umeå, Sweden). All spectra were SNV-preprocessed. Raman spectroscopy was performed 
on the pure compounds, the physical mixtures and the corresponding formulations. 
Modulated DSC 
The thermal behavior of the pure compounds, the physical mixtures and the corresponding 
formulations was evaluated using a differential scanning calorimeter Q2000 (TA Instruments, Zellik, 
Belgium) equipped with a refrigerated cooling system. The DSC was calibrated for temperature and 
enthalpy using an indium standard. Tzero calibration was performed in 2 steps; baseline calibration 
(without samples or pans) and sapphire calibration (using large sapphire disks on both the sample 
and reference positions). Small sapphire disks, placed in a Tzero pan, were used for the heat capacity 
(MDSC) calibration. Samples (± 5 mg) were run in Tzero pans (TA Instruments, Zellik, Belgium) with an 
underlying heating rate of 2 °C/min. The modulation period and amplitude were set at 60 s and 0.318 
°C, respectively (heat-iso method). Dry nitrogen was used as a purge gas through the DSC cell at a 
flow rate of 50 ml/min. MDSC data were analyzed using the Universal Analysis software (TA 
Instruments). Melting enthalpies were determined in the total heat flow signal.  
X-ray diffraction 
Crystallinity was analyzed using X-ray diffraction on the pure compounds, the physical mixtures 
and the corresponding formulations. X-ray diffraction was performed with a D5000 Cu Kα diffractor 
(λ = 1.54 Å) (Siemens, Karlsruhe, Germany) with a voltage of 40 mV in the angular range of 10° < 2θ < 
60° using a step scan mode (step size = 0.02°, counting time = 1s/step). 
Scanning electron microscopy 
Scanning electron microscopy was used to visualize the surface of the prills. Samples were coated 
with platinum by means of a sputter coater (Auto Fine Coater, JFC-1300, Jeol, Tokyo, Japan). 
Photomicrographs were taken with a scanning electron microscope (Jeol JSM 5600 LV, Jeol, Tokyo, 
Japan). 
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RESULTS AND DISCUSSION 
1. Pneumatic nozzle device 
Optimization of the cooling conditions 
The setup of the prilling tower consisted of a vertical 5 m-high temperature-controlled column. 
The column was cooled using a co-current nitrogen stream which was injected next to the melt-inlet. 
The gas was cooled using a heat exchanger coupled with a recirculating chiller. Applying a N2 flow of 
0.5 m³/min, an inlet temperature of -5 °C was obtained, while the temperature at the bottom of the 
column was 14°C. The pneumatic prilling nozzle generating the droplets was placed at the top of the 
prilling tower and integrated in the closed-loop system (Fig. 1).  
 
Figure 1. Pneumatic prilling nozzle integrated on prilling tower. 
 
The first experiments were performed using behenic acid (melting point: 78°C) heated to 100°C 
before droplet formation was initiated. Although the droplets were introduced at the coldest point of 
the system (i.e. close to the N2 inlet), these conditions were insufficient to solidify them: at the 
bottom of the column a cake was formed in the collection recipient due to fusion of droplets (Fig. 2). 
This experiment using the co-current setup indicated that the height of the column was insufficient 
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to induce complete solidification of the droplets. Hence, the residence time of the droplets in the 
column is of major importance to yield solid particles.  
 
Figure 2. Caking in the collection reservoir (positioned at the bottom of the column) due to insufficient 
solidification of the droplets. 
 
To avoid the caking effect, we attempted to increase the residence time of the droplets in the 
column. As the height of the column could not be modified, the setup was converted to a counter-
current system (i.e. N2 injection at the bottom of the column) in order to induce an upward drag on 
the droplets and reduce their fall velocity. A major drawback of this setup is the higher temperature 
(19°C) in the upper part of the column where the droplets are introduced in the system. Although the 
caking effect was reduced and some separated particles were collected, a substantial fraction was 
still adhered to the collection recipient. Moreover, the particles were not spherical, the appearance 
of most particles was that of an empty shell-like structure (Fig. 3). 
 
Figure 3. Particles obtained under counter-current conditions. 
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These initial experiments indicated that a tower height of 5 m, even in combination with a 
counter-current N2 flow, was insufficient to allow complete solidification of the lipid droplets. These 
findings were in agreement with Yuan et al. (2007) who modeled the relationship between the 
effective tower height versus the particle size of urea prills. Their study indicated that the tower 
height increased exponentially as the particle size increased. Using a cooling gas with a temperature 
of 25°C, the effective tower height needed to obtain prills of ± 1.2 mm should be at least 60 m. 
Hence, they concluded that a tower of unrealistic height was required to produce particles ≥ 2 mm 
[7].  
Solidification of a molten droplet starts at its surface and extends towards the center. Taking this 
cooling mechanism into account, Yuan et al. (2007) integrated a fluidized bed system in the prilling 
tower which allows further solidification of the droplets/particles once a solid shell had formed 
around the droplet during its passage through the vertical column. Since a fluidized bed system 
provides a long residence time, efficient hold-up of the particles and intensive heat transfer, the 
tower height required for complete solidification can be reduced significantly [7]. On the other hand, 
the initial cooling in the vertical column remains an essential step during the solidification of the 
droplets. If the shell has insufficiently crystallized before entering the fluidized bed, deformation, 
secondary breaking or coalescence can occur during fluidization, yielding irregularly shaped particles 
[9]. 
In the following experiments, a fluidized bed system was integrated at the bottom of the column 
(Fig. 4). N2 was injected in counter flow and the temperature at the gas inlet was -15°C. A N2 flow of 
at least 0.4 m³/min was needed for acceptable fluidization of the particles. This modified setup 
resulted in higher yield of individual particles, no caking was observed and deposition of material on 
the side walls of the fluid-bed system was limited. However, only a minor fraction of the particles 
were spherical. Most particles were hollow and could be defined as cup-like particles (Fig. 5). This 
phenomenon was attributed to the fact that only the lower part of the droplets (i.e. the part 
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experiencing the drag flow from the cold, counter-current N2 flow) was solidified when they entered 
the fluidized bed system. At this stage, due to collision with the side walls, the liquid part was 
expelled from the solid cups, yielding the empty shell-like structures.  
 
Figure 4. Prilling tower with a fluidized bed integrated at the bottom of the column. 
 
 
Figure 5. Cup-like structures of behenic acid particles processed via the prilling tower with integrated fluidized 
bed. 
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Despite the fact that caking was avoided due to integration of the fluidized bed, the droplet was 
still insufficiently cooled before entering the fluid-bed part of the prilling tower. For this reason, 
liquid nitrogen was vaporized and injected at the bottom of the tower in order to create significantly 
lower temperatures. Although a temperature as low as -40°C was recorded at the gas inlet, the 
temperature at the top of the column remained 17°C (i.e. similar to the previous setup), probably 
attributed to the higher density of the vaporized nitrogen compared to the carrier gas causing 
inadequate distribution of the nitrogen throughout the prilling tower. As the injection of vaporized 
liquid nitrogen did not yield a lower temperature in the upper part of the column, its contribution to 
a faster crystallization rate was lower and again cup-like particles were collected.  
Since the combination of the prilling tower with the fluidized bed showed the best conditions for 
cooling of the lipid droplets, this setup was further explored in order to optimize the process and 
improve particle sphericity by modifications of the composition of the processed formulation.  
Optimization of pellet sphericity 
Unlike several polymers, fatty acids exhibit a very low melt viscosity which makes them suitable 
for pumping through narrow prilling nozzles. During our previous studies (cfr. Chapters 1 and 2), it 
was observed that the addition of a drug or the incorporation of polyethylene glycol (PEG) 10 000 
and 20 000 to the fatty acid matrix increased the melt viscosity of the formulation. These 
observations formed the basis of the following experiments: a higher melt viscosity could reduce the 
probability of material being expelled from the particles in the fluidized bed. Therefore, PEG 10 000 
and PEG 20 000 were added to the fatty acid melt to evaluate the influence on particle 
characteristics. The incorporation of polymers with higher molecular weight, such as polyethylene 
oxide was not feasible because they were not miscible with molten fatty acids. Moreover, the 
increase of the viscosity is limited in order to allow continuous feeding though the prilling nozzle.  
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When a mixture containing 15% PEG 10 000 and 85% behenic acid was processed, the addition of 
PEG 10 000 did not have an impact on particle sphericity. However, when replacing PEG 10 000 by 
PEG 20 000, the sphericity of the particles was significantly improved and only a small fraction of 
hollow, cup-like particles was collected (Fig. 6). Increasing the PEG 20 000 content to 20% yielded 
similar drug product characteristics. Hence, the mixtures containing PEG 20 000 were selected as 
matrices for the processing of drug-containing formulations.  
 
Figure 6. Particles containing 15% PEG 20 000 and 85% behenic acid processed via the prilling tower/fluidized 
bed system. 
 
The following mixtures with 10% drug were evaluated, using a behenic acid/PEG 20 000 ratio of 
85/15 and 80/20: 
- Formulation 1 (F1): 10% MPT, 13.5% PEG 20 000, 76.5% behenic acid 
- Formulation 2 (F2): 10% MPT, 18% PEG 20 000, 72% behenic acid 
In contrast to the drug-free particles, no improvement in shape was observed in case of formulation 
F1, mainly cup-like particles were collected. In contrast, processing of formulation F2 (i.e. with a 
higher PEG 20 000 content) yielded a better product quality with a large fraction of spherical pellets 
(Fig. 7).  
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Figure 7. Particles obtained after processing of formulations F1 (left) and F2 (right) via the prilling 
tower/fluidized bed system. 
 
Influence of cooling conditions 
To study the impact of cooling rate on the size, shape and solid state of the fatty acid-based 
particles, droplets of the mixture containing 18% PEG 20 000 were cooled either via the prilling 
tower/fluidized bed system or quench cooling. Both processing methods yielded prills with a mean 
aspect ratio of about 1.1 (Table 2), which complied with the recommended range (AR between 1 and 
1.2) for acceptable pellet sphericity, defined by Chopra et al. [10]. Moreover, the slower cooling rate 
in the prilling tower/fluidized bed system resulted in a similar particle size compared to the quench 
cooled prills. Hence, these data demonstrated that the initial droplet shape and size were 
successfully maintained during solidification in the prilling tower.  
Table 2. Mean particle size, expressed as mean Feret’s diameter, and aspect ratio of prills containing 10% MPT, 
18% PEG 20 000 and 72% BA 
 
Prilling tower/fluidized bed Quench cooling 
Mean Feret’s diameter ± SD (mm) 2.41 ± 0.17 2.28 ± 0.10 
Aspect ratio ± SD 1.10 ± 0.05 1.08 ± 0.05 
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The impact of the cooling method on MPT release is illustrated in Fig. 8. Prills processed using the 
quench cooling method showed a significantly faster drug release rate (f2 < 50). After 4h, 86% of the 
total drug load was released from the quench cooled prills, compared to only 61% if the prills were 
cooled via the prilling tower/fluidized bed system. The increased drug release rate of the quench 
cooled prills might be attributed to differences in the physical properties of the drug and/or matrix 
since the manufacturing process determines the molecular arrangement of these compounds [11]. 
 
Figure 8. Drug release from prills containing 10% MPT, 18% PEG 20 000 and 72% behenic acid processed via 
quench cooling (dashed line) and prilling tower/fluidized bed system (full line). 
 
The solid state of the formulations was investigated by means of MDSC, Raman spectroscopy and 
X-ray diffraction. The melting behavior of the formulations was quite similar (Fig. 9). As described in 
the previous Chapters, the thermograms of the physical mixture and the formulations did not show a 
melting endotherm of MPT, due to dissolution of the drug in the molten fatty acid phase during the 
DSC experiment. Both samples showed melting transitions for PEG 20 000 and behenic acid at 62°C 
and 76°C, respectively, indicating their crystalline nature. 
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Figure 9. MDSC thermograms of MPT, PEG 20 000, behenic acid, physical mixture containing 10% MPT, 18% 
PEG 20 000 and 72% behenic acid, corresponding prilling tower/fluidized bed prills and quench cooled prills. 
 
 
Figure 10. Raman spectra of prills containing 10% MPT, 18% PEG 20 000 and 72% behenic acid processed via 
prilling tower/fluidized bed system (blue) and quench cooling (red). 
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To study the solid state of MPT, Raman spectroscopy was performed as this technique was 
identified in previous chapters as the most sensitive to detect amorphous MPT fractions. The spectra 
of the prills processed via the prilling tower/fluidized bed system (blue) showed a crystalline band at 
820 cm-1 (Fig. 10). Moreover, no shift was visible for the bands at 1210 and 1255 cm-1 indicating that 
the drug crystallized during cooling in the tower/fluidized bed. These findings were confirmed via X-
ray diffraction (Fig. 11).  
The obtained Raman spectra of the quench cooled prills (red) showed some variations in the 810-
835 cm-1 spectral range (Fig. 10). While most of the spectra indicated crystalline MPT, a few spectra 
showed amorphization of the drug. Although the analysis were performed within 24 hours after 
processing, these variations were possibly caused by rapid recrystallization of the amorphous drug 
clusters. Crystalline diffraction peaks at 10.7°, 16.0° and 20.5° of MPT were clearly visible in the X-ray 
patterns (Fig. 11). In addition, the highly crystalline state of behenic acid was reflected in both 
formulations by its sharp diffraction peaks at 21.6° and 24.2°.  
 
Figure 11.  X-ray patterns of prills containing 10% MPT, 18% PEG 20 000 and 72% behenic acid processed via 
the prilling tower/fluidized bed system (A) and quench cooling (B). 
 
CHAPTER 4 – UPSCALING OF THE PRILLING PROCESS, A PRELIMINARY STUDY 
145 
 
As the signal of MPT interfered with the main X-ray peaks of PEG 20 000 at 19.3° and 23.5° (data 
not shown), this technique was not effective to derive the solid state of PEG 20 000. The same 
problem was encountered using Raman spectroscopy (data not shown). However, since the X-ray 
signal of PEG 20 000 can be easily distinguished from behenic acid, prills containing a binary mixture 
of PEG 20 000 and behenic acid (20:80 ratio) were used to evaluate the impact of the cooling 
conditions on the PEG crystallinity. The intensity of the PEG peaks was remarkably lower in the X-ray 
pattern of the quench cooled prills, indicating a lower crystalline degree (Fig. 12). These results were 
confirmed by Raman spectroscopy (Fig. 13): relative to the behenic acid bands in the 880-920 cm-1 
region, the C-O-C stretching bands of PEG 20 000 in the 830-870 cm-1 region appeared less intense in 
the spectra of the quench cooled prills [12].  
 
Figure 12. X-ray patterns of prills containing 20% PEG 20 000 and 80% behenic acid processed via the prilling 
tower/fluidized bed system (A) and quench cooling (B). 
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Figure 13. Raman spectra of prills containing 20% PEG 20 000 and 80% behenic acid processed via the prilling 
tower/fluidized bed system (blue) and quench cooling (red). 
 
These data identified that the crystal structure of behenic acid was not affected by the cooling 
rate. However, the cooling kinetics did affect the solid state of MPT and PEG 20 000. Whereas 
quench cooling resulted in semi-crystalline MPT in combination with amorphous drug clusters, 
gradual cooling of the prills in the prilling tower/fluidized bed system allowed crystallization of the 
drug. In addition, quench cooling reduced the crystallinity of PEG 20 000.   
Polyethylene glycol is a semi-crystalline polymer of which the crystalline regions are arranged in 
lamellae. Within the lamellae, the polymer chains exist as extended or folded forms. Folded crystals 
are less stable compared to the extended chains and during storage they tend to unfold. PEGs with a 
molecular weight in the range of 3000 to 20 000 have been correlated with a higher fraction of 
metastable, folded crystals [13-15]. Verheyen et al. pointed out that the cooling rate had a significant 
impact on the PEG 6000 crystal: at a lower cooling rate a higher number of the thermodynamically 
stable extended chains were formed [15]. In this study, quench cooling probably resulted in the 
formation of mainly metastable, folded PEG chains since this fast cooling method provided less time 
for orientation and crystallization of the polymer chains. Moreover, the amorphous PEG fractions 
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possess a higher Gibbs free energy and a higher solubility [16]. The formation of the metastable, 
folded PEG chains as well as the presence of amorphous clusters is correlated with the faster MPT 
release observed from the quench cooled prills.  
This study demonstrated that the composition of the lipid melt is of major importance for the 
understanding of the solidification process of large droplets. Physical properties such as density, 
surface tension and dynamic viscosity have to be considered when changing the composition of the 
mixture. For instance, binary mixtures of PEG 20 000 and behenic acid resulted in an acceptable 
particle yield, whereas the addition of MPT to this mixture had a negative impact on product quality. 
Similar problems were encountered when processing stearic acid compared to behenic acid. The 
processing of stearic acid clearly resulted in a higher fraction of irregularly shaped particles (data not 
shown). Therefore, in the following experiments, a reduction of the droplet size was considered in 
order to face less impact of the physicochemical properties of the materials. Since variation of the 
droplet size was not possible via the pneumatic nozzle system, a vibrating nozzle device was applied.  
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2. Vibrating nozzle device 
The technology of a vibrating nozzle device is based on the principle of laminar jet break-up. 
Application of a vibrational frequency breaks a laminar liquid jet into a row of mono-sized droplets 
[6]. Lord Rayleigh demonstrated that controlled break-up of a laminar jet into uniform droplets of 
equal size can be obtained by applying a permanent sinusoidal force at defined frequencies (Fig. 14). 
Droplet characteristics depend mainly on nozzle diameter, jet speed, applied vibration frequency and 
dynamic viscosity [17]. The production of solid and spherically shaped particles of uniform size 
strongly depends on the flow conditions before and during extrusion through the vibrational nozzle. 
These parameters require accurate adjustment as function of the physicochemical properties of the 
lipid mixture [9]. 
 
Figure 14. Mechanism of controlled jet-break up (obtained from [17]). 
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Theoretical background 
Lord Rayleigh analyzed the theoretical aspects of the ability of a jet to break up into droplets. He 
showed that the optimal frequency f (1/s) to break up the jet was related to the wavelength λ (m) 
and jet velocity νjet (m/s) via the following equation: 
  
    
 
 
To determine the optimal wavelength for jet break-up, this equation was extended by Weber (1931) 
and the physicochemical properties of the liquid were included: 
       𝜋          
  
         
                                                
where η is the viscosity (kg/ms), σ the surface tension (N/m) and ρ the mass density (kg/m³) of the 
liquid to be processed. djet represents the jet diameter (m) and is assumed to be equal to the nozzle 
diameter [17]. This equation, generally known as the Rayleigh-Weber equation, indicates that the 
optimal wavelength for jet break-up mainly depends on the nozzle diameter and the viscosity [9]. For 
a given nozzle diameter, the main parameters to optimize the jet break-up mechanism are the 
vibration frequency and the jet velocity. These equations can be used to give an approximation of the 
optimal vibration frequency and flow rate. However, in most cases these parameters are determined 
experimentally via empirical research [17]. By means of a stroboscopic light, the liquid jet break-up 
can be easily visualized and appears as a row of immobile droplets.  
In optimal conditions, the applied frequency breaks up the liquid jet into cylinders of equal 
length and subsequently, every cylinder reorganizes into droplets (Fig. 14). The droplet diameter dd 
(m) can be calculated via the following equation [17, 18]: 
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Setup 
The setup of the vibrating nozzle device is illustrated in Fig. 15. The equipment consisted of a 
heated feeding system (not shown), a vibration unit with control system to control vibration 
frequency and amplitude, a single nozzle to create the liquid jet and a stroboscopic light to visualize 
the jet break-up. The nozzle unit was covered by a thermostated heating cylinder to avoid 
crystallization of the lipid melt and to ensure continuous flow through the nozzle. The vibration 
frequency and amplitude were adjusted by visual control of the jet break-up using the stroboscopic 
light. In this part of the study, the aim was to produce droplets ≤ 1 mm in order to evaluate which 
cooling conditions (length of prilling tower and temperature) were required to obtain complete 
solidification. Therefore, the vibrating nozzle was integrated at the top of a cooling chamber of 2.2 m 
length. Behenic acid as well as binary mixtures of MPT and behenic acid with varying ratios were 
processed. 
 
Figure 15. Illustration of the vibrating nozzle device.  
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Processability and particle size 
Initially, behenic acid was processed using a nozzle diameter of 250 µm. Due to its low melt 
viscosity, behenic acid was successfully pumped through the vibrating nozzle, resulting in a 
continuous jet break-up. The resulting droplets rapidly crystallized and solid particles were formed, 
even using a column at ambient temperature (i.e. without introducing a cold nitrogen flow). When a 
400 µm nozzle was installed, complete cooling of the droplets was also achieved at ambient 
conditions. The collected particles had no tendency to agglomerate and provided excellent flow 
properties. Using the 250 µm nozzle, the behenic acid prills showed a mean Feret’s diameter of 
585.1 µm with narrow particle size distribution (Table 3). Processing by means of the 400 µm nozzle 
increased the mean particle size to 709.2 µm, and resulted in a broader size distribution. Although 
the low aspect ratio indicated that particles processed via both nozzle diameters were highly 
spherical, scanning electron microscopy illustrated that the prills had a quite rough surface (Fig. 16). 
Table 3. Composition, mean particle size and aspect ratio (± SD) of the prills processed via the vibrating nozzle 
device. 
% MPT % BA 
Nozzle 
diameter (µm) 
Mean Feret’s 
diameter (µm) 
Aspect ratio 
- 100 250 585.1 ± 54.2 1.1 ± 0.1 
- 100 400 709.2 ± 118.9 1.1 ± 0.0 
10 90 250 641.0 ± 74.5 1.1 ± 0.1 
20 80 250 508.2 ± 60.4 1.1 ± 0.0 
30 70 250 628.9 ± 58.3 1.1 ± 0.0 
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Figure 16. SEM-images of behenic acid prills processed by means of the 250 µm (A and B) and 400 µm (C and D) 
vibrating nozzle. 
Similar to the behenic acid prills, the mixture containing 10% MPT could be processed via the 
250 µm nozzle without an additional cooling system. However, at a higher MPT content the droplets 
were insufficiently cooled and caking was observed in the collection recipient. Therefore, prilling of 
formulations with 20 and 30% MPT content required a cold co-current N2 flow in the column to lower 
the process temperature to -10°C. This setup allowed to completely solidify the formulation in the 
column and collect individual particles. In contrast, the column was too short in order to obtain 
complete solidification of these mixtures processed via the 400 µm nozzle. 
The addition of MPT to the formulation had no effect on the size of the prills (Table 3). However, 
it had a profound effect on the surface structure of the particles (Fig. 17): whereas the drug-free 
prills had an irregular surface, the MPT prills exhibited a smooth surface structure. No needle-like 
MPT crystals could be observed indicating that all drug crystals were completely embedded by the 
fatty acid.   
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Figure 17. SEM-images of MPT (A), behenic acid (B) and MPT/behenic acid prills containing 10% MPT (C and D), 
20% MPT (E and F) and 30% MPT (G and H).  
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In vitro dissolution 
Drug release from the MPT prills in water is illustrated in Fig 18. A similar trend was observed 
compared to the quench cooled prills described in Chapter 1. Prills containing 10% MPT yielded the 
slowest drug release, while the release from the prills containing 20% MPT and 30% MPT was not 
significantly different (f2 > 50). For all tested drug loads, the release from the prills processed via the 
vibrating nozzle, was significantly faster (f2 < 50) compared to the release from the quench cooled 
prills (± 2.4 mm) which is linked to their smaller size and higher surface area available for drug 
release (Fig. 19). Remarkably, prills processed via the vibrating nozzle device showed an initial burst 
release, but all formulations also suffered from an incomplete drug release as a substantial fraction 
of the total drug load remained entrapped within the matrix after 24h. These findings could be 
possibly attributed to aggregation of the prills in the baskets during dissolution testing.  
 
Figure 18. Drug release from prills containing 10% (●), 20% (■) and 30% (♦) MPT processed via the vibrating 
nozzle device. 
Therefore, to reduce the risk of aggregation and to improve wetting of the prills, a surfactant, 
sodium lauryl sulfate (SLS), was added to the medium at concentrations of 0.1% and 0.5% (Fig. 20). In 
the medium with 0.1% SLS, drug release was significantly faster and the total amount of dissolved 
drug was increased to 86% for the 10% and 20% MPT prills and to 92% for the 30% MPT prills. 
Increasing the surfactant concentration to 0.5% further enhanced the total drug release, however a 
small drug fraction was still retained after 24h of dissolution testing.   
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Figure 19. Drug release from prills containing 10% (A), 20% (B) and 30% MPT (C) processed via the vibrating 
nozzle device (full line) or via quench cooling (dashed line). 
 
Figure 20. Drug release from prills (processed via the vibrating nozzle device) containing 10% (●), 20% (■) and 
30% (♦) MPT in function of surfactant concentration in the dissolution medium: 0.1% SLS (left) and 0.5% SLS 
(right). 
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Influence of cooling conditions on solid state 
The solid state of the behenic acid prills, as well as the 10% MPT prills was compared as function 
of the cooling conditions: quench cooling, the 5m-high prilling tower/fluidized bed system (both used 
in combination with the pneumatic prilling nozzle) and the 2.2 m cooling chamber which was used in 
combination with the vibrating nozzle device. Raman bands, within the 870 – 1520 cm-1 spectral 
range, of the behenic acid prills and unprocessed behenic acid are compared in Fig. 21. Irrespective 
of the cooling method, all Raman spectra are identical. Moreover, no spectral changes were noticed 
compared to unprocessed behenic acid. These findings were confirmed using MDSC (Fig. 22): all 
batches exhibited a similar melting transition with a peak melting temperature at 78°C. No clear 
relationship between the melting enthalpy and the cooling conditions could be defined. Overall, solid 
state analysis indicated that the final crystallinity of the fatty acid was not influenced by the cooling 
method.  
 
Figure 21. Raman spectra of behenic acid prills processed via quench cooling (red), prilling tower/fluidized bed 
system (dark blue), vibrating nozzle 250 µm (green), vibrating nozzle 400 µm (light blue) compared to 
unprocessed behenic acid (black). 
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Figure 22. MDSC thermograms of behenic acid prills processed via the different cooling techniques compared 
to unprocessed behenic acid. 
In case of prills containing 10% MPT and 90% behenic acid, the Raman bands representative of 
MPT in the 800 – 875 cm-1 spectral range showed significant differences depending on the cooling 
method (Fig. 23A). While band broadening was detected in the spectra of prills processed via quench 
cooling and the vibrating nozzle device, the spectra of the prills cooled using the prilling 
tower/fluidized bed system tended more towards the spectra of the corresponding physical mixture. 
A similar trend was observed for the C-N stretching band at 1210 cm-1 (Fig. 23B) [19]. Quench cooling 
as well as processing via the vibrating nozzle device induced a peak shift to a lower wavenumber. 
This shift was not observed for the prills cooled via the prilling tower/fluidized bed system. 
Moreover, the band at 1255 cm-1 had almost disappeared after quench cooling and processing via 
the vibrating nozzle, while the band was still present after cooling in the prilling tower/fluidized bed 
system. In general, these data demonstrated that the crystallinity of MPT depended on the applied 
cooling procedure. The gradual cooling in the prilling tower/fluidized bed system provided more time 
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for the drug to crystallize in the matrix. In contrast, quench cooling or cooling of small droplets 
produced via laminar jet-break up clearly generated amorphous MPT fractions.  
 
Figure 23. MPT bands in Raman spectra of prills containing 10% MPT 90% BA processed via quench cooling 
(red), prilling tower/fluidized bed system (blue) and vibrating nozzle (green) compared to the corresponding 
physical mixture (black). 
 
 
Figure 24. MDSC thermograms of prills containing 10% MPT and 90% BA processed via quench cooling, prilling 
tower/fluidized bed system and vibrating nozzle compared to the corresponding physical mixture. 
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Similar to the behenic acid prills described above, the Raman spectra did not indicate transitions 
of behenic acid in function of cooling procedure (data not shown). These observations were 
confirmed by MDSC (Fig. 24). The melting point of behenic acid remained unchanged compared to 
the physical mixture and pure behenic acid. Also in these samples, the relationship between the melt 
enthalpy and the cooling conditions was not straightforward. Hence, more research is recommended 
in order to fully understand the melting behavior.  
CONCLUSION 
This study demonstrated that a 5m-high prilling tower was of insufficient length to solidify 
droplets ≥ 2 mm. The integration of a fluidized bed system at the lower part of the column prolonged 
residence time and allowed more time for solidification. Despite the improved particle yield and 
product quality, the majority of the pellets had an irregular, cup-like shape. However, the vibrational 
nozzle device offers a promising approach for prilling of lipid-based formulations. The principle of 
laminar jet break-up allows efficient variation of the droplet size. Droplets generated by means of a 
250 µm nozzle were successfully solidified using a prilling tower of acceptable length and hence, the 
process resulted in spherically shaped pellets with uniform size distribution. The combination of the 
vibrating nozzle device with the prilling tower/fluidized bed system shows great potential for 
production of particles of ± 1 mm and needs further investigation. The cooling technique significantly 
influenced drug crystallinity. While slow cooling in the tower fluidized/bed system allowed 
crystallization of the drug, quench cooling or cooling of droplets produced via the vibrating nozzle 
device resulted in amorphous drug clusters. Similarly to MPT, PEG 20 000 showed a higher degree of 
crystallinity after cooling in the prilling tower/fluidized bed system. In contrast, the crystal structure 
of the fatty acids was not affected by the cooling rate. Since it was observed that particle morphology 
strongly depended on the composition of the mixtures, a more thorough understanding of the 
solidification process as well as the impact of the physicochemical properties is required to allow full 
optimization of the process conditions.  
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GENERAL CONCLUSIONS 
AND FUTURE PERSPECTIVES 
The general aim of this work was to evaluate the potential of prilling as manufacturing technique 
for lipid-based multiple-unit systems. Moreover, fatty acids were explored as alternative matrix 
excipients for controlled drug release. 
This study demonstrated that prilling is a valuable technique for the continuous production of 
spherically shaped particles with narrow size distribution. Drug release from fatty acid-based prills 
could be controlled, however it depended on the fatty acid chain-length, drug load, pH and ionic 
strength of the dissolution medium. The in vitro controlled release effect was reflected in a 
bioavailability study in dogs. For binary MPT/fatty acid mixtures, prilling did not affect the crystalline 
state of the fatty acid. Since MPT was initially molecularly dispersed in the molten fatty acids, these 
interactions were partially maintained after cooling, yielding amorphous MPT fractions which were 
distributed throughout the crystalline fatty acid matrix. Stability tests indicated that these 
amorphous fractions recrystallized within 1 week, irrespective of the storage conditions. 
Nevertheless, this phenomenon could not be correlated to changes in drug release upon storage. In 
contrast, there was no evidence for polymorphic transitions of the fatty acid crystals.  
Mixtures of fatty acids with polyethylene glycol (4000 to 10 000) were successfully processed due 
to their excellent melt miscibility. The addition of PEG resulted in a significantly faster drug release 
from the fatty acid matrices and MPT release could be tailored over a wide range by variation of the 
PEG molecular weight and PEG/fatty acid ratio. Prilling of mainly PEG-based matrices further 
extended the possibilities of the technique for pharmaceutical applications as also immediate release 
prills, containing HCT as model drug, could be manufactured. Drug release from these HCT prills was 
independently of PEG molecular weight. Due to a molecular interaction between PEG and HCT, 
amorphous HCT was generated in the prills. The concept of fixed-dose combination, combining 
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controlled release and immediate release prills in one capsule, was also illustrated in vivo. 
Furthermore, drug release from fatty acid/PEG matrices was stable during storage.  
A comparative study of prilling and solid lipid extrusion indicated that these processing 
techniques had a different impact on final drug crystallinity. As solid lipid extrusion induced only 
partial melting of the fatty acids, molecular interaction with the drug was limited, yielding crystalline 
MPT. Although in line monitoring revealed that the addition of a low melting fatty acid allowed more 
molecular interaction between the drug and the fatty acids, crystalline MPT was found after 
processing. Mathematical modeling indicated that drug release was mainly diffusion-controlled from 
both prills and extrudates, however the extrudates showed a higher apparent diffusion coefficient 
resulting in faster drug release kinetics. Independently of the processing method, the incorporation 
of a fatty acid with shorter chain length induced a slower drug release which was correlated with 
molecular interactions between the fatty acids and with a lower matrix porosity. Although the 
crystallinity of fatty acids in binary MPT/fatty acid systems was not affected by thermal processing, 
the processing method had a significant effect on the matrix crystallinity of mixed fatty acid systems 
(e.g. mixtures of myristic acid and behenic acid).  
A scale-up study of the prilling process identified that a 5 m high vertical prilling tower was too 
short for adequate solidification of lipid droplets larger than 2 mm. The incorporation of a fluid-bed 
system at the lower part of the column provided more time for solidification, resulting in a higher 
pellet yield with improved sphericity. However, the major fraction of the particles showed an 
irregular shape attributed to incomplete cooling. A vibrating nozzle technology, whereby droplet size 
can be easily varied, offers a promising approach for prilling of lipid formulations. Drug-free lipid 
droplets generated using a nozzle size up to 400 µm were successfully solidified in a prilling tower of 
acceptable length (i.e. 2.2 m). In addition, this study demonstrated that the crystalline degree of the 
drug depended on the cooling conditions. While a fast cooling rate resulted in the formation of 
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amorphous MPT, crystalline MPT was obtained using slower cooling rates in the tower/fluidized bed 
system. In contrast, the crystallinity of the fatty acids was not affected by the cooling procedure.  
In general, this study identified prilling as a promising technology for manufacturing of lipid-
based multiple-unit dosage forms. Via a continuous, single-step and solvent-free process, pellets 
highly reproducible in size and shape can be successfully obtained. Moreover, fatty acids were 
suitable as oral controlled release matrices of a highly water soluble drug. Nevertheless, additional 
research is required to determine the potential of prilling in pharmaceutical industry as well as to 
evaluate the ability of fatty acids in controlled drug delivery. Below, some topics are summarized 
which should be considered for further investigation: 
- The incorporation of the vibrating nozzle device in the 5 m high prilling tower offers a 
promising future for successful solidification of lipid particles. As this technology allows easy 
variation of the droplet size, the maximum droplet size which can be completely solidified 
using this cooling setup can be determined.  
- The viscosity of the drug/lipid mixture is a critical parameter. In order to provide continuous 
supply of the drug/lipid mixture through the prilling nozzles and to ensure efficient jet break-
up, the viscosity of the mixture during processing is limited. Although MPT was completely 
dissolved, flowability problems were already observed during feeding of mixtures with higher 
drug load. Hence, the processability of suspensions via this technique definitely requires 
further investigation. Moreover, sedimentation of the suspended particles can occur during 
processing resulting in inhomogeneity of the end product. Despite these barriers, it is 
anticipated that the crystallinity of drug particles which were suspended in the fatty acid 
melt during prilling, will be independently of the applied cooling rate. 
- The scale-up study in Chapter 4 identified that product quality (e.g. pellet yield, sphericity 
and surface properties) is affected by formulation parameters. As minor changes of the 
composition can cause variations in viscosity, density and surface tension, a thorough 
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analysis of the impact of these parameters on droplet solidification will improve process 
understanding and increase the success rate of prilling for pharmaceutical applications.  
- As this study suggested that the molecular interaction between MPT and fatty acids is a 
contributing factor to achieve controlled drug release, there is a need to further explore the 
controlled release properties of the fatty acids in combination with drugs which do not 
dissolve in the molten fatty acid phase. 
- As we were unable to correlate changes in drug release upon storage with solid state 
transformations, additional research via advanced characterization techniques is 
recommended to detect aging phenomena of the fatty acid matrices. Also the impact of a 
molecularly dispersed drug on the stability issues should be investigated in comparison to a 
drug which is suspended in the fatty acid matrix.  
- As a wide variety of lipid excipients is available for pharmaceutical industry, the performance 
of other lipid excipients (glycerides, polyoxylglycerides, waxes, oils,…) and their combinations 
to modulate drug release from prills as well as their suitability for processing via prilling can 
be explored.  
- Although this work focused on prilling, other manufacturing techniques such as continuous 
melt granulation and solid lipid extrusion offer interesting alternatives for the development 
of lipid-based dosage forms. In particular, solid lipid extrusion provides more freedom-to-
operate with regard to process temperature and viscosity compared to prilling. For instance, 
the combination of fatty acids with highly viscous polymers such as polyethylene oxide is 
worthwhile to explore. Furthermore, the hydrophobic characteristics of the lipids and the 
low process temperature during solid lipid extrusion seems an interesting combination for 
processing of water- and thermosensitive drugs (e.g. acetylsalicylic acid). 
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SUMMARY 
For many years, prilling has been widely used in chemical industry for the production of 
fertilizers such as urea and ammonium nitrate. Recently, the technique has gained increased 
attention in pharmaceutical industry for processing of oral multiparticulate dosage forms since it 
allows continuous production of narrow-sized particles. Up until now, only a few studies evaluated its 
suitability for pharmaceutical applications. In addition, the use of lipid excipients during the prilling 
process offers great potential for the development of controlled release matrices. Despite the highly 
versatile character of lipid excipients, the number of marketed lipid-based drug delivery systems is 
limited. Therefore, this study aimed to evaluate the potential of prilling as manufacturing technique 
for lipid-based multiple-unit systems. Fatty acids were selected as controlled release matrix formers 
as they show less tendency to polymorphism during storage. In Chapter 1, 2 and 3 prilling was carried 
out using a pneumatic nozzle device producing lipid droplets which were quench cooled in liquid 
nitrogen, whereas in Chapter 4 the droplets were solidified by means of a prilling tower. 
Chapter 1 explored the suitability of prilling as technique to produce multiparticulate dosage 
forms using the fatty acids stearic acid (C18) and behenic acid (C22) as potential matrix formers to 
control the release of metoprolol tartrate (MPT), a highly water soluble drug. Image analysis 
indicated that prilling yielded spherically shaped pellets with narrow particle size distribution. The in 
vitro drug release was dependent on the drug load, type of fatty acid and pH of the dissolution 
medium. Higher drug loads resulted in faster release with behenic acid releasing drug over longer 
periods relative to stearic acid. The in vitro drug release was pH-dependent at low drug load 
(i.e. 10%) with the release being slower at lower pH. Due to ionization of the fatty acid at pH 7.4, 
drug release was susceptible to the ionic strength at this pH value. Solid state characterization 
indicated that the crystalline state of the fatty acids was not affected by thermal processing via 
prilling, while the crystallinity of MPT was decreased. Analysis via FT-IR spectroscopy revealed the 
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formation of hydrogen bonds between the drug and the fatty acids. A stability study indicated that 
the amorphous MPT fraction recrystallized in the entire matrix, irrespective of the storage 
conditions. However, this phenomenon could not be correlated to changes in drug release kinetics: 
storage at 40°C  induced a faster drug release, while drug release during storage at 25°C was stable. 
Furthermore, no polymorphism of behenic acid was detected. The bioavailability of MPT, after oral 
administration to 6 dogs as prills containing 30% and 40% MPT using behenic acid as matrix former, 
was not significantly different from a commercial sustained release reference formulation (Slow-
Lopresor®), although the 40% MPT prills showed a burst release.  
Chapter 2 evaluated the ability of the incorporation of a hydrophilic polymer to the fatty acid 
matrix to tailor drug release from the prills. Prills, providing controlled and immediate drug release, 
were processed and finally combined in capsules yielding a fixed-dose combination. Metoprolol 
tartrate (MPT) and hydrochlorothiazide (HCT) were used as controlled and immediate release model 
drugs, respectively. These drugs were embedded in matrices composed of fatty acids and 
polyethylene glycol (PEG). In order to tailor drug release from the prills, the type of fatty acid, the 
PEG molecular weight and the fatty acid/PEG ratio were varied. To provide controlled drug release, 
MPT (10%, w/w) was embedded in matrices containing PEG and behenic acid. Using different PEG 
molecular weights (PEG 4000, 6000 and 10 000) and varying the PEG concentration, MPT release 
could be tailored over a wide range. To obtain immediate release, HCT (10%, w/w) was incorporated 
in matrices composed of PEG and stearic acid. Since high amounts (at least 60%) of PEG were needed 
for acceptable immediate release, HCT release was independent on PEG molecular weight. Similar to 
the formulations studied in Chapter 1, solid state characterization revealed that MPT crystallinity was 
decreased. Due to molecular interaction with PEG, HCT was molecularly dispersed throughout the 
matrix. Drug release of both MPT and HCT prills was stable during storage. Compared to a fixed-dose 
reference (Zok-Zid®), oral co-administration of the MPT and HCT prills to dogs yielded a similar 
bioavailability for the HCT prills, while the MPT prills resulted in a significant higher bioavailability 
with similar controlled release characteristics. As dissolution experiments using the reciprocating 
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cylinder method revealed that the MPT prills showed a higher sensitivity to hydrodynamic stress 
conditions in the gastro-intestinal tract compared to the reference formulation, this phenomenon 
could be a possible explanation for their higher bioavailability.  
As prilling involves complete melting of the lipid, optimal interaction between MPT and the fatty 
acids can occur. In contrast, solid lipid extrusion operates below the melting point of the lipid at a 
temperature allowing sufficient softening to mould it through the die of the extruder. Therefore, 
Chapter 3 aimed to study the impact of these different process conditions on the solid state 
characteristics, inner structure, drug release and stability of fatty acid-based formulations processed 
via prilling and solid lipid extrusion. Myristic acid (MA), stearic acid (SA) and behenic acid (BA) were 
used as matrix formers combined with metoprolol tartrate (MPT) as model drug. The prilling process 
allowed complete dissolution of MPT in the molten fatty acid phase, generating semi-crystalline MPT 
and the formation of hydrogen bonds between drug and fatty acids in the solid prills. In contrast, as 
solid lipid extrusion (SLE) induced only limited melting of the fatty acids, molecular interaction with 
the drug was inhibited, yielding crystalline MPT. Although the addition of a low melting fatty acid 
allowed more MPT/fatty acid interaction during extrusion, which was observed via in-line Raman 
spectroscopic monitoring, crystalline MPT was detected after processing. Mathematical modeling 
revealed that the extrudates exhibited a higher apparent drug/water mobility than prills of the same 
composition, probably due to differences in the inner systems’ structure. Irrespective of the 
processing method, mixed fatty acid systems (e.g. MA/BA) exhibited a lower matrix porosity, 
resulting in a slower drug release rate. Solid state analysis of these systems indicated that the 
crystalline structure of the fatty acids was maintained after SLE, while prilling generated a reduced 
MA crystallinity. Binary MPT/behenic acid systems processed via extrusion showed better stability 
during storage at 40°C than the corresponding prills. Although mixed fatty acid systems were stable 
at 25°C, stability problems were encountered during storage at 40°C: a faster release was obtained 
from the prills, whereas drug release from the extrudates was slower.  
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In the previous chapters, lipid droplets were solidified via quench cooling in liquid nitrogen. 
Although this lab-scale method provided a fast and feasible tool for production of lipid particles, the 
influence of the extreme cooling rate on drug and matrix crystallinity must be considered. Therefore, 
Chapter 4 explored the use of a 5m-high temperature-controlled prilling tower whereby the lipid 
droplets are exposed to slower cooling rates. Different cooling setups were evaluated: co-current 
and counter-current N2-flow as well as a combined tower/fluidized bed system. Using the co-current 
and counter-current setups, caking effects were observed in the collection reservoir due to 
insufficient solidification of the lipid droplets in the vertical prilling tower. To overcome these issues, 
a fluid-bed system was incorporated in the lower part of the prilling tower to increase the residence 
time of the droplets and thus, to provide more time for solidification. Although this setup 
significantly improved the particle yield, only a minor fraction of the particles exhibited a spherical 
shape. Most particles were hollow and could be defined as cup-like particles. In general, these 
experiments indicated that the prilling tower/fluidized bed system was of insufficient length to 
solidify droplets exceeding 2 mm. Therefore, a reduction of the droplet size was considered in the 
second part of the study. A vibrating nozzle device generating droplets smaller than 1 mm was 
incorporated in a 2.2 m vertical cooling cylinder. Using a nozzle size up to 400 µm, complete 
solidification of pure behenic acid droplets was achieved at ambient conditions (i.e. without 
additional cooling system). Mixtures containing 10% MPT, processed via the 250 µm nozzle, were 
also successfully cooled via this setup. However, formulations containing 20% and 30% MPT required 
a cold co-current N2-flow (-10°C) to allow complete solidification. Using the vibrating nozzle, all 
mixtures resulted in narrow-sized spherically shaped particles. Furthermore, this study revealed that 
the cooling rate significantly affected MPT crystallinity. Fast cooling rates (via quench cooling or via 
cooling of droplets produced with the vibrating nozzle) yielded amorphous MPT fractions, whereas 
slow cooling in the tower/fluidized bed system resulted in crystalline MPT. Similarly, PEG 20 000 
showed a higher degree of crystallinity after slow cooling. In contrast, the crystallinity of the fatty 
acids did not depend on the applied cooling rate. Overall, this study demonstrated that incorporation 
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of the vibrating nozzle device in the 5m-high prilling tower shows great potential for production of 
lipid particles of ± 1 mm. 
Based on this work, it can be concluded that prilling of fatty acids is a promising technology for 
continuous processing of controlled release multiple-unit dosage forms. Nevertheless, an extension 
of this work is required to fully evaluate the potential of this technique in pharmaceutical industry.   
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SAMENVATTING 
Prilling is een proces dat reeds vele jaren gebruikt wordt voor het produceren van 
kunstmeststoffen zoals ureum en ammonium nitraat. Recentelijk wekte deze techniek interesse van 
de farmaceutische industrie als mogelijke productiemethode voor orale multiparticulaire 
doseervormen omdat partikels met nauwe deeltjesgrootte kunnen geproduceerd worden op een 
continue manier. Tot hiertoe werden slechts enkele studies uitgevoerd die het potentieel van de 
techniek voor farmaceutische toepassingen evalueerden. Door het gebruik van vette materialen is 
prilling een veelbelovende technologie voor de productie van geneesmiddelvormen met 
gecontroleerde vrijstelling. Desondanks het veelzijdige karakter van vette hulpstoffen, is het aantal 
gecommercialiseerde formulaties op basis van deze materialen zeer teleurstellend. Bijgevolg was dit 
onderzoek erop gericht om het potentieel van prilling te evalueren voor de productie van 
multiparticulaire doseervormen op basis van vette matrices. Als matrix hulpstof voor gecontroleerde 
vrijstelling werden vetzuren geselecteerd, omdat deze klasse van vette bestanddelen minder risico 
vertoont op polymorfisme tijdens bewaring. In Hoofdstuk 1, 2 en 3 werd prilling uitgevoerd met 
behulp van een pneumatisch nozzle systeem waarbij de druppels gekoeld werden in vloeibare 
stikstof. In Hoofdstuk 4 werd gebruik gemaakt van een priltoren voor het koelen van de druppels. 
In Hoofdstuk 1 werd geëvalueerd of prilling geschikt was voor de productie van multiparticulaire 
doseervormen samengesteld uit de vetzuren stearinezuur (C18) of beheenzuur (C22). Bovendien 
werd nagegaan of deze vetzuren kunnen fungeren als matrix voor gecontroleerde vrijstelling van een 
sterk wateroplosbaar geneesmiddel, namelijk metoprolol tartraat (MPT). Microscopische analyse 
toonde aan dat met behulp van prilling sferische partikels met nauwe deeltjesgroottedistributie 
konden bekomen worden. De in vitro geneesmiddelvrijstelling was afhankelijk van de 
geneesmiddelconcentratie, het vetzuurtype en de pH van het dissolutiemedium. Een hogere 
geneesmiddelconcentratie resulteerde in een snellere vrijstelling waarbij beheenzuur het 
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geneesmiddel trager vrijstelde in vergelijking met stearinezuur. Enkel in het geval van een lage 
geneesmiddelconcentratie (i.e. 10%) was de vrijstelling pH-afhankelijk. Door ionisatie van het vetzuur 
bij hogere pH, was de geneesmiddelvrijstelling afhankelijk van de ionensterkte in het 
dissolutiemedium met pH gelijk aan 7.4. Vaste stof karakterisatie toonde aan dat de kristalliniteit van 
de vetzuren niet aangetast werd door de prilling techniek, terwijl de kristalliniteit van MPT was 
verlaagd. Analyse met behulp van FT-IR spectroscopie bracht aan het licht dat waterstofbruggen 
gevormd werden tussen het geneesmiddel en de vetzuren onder invloed van het productieproces. 
Een stabiliteitsstudie toonde aan dat de amorfe MPT fracties uitkristalliseerden, onafhankelijk van de 
bewaringscondities. Nochtans kon dit fenomeen niet gecorreleerd worden met een verandering van 
de geneesmiddelvrijstelling tijdens bewaring: enkel bewaring bij 40°C resulteerde in een snellere 
vrijstelling, de vrijstelling tijdens bewaring bij 25°C daarentegen was stabiel. Verder werd geen 
polymorfisme van beheenzuur gedetecteerd. De biologische beschikbaarheid van MPT, na orale 
toediening van de prills die 30% en 40% MPT bevatten aan 6 honden, was niet significant verschillend 
van een commercieel beschikbare referentieformulatie (Slow-Lopresor®), ondanks het feit dat de 
prills met 40% MPT een snelle initiële vrijstelling vertoonden. 
Hoofdstuk 2 onderzocht de mogelijkheid om de geneesmiddelvrijstelling te sturen door 
incorporatie van een hydrofiel polymeer in de vetzuurmatrix. Prills met gecontroleerde en 
onmiddellijke vrijstelling werden geproduceerd en samen afgevuld in capsules zodat een 
combinatiepreparaat gevormd werd. Metoprolol tartraat (MPT) en hydrochloorthiazide (HCT) 
werden gebruikt als modelgeneesmiddelen voor respectievelijk gecontroleerde en onmiddellijke 
vrijgave. Deze geneesmiddelen werden ingebed in matrices samengesteld uit vetzuren en 
polyethyleen glycol (PEG). Om de geneesmiddelvrijstelling te sturen, werden het vetzuurtype, het 
moleculair gewicht van PEG en de ratio vetzuur/PEG gevarieerd. Voor het beogen van 
gecontroleerde vrijstelling werd MPT (10% w/w) ingebed in matrices samengesteld uit PEG en 
beheenzuur. Door het gebruik van verschillende moleculaire gewichten van PEG (4000, 6000 en 
10 000) kon de vrijstelling van MPT gestuurd worden over een breed tijdsgebied. Voor het bekomen 
SAMENVATTING 
175 
 
van onmiddellijke geneesmiddelvrijgave werd HCT (10% w/w) geïncorporeerd in matrices 
samengesteld uit PEG en stearinezuur. Doordat hoge concentraties aan PEG (i.e. 60%) vereist waren 
om een acceptabel vrijstellingsprofiel te bekomen, was de vrijstelling onafhankelijk van het 
moleculair gewicht van PEG. Gelijkaardig aan de formulaties die bestudeerd werden in Hoofdstuk 1, 
was ook de kristalliniteit van MPT in deze formulaties verlaagd. Door moleculaire interactie met PEG, 
was HCT moleculair verdeeld doorheen de matrix. De geneesmiddelvrijstelling uit de MPT en HCT 
prills was stabiel tijdens bewaring. In vergelijking met een commercieel beschikbaar 
combinatiepreparaat (Zok-Zid®), resulteerde simultane toediening van de HCT en MPT prills aan 
honden in een gelijkaardige biologische beschikbaarheid voor HCT, terwijl voor MPT een hogere 
biologische beschikbaarheid met gelijkaardige gecontroleerde vrijstelling bekomen werd. Doordat 
bijkomende dissolutie experimenten met behulp van de ‘reciprocating cylinder’ methode 
aantoonden dat de MPT prills, in vergelijking met de referentieformulatie, meer gevoelig zijn aan 
hydrodynamische stress condities in het gastro-intestinaal systeem, kon dit een mogelijke verklaring 
bieden voor de hogere biologische beschikbaarheid van de prills.  
Omdat voor prilling een volledig gesmolten vetfase vereist is, kan optimale interactie tussen 
MPT en de vetzuren optreden. Daarentegen wordt ‘solid lipid extrusion’ uitgevoerd onder het 
smeltpunt van de vette matrix, bij een temperatuur die voldoende is om vervorming van het 
materiaal te veroorzaken zodat extrusie door de matrijs mogelijk is. Daarom werd in Hoofdstuk 3 de 
invloed bestudeerd van deze verschillende procescondities. Formulaties op basis van vetzuren 
werden geproduceerd via prilling en solid lipid extrusion en nadien werden de kristalliniteit, interne 
structuur, geneesmiddelvrijgave en stabiliteit van de prills en extrudaten vergeleken. Myristinezuur 
(MA), stearinezuur (SA) en beheenzuur (BA) werden geselecteerd als matrixvormers en 
gecombineerd met metoprolol tartraat als modelgeneesmiddel. Doordat tijdens prilling MPT volledig 
opgelost is in de gesmolten vetfase, resulteerde deze productiemethode in de vorming van semi-
kristallijn MPT. Bovendien werden waterstofbruggen gevormd tussen het geneesmiddel en de 
vetzuren. Omdat slechts een kleine fractie van de vetzuren smelt tijdens het extrusieproces, werd 
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moleculaire interactie tussen MPT en de vetzuren verhinderd, resulterend in de vorming van 
kristallijn MPT. Desondanks het feit dat in-line Raman spectra, opgenomen tijdens het 
extrusieproces, aantoonden dat de toevoeging van een vetzuur met lager smeltpunt resulteerde in 
meer MPT/vetzuur interactie, werd toch kristallijn MPT gedetecteerd na het productieproces. Met 
behulp van wiskundige modellering kon aangetoond worden dat de mobiliteit van het geneesmiddel 
(of van water) hoger was in de extrudaten, mogelijks te wijten aan een verschillende interne 
structuur. Onafhankelijk van de productiemethode, vertoonden systemen waarbij 2 vetzuren 
geïncorporeerd werden (i.e. MA/BA) een verlaagde porositeit, resulterend in een tragere 
geneesmiddelvrijgave. Vaste stof karakterisatie van deze formulaties onthulde dat de kristalliniteit 
van de vetzuren behouden werd na extrusie, terwijl de kristalliniteit van myristinezuur verlaagd was 
na prilling. Extrudaten op basis van MPT en beheenzuur vertoonden een betere stabiliteit tijdens 
bewaring bij 40°C in vergelijking met de overeenkomstige prills. Hoewel mengsels van MPT met 2 
vetzuren stabiel bleven tijdens bewaring bij 25°C, wijzigde de vrijstelling significant tijdens bewaring 
bij 40°C: de prills vertoonden een snellere vrijstelling en de extrudaten vertoonden een tragere 
vrijstelling. 
In de vorige hoofdstukken werden de vetdruppels snel gekoeld in vloeibare stikstof. Hoewel dit 
een snelle en praktisch haalbare methode was voor de laboratoriumproductie van vette matrices, is 
er nood aan onderzoek naar de invloed van deze extreme koelsnelheid op de kristalliniteit van het 
geneesmiddel en de matrixvormers. Daarom werd in Hoofdstuk 4 het gebruik van een 5m hoge 
priltoren met ingebouwde temperatuurscontrole onderzocht waarbij de druppels blootgesteld 
werden aan een tragere koelsnelheid. Verschillende opstellingen voor koeling werden geëvalueerd: 
co-current en counter-current N2-stroom, alsook de combinatie van een priltoren/wervelbed 
systeem. Bij het gebruik van de co-current en counter-current opstellingen werd ‘caking’ 
geobserveerd onderaan de kolom, veroorzaakt door onvoldoende koeling van de druppels bij het 
bereiken van de bodem. Omwille van deze problemen, werd een wervelbed systeem geïntegreerd in 
het onderste deel van de priltoren om de residentietijd van de druppels in de kolom te verhogen 
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zodat deze meer tijd kregen om te stollen. Hoewel deze aanpassing de opbrengst aan individuele 
partikels significant verhoogde, vertoonde slechts een kleine fractie van de partikels een sferische 
vorm. De meeste partikels waren hol en konden gedefinieerd worden als schaalvormige partikels. 
Algemeen gezien kon uit deze experimenten besloten worden dat een priltoren van 5 m te kort is om 
druppels te koelen die groter zijn dan 2 mm. Daarom werd in het tweede deel van deze studie een 
kleinere druppelgrootte beoogd. Een vibrerend nozzle systeem dat druppels genereert die kleiner 
zijn dan 1 mm, werd ingebouwd in een 2.2 m hoge verticale koelkamer. Gebruik makend van nozzle 
diameters tot 400 µm konden druppels samengesteld uit 100% beheenzuur volledig gekoeld worden 
bij kamertemperatuur (zonder extra koelingsysteem). Ook druppels gevormd met een 250 µm nozzle 
en samengesteld uit 10% MPT en 90% beheenzuur konden op deze manier gekoeld worden. 
Daarentegen, voor mengsels met 20% en 30% MPT was een gekoelde co-current N2-stroom (-10°C) 
nodig opdat de druppels volledig konden stollen. Verder kon met deze studie aangetoond worden 
dat de koelsnelheid een duidelijke invloed had op de kristalstructuur van MPT. Hoge koelsnelheden 
(verkregen door koeling in vloeibare stikstof of door koeling van de druppels geproduceerd met het 
vibrerend nozzle systeem) resulteerden in de vorming van amorfe geneesmiddelfracties, terwijl een 
trage koelsnelheid in het gecombineerd priltoren/wervelbed systeem kristallijn MPT opleverde. 
Analoog met MPT, veroorzaakte een tragere koeling een hogere kristalliniteit van PEG. Daarentegen 
werd de kristalstructuur van beheenzuur niet beïnvloed door de koelsnelheid. Met deze studie werd 
aangetoond dat de combinatie van het vibrerend nozzle systeem met de 5 m hoge priltoren een 
groot potentieel heeft voor het produceren van partikels van ongeveer 1 mm diameter.  
Gebaseerd op dit onderzoekswerk kan geconcludeerd worden dat prilling van vetzuren een 
veelbelovende techniek is voor de continue productie van multiparticulaire doseervormen met 
gecontroleerde vrijstelling. Desondanks is extra onderzoek vereist om het potentieel van deze 
techniek in de farmaceutische industrie verder te kunnen evalueren.  
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